-- Table structure for table `node__field_comments`
--

CREATE TABLE `node__field_comments` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_comments_value` longtext NOT NULL,
  `field_comments_format` varchar(255) CHARACTER SET ascii DEFAULT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_comments_format` (`field_comments_format`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_comments.';

--
-- Dumping data for table `node__field_comments`
--

INSERT INTO `node__field_comments` VALUES ('indicator',0,401,410,'en',0,'<p>Certifications could be used as a proxy.</p>\r\n','basic_html'),('indicator',0,406,415,'en',0,'<p>Ideally, an initiative/project&nbsp;should provide the ROI specific for health research. Given the complexity of its calculation, it can opt for the general ROI if the first option is too demanding.</p>\r\n','basic_html'),('indicator',0,407,416,'en',0,'<p>Process to calculate it considering the information provided in financial statements. For instance, in the&nbsp;Burnet Institute 2018 Financial Report,&nbsp;divide \"total liabilities\" (p. 10) by \"results from operating activity\" (p. 9) times 100.</p>\r\n\r\n<p>The&nbsp;Burnet Institute 2018 Financial Report is available at:&nbsp;<a href=\"https://www.burnet.edu.au/system/annual_report/file/25/Financial_Report_2018_-_digital.pdf\">https://www.burnet.edu.au/system/annual_report/file/25/Financial_Report_2018_-_digital.pdf</a></p>\r\n','basic_html'),('indicator',0,408,417,'en',0,'<p>Process to calculate it considering the information provided in financial statements. For instance, in&nbsp;Sanofi 2018 Annual Report,&nbsp;divide \"other intangible assets\" (see note D.35.3 - page F111) by \"carrying amount of products, trademarks and other rights\" (see note D.4 - page F44). Sanofi 2018 Annual Report is available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Sanofi-20-F-2018-EN-PDF-e-accessible_02.pdf?la=en&amp;hash=0E0CB0122FEDA3881B3857221DB9345A\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Sanofi-20-F-2018-EN-PDF-e-accessible_02.pdf?la=en&amp;hash=0E0CB0122FEDA3881B3857221DB9345A</a></p>\r\n\r\n<p>If the indicator is difficult to calculate to some initiatives/projects, it could be simplified by dividing the revenues obtained from the exploitation of patents and intellectual property rights by the total number of patents/intellectual property rights owned by the initiative/project.</p>\r\n','basic_html'),('indicator',0,409,418,'en',0,'<p>The data can&nbsp;be provided in a graphic, like in the example.</p>\r\n','basic_html'),('indicator',0,410,419,'en',0,'<p>This indicator can be used to compute the indicator \"return on intellectual property\".</p>\r\n','basic_html'),('indicator',0,412,421,'en',0,'<p>The example only provide the number of new products developed during the reporting period.</p>\r\n','basic_html'),('indicator',0,414,423,'en',0,'<p>The indicator must be tested and adjusted through a regular, double-feedback-loop process (Kaplan &amp; Norton, 2006), which analyses the differences between what was foreseen and the actual results and accordingly changes the model and the strategic assumptions at the basis of its construction.</p>\r\n','basic_html'),('indicator',0,417,426,'en',0,'<p>The example does not disaggregate the number of jobs created by gender.</p>\r\n','basic_html'),('indicator',0,419,428,'en',0,'<p>The indicator can also be provided in a graphic, like in the example.</p>\r\n','basic_html'),('indicator',0,425,434,'en',0,'<p>Additional information:&nbsp;Hogan, D. R., Stevens, G. A., Hosseinpoor, A. R., &amp; Boerma, T. (2018). Monitoring universal health coverage within the Sustainable Development Goals: development and baseline data for an index of essential health services.&nbsp;<em>The Lancet Global Health</em>,&nbsp;<em>6</em>(2), e152-e168.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(17)30472-2/fulltext\">https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(17)30472-2/fulltext</a></p>\r\n','basic_html'),('indicator',0,426,435,'en',0,'<p>Companies should track progress in access-to-medicine outcomes against defined goals, conduct impact assessments of access activities and make results publicly available</p>\r\n','basic_html'),('indicator',0,429,438,'en',0,'<p>The example lists the training courses. It is possible to compute the number by counting the training courses provided.</p>\r\n','basic_html'),('indicator',0,430,439,'en',0,'<p>The example provide the information as a percentage. The number can be calculate by applying the percentage to the total number of employees reported in the same page.&nbsp;The indicator&nbsp;does not disaggregate the number of employed academics by gender.</p>\r\n','basic_html'),('indicator',0,432,441,'en',0,'<p>For how to develop a predictive risk model, see the guide \"A risk stratification tool for hospitalisation in Australia using primary care data\". Available at:&nbsp;<a href=\"https://www.nature.com/articles/s41598-019-41383-y\">https://www.nature.com/articles/s41598-019-41383-y</a><br />\r\nFor how to compute the indicator, see Sigakis et al. (2013): \"Validation of a Risk Stratification Index and Risk Quantification Index for Predicting Patient Outcomes\". Available at:&nbsp;<a href=\"https://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918181\">https://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918181</a></p>\r\n\r\n<p>Data can also be provided graphically (see example).</p>\r\n','basic_html'),('indicator',0,436,445,'en',0,'<p>Full paper of Prieto &amp; Sacristán on computing QALYs is available at: <a href=\"https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-1-80\">https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-1-80</a></p>\r\n','basic_html'),('indicator',0,442,451,'en',0,'<p>Use the Journal Citation Report Impact Factor as benchmark to categorize journal as high-impact. Otherwise, the initiative should clearly indicate if a different ranking is used for the sake of comparability.</p>\r\n','basic_html'),('indicator',0,444,453,'en',0,'<p>The example provided is not specific of health research initiatives, but it can be adapted to their scope.</p>\r\n','basic_html'),('indicator',0,446,455,'en',0,'<p>Adopt Google Scholar as a reference for academic citations to make the indicator more comparable among different initiatives</p>\r\n','basic_html'),('indicator',0,456,465,'en',0,'<p>More information on the indicator is available in MoRRI – The Evolution and Benefits of Responsible Research and Innovation (p. 74).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1\">https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1</a></p>\r\n','basic_html'),('indicator',0,466,475,'en',0,'<p>Those initiatives/project&nbsp;that have not a a shared strategy yet can develop one, and those that already have one should update its strategy so that it is&nbsp;aligned with the scientific priorities as defined in the project/initiative\'s Research Strategy.</p>\r\n','basic_html'),('indicator',0,470,479,'en',0,'<p>This indicator provides additional information to the indicator \"Revenue from intellectual property\".</p>\r\n','basic_html'),('indicator',0,472,481,'en',0,'<p>Link to the World Intellectual Property Organization Database:&nbsp;<a href=\"https://www.wipo.int/branddb/en/\">https://www.wipo.int/branddb/en/</a></p>\r\n\r\n<p>The tabulated data can also be presented as a graphic.<br />\r\nThis indicator can be used to compute the indicator \"return on intellectual property\".</p>\r\n','basic_html'),('indicator',0,478,487,'en',0,'<p>This indicator complement the information provided by indicators \"New products\" and \"Therapeutic advances\".</p>\r\n','basic_html'),('indicator',0,481,490,'en',0,'<p>The example provides additional information on consortia members and not the number of consortia.</p>\r\n','basic_html'),('indicator',0,483,492,'en',0,'<p>See AIHS health research&nbsp;impact framework (Graham et al., 2012).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://academic.oup.com/rev/article-abstract/21/5/354/1559212\">https://academic.oup.com/rev/article-abstract/21/5/354/1559212</a></p>\r\n','basic_html'),('indicator',0,484,493,'en',0,'<p>The example does not disaggregate the number by gender.</p>\r\n','basic_html'),('indicator',0,491,500,'en',0,'<p>Consider the relationship with the Governance Model established in Multi-Act.</p>\r\n\r\n<p>Normally this&nbsp;information is&nbsp;available on the website of the organization/project and in its statutes.</p>\r\n','basic_html'),('indicator',0,494,503,'en',0,'<p>The example is overwhelming; usually the indicator could just consist in one table. Also, it does not present stakeholders per category. &nbsp;</p>\r\n','basic_html'),('indicator',0,503,512,'en',0,'<p>In reserch organizations, this information is often implicit. Indicators 66 &amp; 107 provide complementary perspectives.</p>\r\n','basic_html'),('indicator',0,504,513,'en',0,'<p>More information in how to compute the indicators in&nbsp;MoRRI – Monitoring the Evolution and Benefits of Responsible Research and Innovation (see pp. 77-81).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1/language-en\">https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1/language-en</a></p>\r\n','basic_html'),('indicator',0,505,514,'en',0,'<p>This information is often embedded in the general section about stakeholder engagement (see example). If that is the case, the initiative can refer to that section.</p>\r\n','basic_html'),('indicator',0,551,561,'en',0,'<p><span><span><span><span><span>Indicators disease-specific (MS)</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,552,562,'en',0,'<p><span><span><span><span><span>Indicators disease-specific (MS)</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,585,612,'en',0,'<p>Indicators disease-specific (MS)</p>\r\n','basic_html');

--
-- Table structure for table `node__field_core_activities`
--

CREATE TABLE `node__field_core_activities` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_core_activities_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_core_activities_value` (`field_core_activities_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_core_activities.';

--
-- Dumping data for table `node__field_core_activities`
--

INSERT INTO `node__field_core_activities` VALUES ('initiative',0,309,318,'en',0,'Community care research'),('initiative',0,309,318,'en',1,'Detection, screening and diagnosis'),('initiative',0,310,319,'en',0,'Detection, screening and diagnosis'),('initiative',0,516,525,'en',0,'Health and social care services research'),('initiative',0,518,528,'en',0,'Community care research'),('initiative',0,519,529,'en',0,'Community care research'),('initiative',0,520,530,'en',0,'Detection, screening and diagnosis'),('initiative',0,521,531,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,522,532,'en',0,'Digital transformation of health sector'),('initiative',0,523,533,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,524,534,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,525,535,'en',0,'Detection, screening and diagnosis'),('initiative',0,526,536,'en',0,'Community care research'),('initiative',0,527,537,'en',0,'Community care research'),('initiative',0,528,538,'en',0,'Community care research'),('initiative',0,529,539,'en',0,'Detection, screening and diagnosis'),('initiative',0,529,539,'en',1,'Digital transformation of health sector'),('initiative',0,530,540,'en',0,'Detection, screening and diagnosis'),('initiative',0,530,540,'en',1,'Digital transformation of health sector'),('initiative',0,530,540,'en',2,'Health and social care services research'),('initiative',0,530,540,'en',3,'Prevention of diseases and conditions / promotion of health and wellbeing'),('initiative',0,531,541,'en',0,'Detection, screening and diagnosis'),('initiative',0,531,541,'en',1,'Development of treatments and therapeutic interventions'),('initiative',0,534,544,'en',0,'Prevention of diseases and conditions / promotion of health and wellbeing'),('initiative',0,535,545,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,536,546,'en',0,'Health and social care services research'),('initiative',0,537,547,'en',0,'Community care research'),('initiative',0,538,548,'en',0,'Underpinning research and aetiology'),('initiative',0,539,549,'en',0,'Underpinning research and aetiology'),('initiative',0,540,550,'en',0,'Management of diseases and conditions'),('initiative',0,541,551,'en',0,'Digital transformation of health sector'),('initiative',0,542,552,'en',0,'Prevention of diseases and conditions / promotion of health and wellbeing'),('initiative',0,543,553,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,544,554,'en',0,'Community care research'),('initiative',0,544,554,'en',1,'Detection, screening and diagnosis'),('initiative',0,545,555,'en',0,'Digital transformation of health sector'),('initiative',0,555,565,'en',0,'Community care research'),('initiative',0,555,565,'en',1,'Detection, screening and diagnosis'),('initiative',0,556,566,'en',0,'Management of diseases and conditions'),('initiative',0,557,567,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,589,616,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,590,617,'en',0,'Community care research'),('initiative',0,592,621,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,593,622,'en',0,'Underpinning research and aetiology');

--
-- Table structure for table `node__field_core_additional`
--

CREATE TABLE `node__field_core_additional` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_core_additional_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_core_additional_value` (`field_core_additional_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_core_additional.';

--
-- Dumping data for table `node__field_core_additional`
--

INSERT INTO `node__field_core_additional` VALUES ('indicator',0,399,408,'en',0,'Core'),('indicator',0,400,409,'en',0,'Core'),('indicator',0,401,410,'en',0,'Additional'),('indicator',0,402,411,'en',0,'Core'),('indicator',0,403,412,'en',0,'Additional'),('indicator',0,404,413,'en',0,'Additional'),('indicator',0,405,414,'en',0,'Additional'),('indicator',0,406,415,'en',0,'Core'),('indicator',0,407,416,'en',0,'Additional'),('indicator',0,408,417,'en',0,'Additional'),('indicator',0,409,418,'en',0,'Core'),('indicator',0,410,419,'en',0,'Core'),('indicator',0,411,420,'en',0,'Core'),('indicator',0,412,421,'en',0,'Additional'),('indicator',0,413,422,'en',0,'Additional'),('indicator',0,414,423,'en',0,'Core'),('indicator',0,415,424,'en',0,'Additional'),('indicator',0,416,425,'en',0,'Additional'),('indicator',0,417,426,'en',0,'Core'),('indicator',0,418,427,'en',0,'Additional'),('indicator',0,419,428,'en',0,'Core'),('indicator',0,420,429,'en',0,'Additional'),('indicator',0,421,430,'en',0,'Core'),('indicator',0,422,431,'en',0,'Core'),('indicator',0,423,432,'en',0,'Additional'),('indicator',0,424,433,'en',0,'Additional'),('indicator',0,425,434,'en',0,'Core'),('indicator',0,426,435,'en',0,'Additional'),('indicator',0,427,436,'en',0,'Additional'),('indicator',0,428,437,'en',0,'Core'),('indicator',0,429,438,'en',0,'Additional'),('indicator',0,430,439,'en',0,'Additional'),('indicator',0,431,440,'en',0,'Core'),('indicator',0,432,441,'en',0,'Additional'),('indicator',0,433,442,'en',0,'Additional'),('indicator',0,434,443,'en',0,'Core'),('indicator',0,435,444,'en',0,'Additional'),('indicator',0,436,445,'en',0,'Core'),('indicator',0,437,446,'en',0,'Additional'),('indicator',0,438,447,'en',0,'Additional'),('indicator',0,439,448,'en',0,'Core'),('indicator',0,440,449,'en',0,'Core'),('indicator',0,441,450,'en',0,'Additional'),('indicator',0,442,451,'en',0,'Core'),('indicator',0,443,452,'en',0,'Additional'),('indicator',0,444,453,'en',0,'Additional'),('indicator',0,445,454,'en',0,'Core'),('indicator',0,446,455,'en',0,'Core'),('indicator',0,447,456,'en',0,'Additional'),('indicator',0,448,457,'en',0,'Additional'),('indicator',0,449,458,'en',0,'Core'),('indicator',0,450,459,'en',0,'Additional'),('indicator',0,451,460,'en',0,'Additional'),('indicator',0,452,461,'en',0,'Additional'),('indicator',0,453,462,'en',0,'Additional'),('indicator',0,454,463,'en',0,'Core'),('indicator',0,455,464,'en',0,'Additional'),('indicator',0,456,465,'en',0,'Additional'),('indicator',0,457,466,'en',0,'Core'),('indicator',0,458,467,'en',0,'Additional'),('indicator',0,459,468,'en',0,'Additional'),('indicator',0,460,469,'en',0,'Core'),('indicator',0,461,470,'en',0,'Additional'),('indicator',0,462,471,'en',0,'Additional'),('indicator',0,463,472,'en',0,'Core'),('indicator',0,464,473,'en',0,'Core'),('indicator',0,465,474,'en',0,'Additional'),('indicator',0,466,475,'en',0,'Additional'),('indicator',0,467,476,'en',0,'Core'),('indicator',0,468,477,'en',0,'Additional'),('indicator',0,469,478,'en',0,'Additional'),('indicator',0,470,479,'en',0,'Core'),('indicator',0,471,480,'en',0,'Additional'),('indicator',0,472,481,'en',0,'Additional'),('indicator',0,473,482,'en',0,'Core'),('indicator',0,474,483,'en',0,'Additional'),('indicator',0,475,484,'en',0,'Core'),('indicator',0,476,485,'en',0,'Additional'),('indicator',0,477,486,'en',0,'Additional'),('indicator',0,478,487,'en',0,'Additional'),('indicator',0,479,488,'en',0,'Core'),('indicator',0,480,489,'en',0,'Additional'),('indicator',0,481,490,'en',0,'Additional'),('indicator',0,482,491,'en',0,'Core'),('indicator',0,483,492,'en',0,'Additional'),('indicator',0,484,493,'en',0,'Core'),('indicator',0,485,494,'en',0,'Additional'),('indicator',0,486,495,'en',0,'Additional'),('indicator',0,487,496,'en',0,'Additional'),('indicator',0,488,497,'en',0,'Core'),('indicator',0,489,498,'en',0,'Additional'),('indicator',0,490,499,'en',0,'Additional'),('indicator',0,491,500,'en',0,'Core'),('indicator',0,492,501,'en',0,'Additional'),('indicator',0,493,502,'en',0,'Additional'),('indicator',0,494,503,'en',0,'Core'),('indicator',0,495,504,'en',0,'Additional'),('indicator',0,496,505,'en',0,'Additional'),('indicator',0,497,506,'en',0,'Core'),('indicator',0,498,507,'en',0,'Core'),('indicator',0,499,508,'en',0,'Core'),('indicator',0,500,509,'en',0,'Additional'),('indicator',0,501,510,'en',0,'Additional'),('indicator',0,502,511,'en',0,'Additional'),('indicator',0,503,512,'en',0,'Core'),('indicator',0,504,513,'en',0,'Additional'),('indicator',0,505,514,'en',0,'Additional'),('indicator',0,506,515,'en',0,'Core'),('indicator',0,507,516,'en',0,'Core'),('indicator',0,508,517,'en',0,'Additional'),('indicator',0,509,518,'en',0,'Additional'),('indicator',0,510,519,'en',0,'Core'),('indicator',0,512,521,'en',0,'Core'),('indicator',0,547,557,'en',0,'Additional'),('indicator',0,548,558,'en',0,'Additional'),('indicator',0,549,559,'en',0,'Core'),('indicator',0,550,560,'en',0,'Core'),('indicator',0,551,561,'en',0,'Core'),('indicator',0,552,562,'en',0,'Core'),('indicator',0,553,563,'en',0,'Core'),('indicator',0,554,564,'en',0,'Core'),('indicator',0,585,612,'en',0,'Core');

--
-- Table structure for table `node__field_data_type_representation`
--

CREATE TABLE `node__field_data_type_representation` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_data_type_representation_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_data_type_representation_value` (`field_data_type_representation_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_data_type_representation.';

--
-- Dumping data for table `node__field_data_type_representation`
--

INSERT INTO `node__field_data_type_representation` VALUES ('indicator',0,399,408,'en',0,'Qualitative'),('indicator',0,400,409,'en',0,'Quantitative'),('indicator',0,401,410,'en',0,'Quantitative'),('indicator',0,402,411,'en',0,'Quantitative/Qualitative'),('indicator',0,403,412,'en',0,'Qualitative'),('indicator',0,404,413,'en',0,'Qualitative'),('indicator',0,405,414,'en',0,'Quantitative'),('indicator',0,406,415,'en',0,'Quantitative'),('indicator',0,407,416,'en',0,'Quantitative'),('indicator',0,408,417,'en',0,'Quantitative'),('indicator',0,409,418,'en',0,'Quantitative'),('indicator',0,410,419,'en',0,'Quantitative'),('indicator',0,411,420,'en',0,'Quantitative'),('indicator',0,412,421,'en',0,'Quantitative'),('indicator',0,413,422,'en',0,'Quantitative/Qualitative'),('indicator',0,414,423,'en',0,'Quantitative'),('indicator',0,415,424,'en',0,'Quantitative/Qualitative'),('indicator',0,416,425,'en',0,'Quantitative/Qualitative'),('indicator',0,417,426,'en',0,'Quantitative'),('indicator',0,418,427,'en',0,'Quantitative'),('indicator',0,419,428,'en',0,'Quantitative'),('indicator',0,420,429,'en',0,'Quantitative'),('indicator',0,421,430,'en',0,'Qualitative'),('indicator',0,422,431,'en',0,'Quantitative/Qualitative'),('indicator',0,423,432,'en',0,'Quantitative'),('indicator',0,424,433,'en',0,'Qualitative'),('indicator',0,425,434,'en',0,'Quantitative'),('indicator',0,426,435,'en',0,'Qualitative'),('indicator',0,427,436,'en',0,'Quantitative'),('indicator',0,428,437,'en',0,'Quantitative'),('indicator',0,429,438,'en',0,'Quantitative'),('indicator',0,430,439,'en',0,'Quantitative'),('indicator',0,431,440,'en',0,'Qualitative'),('indicator',0,432,441,'en',0,'Quantitative'),('indicator',0,433,442,'en',0,'Quantitative'),('indicator',0,434,443,'en',0,'Qualitative'),('indicator',0,435,444,'en',0,'Quantitative'),('indicator',0,436,445,'en',0,'Quantitative'),('indicator',0,437,446,'en',0,'Quantitative/Qualitative'),('indicator',0,438,447,'en',0,'Qualitative'),('indicator',0,439,448,'en',0,'Quantitative'),('indicator',0,440,449,'en',0,'Qualitative'),('indicator',0,441,450,'en',0,'Qualitative'),('indicator',0,442,451,'en',0,'Quantitative/Qualitative'),('indicator',0,443,452,'en',0,'Quantitative'),('indicator',0,444,453,'en',0,'Quantitative'),('indicator',0,445,454,'en',0,'Qualitative'),('indicator',0,446,455,'en',0,'Quantitative'),('indicator',0,447,456,'en',0,'Quantitative'),('indicator',0,448,457,'en',0,'Quantitative'),('indicator',0,449,458,'en',0,'Quantitative'),('indicator',0,450,459,'en',0,'Quantitative'),('indicator',0,451,460,'en',0,'Quantitative'),('indicator',0,452,461,'en',0,'Qualitative'),('indicator',0,453,462,'en',0,'Qualitative'),('indicator',0,454,463,'en',0,'Qualitative'),('indicator',0,455,464,'en',0,'Qualitative'),('indicator',0,456,465,'en',0,'Qualitative'),('indicator',0,457,466,'en',0,'Quantitative'),('indicator',0,458,467,'en',0,'Quantitative'),('indicator',0,459,468,'en',0,'Qualitative'),('indicator',0,460,469,'en',0,'Quantitative'),('indicator',0,461,470,'en',0,'Qualitative'),('indicator',0,462,471,'en',0,'Qualitative'),('indicator',0,463,472,'en',0,'Qualitative'),('indicator',0,464,473,'en',0,'Qualitative'),('indicator',0,465,474,'en',0,'Qualitative'),('indicator',0,466,475,'en',0,'Qualitative'),('indicator',0,467,476,'en',0,'Quantitative/Qualitative'),('indicator',0,468,477,'en',0,'Qualitative'),('indicator',0,469,478,'en',0,'Qualitative'),('indicator',0,470,479,'en',0,'Quantitative'),('indicator',0,471,480,'en',0,'Quantitative'),('indicator',0,472,481,'en',0,'Quantitative'),('indicator',0,473,482,'en',0,'Quantitative'),('indicator',0,474,483,'en',0,'Qualitative'),('indicator',0,475,484,'en',0,'Quantitative/Qualitative'),('indicator',0,476,485,'en',0,'Quantitative'),('indicator',0,477,486,'en',0,'Quantitative/Qualitative'),('indicator',0,478,487,'en',0,'Qualitative'),('indicator',0,479,488,'en',0,'Quantitative/Qualitative'),('indicator',0,480,489,'en',0,'Quantitative'),('indicator',0,481,490,'en',0,'Quantitative'),('indicator',0,482,491,'en',0,'Quantitative'),('indicator',0,483,492,'en',0,'Quantitative'),('indicator',0,484,493,'en',0,'Quantitative'),('indicator',0,485,494,'en',0,'Qualitative'),('indicator',0,486,495,'en',0,'Quantitative'),('indicator',0,487,496,'en',0,'Quantitative'),('indicator',0,488,497,'en',0,'Quantitative'),('indicator',0,489,498,'en',0,'Qualitative'),('indicator',0,490,499,'en',0,'Quantitative'),('indicator',0,491,500,'en',0,'Qualitative'),('indicator',0,492,501,'en',0,'Quantitative'),('indicator',0,493,502,'en',0,'Quantitative/Qualitative'),('indicator',0,494,503,'en',0,'Quantitative'),('indicator',0,495,504,'en',0,'Quantitative/Qualitative'),('indicator',0,496,505,'en',0,'Quantitative'),('indicator',0,497,506,'en',0,'Qualitative'),('indicator',0,498,507,'en',0,'Qualitative'),('indicator',0,499,508,'en',0,'Quantitative'),('indicator',0,500,509,'en',0,'Qualitative'),('indicator',0,501,510,'en',0,'Quantitative'),('indicator',0,502,511,'en',0,'Quantitative'),('indicator',0,503,512,'en',0,'Quantitative/Qualitative'),('indicator',0,504,513,'en',0,'Qualitative'),('indicator',0,505,514,'en',0,'Qualitative'),('indicator',0,506,515,'en',0,'Quantitative'),('indicator',0,507,516,'en',0,'Quantitative'),('indicator',0,508,517,'en',0,'Quantitative'),('indicator',0,509,518,'en',0,'Quantitative'),('indicator',0,510,519,'en',0,'Qualitative'),('indicator',0,512,521,'en',0,'Qualitative'),('indicator',0,547,557,'en',0,'Qualitative'),('indicator',0,548,558,'en',0,'Qualitative'),('indicator',0,549,559,'en',0,'Quantitative'),('indicator',0,550,560,'en',0,'Quantitative'),('indicator',0,551,561,'en',0,'Quantitative'),('indicator',0,552,562,'en',0,'Quantitative'),('indicator',0,553,563,'en',0,'Quantitative'),('indicator',0,554,564,'en',0,'Quantitative'),('indicator',0,585,612,'en',0,'Quantitative');

--
-- Table structure for table `node__field_description`
--

CREATE TABLE `node__field_description` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_description_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_description.';

--
-- Dumping data for table `node__field_description`
--



--
-- Table structure for table `node__field_dimension`
--

CREATE TABLE `node__field_dimension` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_dimension_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_dimension_target_id` (`field_dimension_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_dimension.';

--
-- Dumping data for table `node__field_dimension`
--

INSERT INTO `node__field_dimension` VALUES ('impact_analysis',0,532,542,'en',0,10),('impact_analysis',0,533,543,'en',0,10),('impact_analysis',0,559,577,'en',0,10),('impact_analysis',0,560,578,'en',0,11),('impact_analysis',0,561,579,'en',0,13),('impact_analysis',0,562,580,'en',0,11),('impact_analysis',0,563,581,'en',0,14),('impact_analysis',0,565,583,'en',0,10),('impact_analysis',0,566,584,'en',0,13),('impact_analysis',0,567,585,'en',0,48),('impact_analysis',0,568,586,'en',0,11),('impact_analysis',0,569,587,'en',0,14),('impact_analysis',0,574,601,'en',0,13),('impact_analysis',0,575,602,'en',0,11),('impact_analysis',0,576,603,'en',0,10),('impact_analysis',0,577,604,'en',0,14),('impact_analysis',0,578,605,'en',0,11),('impact_analysis',0,579,606,'en',0,48),('impact_analysis',0,580,607,'en',0,11),('impact_analysis',0,581,608,'en',0,11),('impact_analysis',0,582,609,'en',0,14),('impact_analysis',0,583,610,'en',0,11),('impact_analysis',0,584,611,'en',0,11),('impact_analysis',0,586,613,'en',0,14),('impact_analysis',0,587,614,'en',0,14),('impact_analysis',0,588,615,'en',0,14),('impact_analysis',0,591,620,'en',0,14);

--
-- Table structure for table `node__field_example`
--

CREATE TABLE `node__field_example` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_example_value` longtext NOT NULL,
  `field_example_format` varchar(255) CHARACTER SET ascii DEFAULT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_example_format` (`field_example_format`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_example.';

--
-- Dumping data for table `node__field_example`
--

INSERT INTO `node__field_example` VALUES ('indicator',0,399,408,'en',0,'<img alt=\"Extract from Sanofi CSR report 2011 (p. 463).\" data-align=\"center\" data-caption=\"Extract from Sanofi CSR report 2011 (p. 463).\" data-entity-type=\"file\" data-entity-uuid=\"39d57e0c-e30a-4e96-857f-fab6ea779bce\" src=\"/sites/default/files/inline-images/1.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/publications/33109_CSR_reporting_2011.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/publications/33109_CSR_reporting_2011.pdf</a></p>\r\n','basic_html'),('indicator',0,400,409,'en',0,'<img alt=\"Extract from McKinsey &amp; Company 2012 (p. 4).\" data-align=\"center\" data-caption=\"Extract from McKinsey &amp;amp; Company 2012 (p. 4).\" data-entity-type=\"file\" data-entity-uuid=\"4ec10ea9-ad28-4540-8bf5-514ea6c16a7b\" src=\"/sites/default/files/inline-images/2_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.mckinsey.com/~/media/McKinsey/dotcom/client_service/BTO/PDF/MOBT_27_Delivering_large-scale_IT_projects_on_time_budget_and_value.ashx\">https://www.mckinsey.com/~/media/McKinsey/dotcom/client_service/BTO/PDF/MOBT_27_Delivering_large-scale_IT_projects_on_time_budget_and_value.ashx</a></p>\r\n','basic_html'),('indicator',0,401,410,'en',0,'<img alt=\"Extract from Bayer Annual Report 2017 (p. 105).\" data-align=\"center\" data-caption=\"Extract from Bayer Annual Report 2017 (p. 105).\" data-entity-type=\"file\" data-entity-uuid=\"98907d9d-0d17-4608-b565-edb3d0259b0b\" src=\"/sites/default/files/inline-images/3.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.annualreport2017.bayer.com/downloads.html\">https://www.annualreport2017.bayer.com/downloads.html</a></p>\r\n','basic_html'),('indicator',0,402,411,'en',0,'<img alt=\"Extract from Novartis Corporate Responsibility Report 2017 (p. 15).\" data-align=\"center\" data-caption=\"Extract from Novartis Corporate Responsibility Report 2017 (p. 15).\" data-entity-type=\"file\" data-entity-uuid=\"5728fde1-2cbc-4a83-bb07-23adb83b4596\" src=\"/sites/default/files/inline-images/15_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.novartis.com/sites/www.novartis.com/files/novartis-cr-performance-report-2017.pdf\">https://www.novartis.com/sites/www.novartis.com/files/novartis-cr-performance-report-2017.pdf</a></p>\r\n','basic_html'),('indicator',0,405,414,'en',0,'<img alt=\"Extract from Rovi Annual Report 2017 (p .9)\" data-align=\"center\" data-caption=\"Rovi Annual Report 2017 (p .9)\" data-entity-type=\"file\" data-entity-uuid=\"1ae2cb12-cba8-4fa2-89b9-891ce9ffc127\" src=\"/sites/default/files/inline-images/7.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.rovi.es/sites/default/files/MEMORIA_ROVI_2017_EN_%2814-05-2018%29-INTERACTIVE_0.pdf\">https://www.rovi.es/sites/default/files/MEMORIA_ROVI_2017_EN_%2814-05-2018%29-INTERACTIVE_0.pdf</a></p>\r\n','basic_html'),('indicator',0,406,415,'en',0,'<p>For the ROI specific for health research:</p>\r\n<img alt=\"Extract from KPMG, Economic Impact of Medical Research in Australia (2018) (p. 42).\" data-align=\"center\" data-caption=\"Extract from KPMG, Economic Impact of Medical Research in Australia (2018) (p. 42).\" data-entity-type=\"file\" data-entity-uuid=\"f03d1ecc-b135-4533-85d5-7b2a08e8048e\" src=\"/sites/default/files/inline-images/8.1.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://aamri.org.au/wp-content/uploads/2018/10/Economic-Impact-of-Medical-Research-exec-summary.pdf\">https://aamri.org.au/wp-content/uploads/2018/10/Economic-Impact-of-Medical-Research-exec-summary.pdf</a></p>\r\n\r\n<p>For the general ROI (also named as ROCE):</p>\r\n<img alt=\"Extract from Bayer Annual report 2018 (p. 103).\" data-align=\"center\" data-caption=\"Extract from Bayer Annual Report 2018 (p. 103).\" data-entity-type=\"file\" data-entity-uuid=\"554d37be-7b83-4c53-a71f-1a7db6ef04a3\" src=\"/sites/default/files/inline-images/8.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.bayer.com/en/bayer-annual-report-2018.pdfx\">https://www.bayer.com/en/bayer-annual-report-2018.pdfx</a></p>\r\n','basic_html'),('indicator',0,409,418,'en',0,'<img alt=\"Extract from &quot;Exceptional returns: the value of investing in health R&amp;D in Australia II&quot; (pp. 34).\" data-align=\"center\" data-caption=\"Extract from &quot;Exceptional returns: the value of investing in health R&amp;amp;D in Australia II&quot; (pp. 34).\" data-entity-type=\"file\" data-entity-uuid=\"3f76c2ea-55f1-4ff8-9048-3204b8445794\" src=\"/sites/default/files/inline-images/11.1_0.png\" /><img alt=\"Extract from &quot;Exceptional returns: the value of investing in health R&amp;D in Australia II&quot; (pp. 35).\" data-align=\"center\" data-caption=\"Extract from &quot;Exceptional returns: the value of investing in health R&amp;amp;D in Australia II&quot; (pp. 35).\" data-entity-type=\"file\" data-entity-uuid=\"0e94fb97-2d93-4d42-a1ba-7cbcad37af8c\" src=\"/sites/default/files/inline-images/11.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://asmr.org.au/wp-content/uploads/library/ExceptII08.pdf\">https://asmr.org.au/wp-content/uploads/library/ExceptII08.pdf</a></p>\r\n','basic_html'),('indicator',0,410,419,'en',0,'<img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 33).\" data-align=\"center\" data-caption=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 33).\" data-entity-type=\"file\" data-entity-uuid=\"629742d5-99a9-4967-9c49-e7e2846ff73f\" src=\"/sites/default/files/inline-images/12.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,411,420,'en',0,'<img alt=\"Extract from Australia and New Zealand CRC for Spatial Information Annual Report 2016-17 (p. 9).\" data-align=\"center\" data-caption=\"Extract from Australia and New Zealand CRC for Spatial Information Annual Report 2016-17 (p. 9).\" data-entity-type=\"file\" data-entity-uuid=\"50803b34-38ac-4718-b03e-a94cfe778b8b\" src=\"/sites/default/files/inline-images/13.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.crcsi.com.au/assets/Resources/CRCSI-AnnualReport2017-web.pdf\">https://www.crcsi.com.au/assets/Resources/CRCSI-AnnualReport2017-web.pdf</a></p>\r\n','basic_html'),('indicator',0,412,421,'en',0,'<img alt=\"Extract from Sanofi Integrated Report 2018 (p. 6).\" data-align=\"center\" data-caption=\"Extract from Sanofi Integrated Report 2018 (p. 6).\" data-entity-type=\"file\" data-entity-uuid=\"ae6e372a-55ec-459f-807c-73184d48b56c\" src=\"/sites/default/files/inline-images/14_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/about-us/Sanofi-RI2018-EN-PDF-e-accessible_02.pdf?la=en\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/about-us/Sanofi-RI2018-EN-PDF-e-accessible_02.pdf?la=en</a></p>\r\n','basic_html'),('indicator',0,417,426,'en',0,'<img alt=\"Extract from PhRMA web page.\" data-align=\"center\" data-caption=\"Extract from PhRMA web page.\" data-entity-type=\"file\" data-entity-uuid=\"e4ea07e1-1de1-4fa6-9760-884153944c35\" src=\"/sites/default/files/inline-images/19.png\" />\r\n<p>Available at:<a href=\"https://www.phrma.org/media/industry-economic-impact\">https://www.phrma.org/media/industry-economic-impact</a></p>\r\n','basic_html'),('indicator',0,418,427,'en',0,'<img alt=\"Extract from Bayer Annual Report 2018 (p. 53).\" data-align=\"center\" data-caption=\"Extract from Bayer Annual Report 2018 (p. 53).\" data-entity-type=\"file\" data-entity-uuid=\"34dad937-fd41-42d7-822c-5778b845bd30\" src=\"/sites/default/files/inline-images/20.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.bayer.com/en/bayer-annual-report-2018.pdfx\">https://www.bayer.com/en/bayer-annual-report-2018.pdfx</a></p>\r\n','basic_html'),('indicator',0,419,428,'en',0,'<img alt=\"Extract from Frahm et al. (2018) (p. 5).\" data-align=\"center\" data-caption=\"Extract from Frahm et al. (2018) (p. 5).\" data-entity-type=\"file\" data-entity-uuid=\"1f5f82e9-9894-4d9d-ab54-c25c9fb564a0\" src=\"/sites/default/files/inline-images/21.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.nature.com/articles/s41598-019-40283-5\">https://www.nature.com/articles/s41598-019-40283-5</a></p>\r\n','basic_html'),('indicator',0,420,429,'en',0,'<img alt=\"Table 3 in Thiruthopu et al. (2014). Drug utilization pattern in South Indian pediatric population: A prospective study. Perspectives in clinical research, 5(4).\" data-align=\"center\" data-caption=\"Table 3 in Thiruthopu et al. (2014). Drug utilization pattern in South Indian pediatric population: A prospective study. Perspectives in clinical research, 5(4).\" data-entity-type=\"file\" data-entity-uuid=\"95d6565f-3bcf-4ef1-a494-c92c8fe33ff0\" src=\"/sites/default/files/inline-images/22.png\" />\r\n<p>&nbsp;</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170536/\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170536/</a></p>\r\n','basic_html'),('indicator',0,423,432,'en',0,'<p>See the National Comprehensive Cancer Control Program (NCCCP), Colorectal Cancer Screening Rates.&nbsp;For instance:</p>\r\n<img alt=\"Extract from Comprehensive Cancer Control Program (NCCCP).\" data-align=\"center\" data-caption=\"Extract from Comprehensive Cancer Control Program (NCCCP)\" data-entity-type=\"file\" data-entity-uuid=\"34e7bd97-3965-42f1-8d14-f24f7e1d83ef\" src=\"/sites/default/files/inline-images/25.png\" />\r\n<p>Available at&nbsp;<a href=\"https://www.cdc.gov/cancer/ncccp/screening-rates/ \">https://www.cdc.gov/cancer/ncccp/screening-rates/ </a></p>\r\n','basic_html'),('indicator',0,424,433,'en',0,'<img alt=\"Extract from Finland: Healthcare system and eHealth strategy (p. 11)\" data-align=\"center\" data-caption=\"Extract from Finland: Healthcare system and eHealth strategy (p. 11)\" data-entity-type=\"file\" data-entity-uuid=\"f03bc1a7-97c3-447e-a884-511f3cc1b098\" src=\"/sites/default/files/inline-images/26.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://ec.europa.eu/health/sites/health/files/ehealth/docs/ev_20150512_co53_en.pdf\">https://ec.europa.eu/health/sites/health/files/ehealth/docs/ev_20150512_co53_en.pdf</a></p>\r\n','basic_html'),('indicator',0,425,434,'en',0,'<img alt=\"Extract from Tracking Universal Health Coverage - WHO (p. 21).\" data-align=\"center\" data-caption=\"Extract from Tracking Universal Health Coverage - WHO (p. 21).\" data-entity-type=\"file\" data-entity-uuid=\"f9c274f5-a6ec-494e-afab-3ea6ce26b4ca\" src=\"/sites/default/files/inline-images/27.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://apps.who.int/iris/bitstream/handle/10665/174536/9789241564977_eng.pdf;jsessionid=FB2C13C6BAE47431FF604534502C84C0?sequence=1\">https://apps.who.int/iris/bitstream/handle/10665/174536/9789241564977_eng.pdf;jsessionid=FB2C13C6BAE47431FF604534502C84C0?sequence=1</a></p>\r\n','basic_html'),('indicator',0,426,435,'en',0,'<p>Example on how GSK offers information on access to medicine:</p>\r\n<img alt=\"​​Extract from GSK ESG Summary 2018 (pp. 2-3).\" data-align=\"center\" data-caption=\"​​Extract from GSK ESG Performance Summary 2018 (p. 2).\" data-entity-type=\"file\" data-entity-uuid=\"d5ee8902-7547-4366-8676-8101d168bc0b\" src=\"/sites/default/files/inline-images/28.1_0.png\" /><img alt=\"​​Extract from GSK ESG Summary 2018 (pp. 2-3).\" data-align=\"center\" data-caption=\"​​Extract from GSK ESG Performance Summary 2018 (p. 3).\" data-entity-type=\"file\" data-entity-uuid=\"99199ed9-09e8-4142-9472-c0536e92947f\" src=\"/sites/default/files/inline-images/28.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.gsk.com/media/5308/esg-performance-summary-2018.pdf\">https://www.gsk.com/media/5308/esg-performance-summary-2018.pdf</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,427,436,'en',0,'<img alt=\"Extract from Inequalities in access to healthcare - A study of national policies (p. 37).\" data-align=\"center\" data-caption=\"Extract from &quot;Inequalities in access to healthcare - A study of national policies&quot; (p. 37).\" data-entity-type=\"file\" data-entity-uuid=\"ebdab83f-7380-4dab-b24d-7df48e8cca5f\" src=\"/sites/default/files/inline-images/29.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://ec.europa.eu/social/main.jsp?catId=738&amp;langId=en&amp;pubId=8152&amp;furtherPubs=yes\">https://ec.europa.eu/social/main.jsp?catId=738&amp;langId=en&amp;pubId=8152&amp;furtherPubs=yes</a></p>\r\n','basic_html'),('indicator',0,429,438,'en',0,'<p>The report \"Understanding the development needs of the primary care and community health workforces with regard to sexual health in NHSScotland to enable the successful implementation of ‘The Sexual Health and Blood Borne Virus&nbsp;Framework 2011-2015’: a scoping study\". Report for NHS Scotland&nbsp;(pp. 19-29 show examples of existing training).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://pdfs.semanticscholar.org/f2c1/8ab9a6d6b7a3c49d92bffa39c192ca36cd5e.pdf\">https://pdfs.semanticscholar.org/f2c1/8ab9a6d6b7a3c49d92bffa39c192ca36cd5e.pdf</a></p>\r\n','basic_html'),('indicator',0,430,439,'en',0,'<img alt=\"Extract from Vall D\'Hebron Strategic Plan 2011-15 (p. 34)\" data-align=\"center\" data-caption=\"Extract from Vall D\'Hebron Strategic Plan 2011-15 (p. 34)\" data-entity-type=\"file\" data-entity-uuid=\"406670e0-0440-4d47-bdf3-f65053fcd325\" src=\"/sites/default/files/inline-images/32.png\" />\r\n<p>Available at:&nbsp;<a href=\"http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf\">http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf</a></p>\r\n','basic_html'),('indicator',0,432,441,'en',0,'<img alt=\"Extract from Sigakis et al. (2013) (p. 528).\" data-align=\"center\" data-caption=\"Extract from Sigakis et al. (2013) (p. 528).\" data-entity-type=\"file\" data-entity-uuid=\"c9334010-a380-4d31-bc05-f156d15f3212\" src=\"/sites/default/files/inline-images/34.1.png\" /><img alt=\"Extract from Sigakis et al. (2013) (p. 528).\" data-align=\"center\" data-caption=\"Extract from Sigakis et al. (2013) (p. 528).\" data-entity-type=\"file\" data-entity-uuid=\"7b118928-5187-47d7-b750-3367b7c83628\" src=\"/sites/default/files/inline-images/34.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"http://anesthesiology.pubs.asahq.org/article.aspx?doi=10.1097/ALN.0b013e31829ce6e6\">http://anesthesiology.pubs.asahq.org/article.aspx?doi=10.1097/ALN.0b013e31829ce6e6</a></p>\r\n','basic_html'),('indicator',0,433,442,'en',0,'<img alt=\"Extract from &quot;Khanna et al. (2019) (p. 8).\" data-align=\"center\" data-caption=\"Extract from &quot;Khanna et al. (2019) (p. 8).\" data-entity-type=\"file\" data-entity-uuid=\"cb2ad6c4-cf78-4f6b-85fe-d6f9cabbccf6\" src=\"/sites/default/files/inline-images/35.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.nature.com/articles/s41598-019-41383-y\">https://www.nature.com/articles/s41598-019-41383-y</a></p>\r\n','basic_html'),('indicator',0,435,444,'en',0,'<p>NCCN Guidelines for Patients&nbsp;develops research activities in supporting patients through guidelines and tools.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.nccn.org/patients/guidelines/cancers.aspx\">https://www.nccn.org/patients/guidelines/cancers.aspx</a></p>\r\n','basic_html'),('indicator',0,436,445,'en',0,'<img alt=\"Extract from Prieto &amp; Sacristán (2013) (p. 7).\" data-align=\"center\" data-caption=\"Extract from Prieto &amp;amp; Sacristán (2013) (p. 7).\" data-entity-type=\"file\" data-entity-uuid=\"7fea882e-bc63-427d-a6a9-3b0ebc6aa4cc\" src=\"/sites/default/files/inline-images/38.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-1-80\">https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-1-80</a></p>\r\n','basic_html'),('indicator',0,437,446,'en',0,'<p>Example for percentage of&nbsp;deaths due to multiple sclerosis:</p>\r\n<img alt=\"Figure 2 of Scalfari, A., Knappertz, V., Cutter, G., Goodin, D. S., Ashton, R., &amp; Ebers, G. C. (2013). Mortality in patients with multiple sclerosis. Neurology, 81(2), 184-192. (p. 188). \" data-align=\"center\" data-caption=\"Figure 2 of Scalfari, A., Knappertz, V., Cutter, G., Goodin, D. S., Ashton, R., &amp;amp; Ebers, G. C. (2013). Mortality in patients with multiple sclerosis. Neurology, 81(2), 184-192. (p. 188).&amp;nbsp;\" data-entity-type=\"file\" data-entity-uuid=\"0af90ae2-1c21-4356-b94e-faf661bc3dc0\" src=\"/sites/default/files/inline-images/39.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://n.neurology.org/content/81/2/184.short\">https://n.neurology.org/content/81/2/184.short</a></p>\r\n','basic_html'),('indicator',0,440,449,'en',0,'<img alt=\"Extract from Ottawa Public Health Strategic Direction A Background Document 2016 (p. 15).\" data-align=\"center\" data-caption=\"Extract from Ottawa Public Health Strategic Direction A Background Document 2016 (p. 15).\" data-entity-type=\"file\" data-entity-uuid=\"e98f459c-f340-41ff-a370-e841cf9dc37a\" src=\"/sites/default/files/inline-images/42.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ottawapublichealth.ca/en/reports-research-and-statistics/resources/Documents/fostering_mental_health_in_our_community_external_acc_final_en.pdf\">https://www.ottawapublichealth.ca/en/reports-research-and-statistics/resources/Documents/fostering_mental_health_in_our_community_external_acc_final_en.pdf</a></p>\r\n','basic_html'),('indicator',0,441,450,'en',0,'<img alt=\"Extract from Sanofi CSR report 2013 (p. 30).\" data-align=\"center\" data-caption=\"Extract from Sanofi CSR report 2013 (p. 30).\" data-entity-type=\"file\" data-entity-uuid=\"eabeeae2-af6c-4f5e-9cfc-3f85dd37ea48\" src=\"/sites/default/files/inline-images/43.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf</a></p>\r\n','basic_html'),('indicator',0,442,451,'en',0,'<p>For the classified list of articles, see&nbsp;Cancer Research UK Manchester Institute Scientific Report 2018 (p. 62-69).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.cruk.manchester.ac.uk/Portals/18/Documents/Annual%20Report/CRUK-Manchester-Annual-Report-2018-web.pdf\">https://www.cruk.manchester.ac.uk/Portals/18/Documents/Annual%20Report/CRUK-Manchester-Annual-Report-2018-web.pdf</a></p>\r\n\r\n<p><br />\r\nFor the number of articles and percentage of articles in high-impact journals, see&nbsp;University of Limerick Health Research Institute Annual Report 2017:</p>\r\n<img alt=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 20).\" data-align=\"center\" data-caption=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 20).\" data-entity-type=\"file\" data-entity-uuid=\"f85c0980-d4de-4d58-871f-12cc32459bf4\" src=\"/sites/default/files/inline-images/44.png\" />\r\n<p>Available at:<a href=\"https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf\">https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,443,452,'en',0,'<p>For the number of international collaborating organizations:</p>\r\n<img alt=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 21)\" data-align=\"center\" data-caption=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 21)\" data-entity-type=\"file\" data-entity-uuid=\"7233431e-0a9e-459e-97cd-56f8d8b30b86\" src=\"/sites/default/files/inline-images/45.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf\">https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf</a></p>\r\n','basic_html'),('indicator',0,444,453,'en',0,'<p>For the share of OA publications in Europe:</p>\r\n<img alt=\"Extract from MoRRI, The evolution of Responsible Research and Innovation in Europe: The MoRRI indicators report (p. 64).\" data-align=\"center\" data-caption=\"Extract from MoRRI, The evolution of Responsible Research and Innovation in Europe: The MoRRI indicators report (p. 64).\" data-entity-type=\"file\" data-entity-uuid=\"a181d7d8-2b33-402c-8f78-31fc3a3c5719\" src=\"/sites/default/files/inline-images/46_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.rri-tools.eu/-/the-evolution-of-responsible-research-and-innovation-in-europe-the-morri-indicators-report\">https://www.rri-tools.eu/-/the-evolution-of-responsible-research-and-innovation-in-europe-the-morri-indicators-report</a></p>\r\n','basic_html'),('indicator',0,446,455,'en',0,'<img alt=\"Example on how to obtain number of citations using Google Scholar.\" data-align=\"center\" data-caption=\"Example on how to obtain number of citations using Google Scholar.\" data-entity-type=\"file\" data-entity-uuid=\"7868384e-2859-4bb2-91ca-dcd8e04c2dc7\" src=\"/sites/default/files/inline-images/48.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://scholar.google.com\">https://scholar.google.com</a></p>\r\n','basic_html'),('indicator',0,449,458,'en',0,'<p>See the Max-Planck-Gesellschaft newsroom:&nbsp;<a href=\" https://www.mpg.de/research\"> https://www.mpg.de/research</a></p>\r\n\r\n<p>It indicates news, events, articles, podcasts, and videos by categories as well as latest science magazines.</p>\r\n','basic_html'),('indicator',0,454,463,'en',0,'<p>For a description of the structure and functions of ethical committees&nbsp;see:</p>\r\n\r\n<p>1) \"Research ethics committees\" (World Health Organization, pp. 11-15).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.who.int/ethics/Ethics_basic_concepts_ENG.pdf\">https://www.who.int/ethics/Ethics_basic_concepts_ENG.pdf</a></p>\r\n\r\n<p>2) \"Guide for Research Ethics Committee Members\" (Council of Europe, pp. 15-26).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.coe.int/t/dg3/healthbioethic/activities/02_biomedical_research_en/Guide/Guide_EN.pdf\">https://www.coe.int/t/dg3/healthbioethic/activities/02_biomedical_research_en/Guide/Guide_EN.pdf</a></p>\r\n','basic_html'),('indicator',0,457,466,'en',0,'<img alt=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 24).\" data-align=\"center\" data-caption=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 24).\" data-entity-type=\"file\" data-entity-uuid=\"0eb29c5b-7840-45e0-b250-17eba0aa37a5\" src=\"/sites/default/files/inline-images/60.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf\">https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf</a></p>\r\n','basic_html'),('indicator',0,458,467,'en',0,'<p>See ERA-Net for Research Programmes on Rare Diseases; European Research Projects on External Insults to the Nervous System:</p>\r\n\r\n<p><a href=\"http://www.erare.eu/joint-call/1st-joint-call-european-joint-programme-rare-diseases-jtc-2019\">http://www.erare.eu/joint-call/1st-joint-call-european-joint-programme-rare-diseases-jtc-2019</a></p>\r\n','basic_html'),('indicator',0,459,468,'en',0,'<img alt=\"Extract from Public Health Wales Research Strategy 2015-2018 (p. 4)\" data-align=\"center\" data-caption=\"Extract from Public Health Wales Research Strategy 2015-2018 (p. 4)\" data-entity-type=\"file\" data-entity-uuid=\"08a3c9ea-7f1c-4c7b-89d1-123b61a90ff2\" src=\"/sites/default/files/inline-images/62.png\" />\r\n<p>Available at: &nbsp;<a href=\"https://research.publichealthnetwork.cymru/files/7014/8708/7189/PHW_Research_Strategy_report.pdf\">https://research.publichealthnetwork.cymru/files/7014/8708/7189/PHW_Research_Strategy_report.pdf</a></p>\r\n','basic_html'),('indicator',0,460,469,'en',0,'<img alt=\"Extract from FIND Annual Report 2013 (p. 5).\" data-align=\"center\" data-caption=\"Extract from FIND Annual Report 2013 (p. 5).\" data-entity-type=\"file\" data-entity-uuid=\"bd7d3594-fdbd-4003-877d-f59e23d3d842\" src=\"/sites/default/files/inline-images/63.1.png\" /><img alt=\"Extract from FIND Annual Report 2013 (p. 10).\" data-align=\"center\" data-caption=\"Extract from FIND Annual Report 2013 (p. 10).\" data-entity-type=\"file\" data-entity-uuid=\"64689d9b-566d-4dfa-a11f-9551645c1c59\" src=\"/sites/default/files/inline-images/63.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.finddx.org/wp-content/uploads/2016/02/Annual-report_2013.pdf\">https://www.finddx.org/wp-content/uploads/2016/02/Annual-report_2013.pdf</a></p>\r\n','basic_html'),('indicator',0,463,472,'en',0,'<p>Breast International Group - Annual Report 2016, (pp. 3-7).<br />\r\nAvailable at:&nbsp;<a href=\"https://research.bigagainstbreastcancer.org/sites/default/files/big_ar_2016_-_final_final_0.pdf\">https://research.bigagainstbreastcancer.org/sites/default/files/big_ar_2016_-_final_final_0.pdf</a></p>\r\n','basic_html'),('indicator',0,466,475,'en',0,'<p>&nbsp;</p>\r\n<img alt=\"Extract from PHW Research Strategy 2015-2018 (p. 11)\" data-align=\"center\" data-caption=\"Extract from Public Health Wales Research Strategy 2015-2018 (p. 11)\" data-entity-type=\"file\" data-entity-uuid=\"961f5be7-ef60-4af4-beda-2ba8232f5af3\" src=\"/sites/default/files/inline-images/69.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://research.publichealthnetwork.cymru/files/7014/8708/7189/PHW_Research_Strategy_report.pdf\">https://research.publichealthnetwork.cymru/files/7014/8708/7189/PHW_Research_Strategy_report.pdf</a></p>\r\n','basic_html'),('indicator',0,472,481,'en',0,'<p>For the number of patens owned and awarded:</p>\r\n<img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 32).\" data-align=\"center\" data-caption=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 32).\" data-entity-type=\"file\" data-entity-uuid=\"44c09851-9ad9-4d1c-b352-05b9cac9b0d5\" src=\"/sites/default/files/inline-images/75.1.png\" /><img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 33).\" data-align=\"center\" data-caption=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 33).\" data-entity-type=\"file\" data-entity-uuid=\"03fbf964-f064-4b33-9370-f47dae0d056b\" src=\"/sites/default/files/inline-images/75.2.png\" />\r\n<p>&nbsp;</p>\r\n\r\n<p>For the classification of patens based on their expiration date and country:</p>\r\n<img alt=\"Extract from Bayer Annual Report 2018 (p. 40).\" data-align=\"center\" data-caption=\"Extract from Bayer Annual Report 2018 (p. 40).\" data-entity-type=\"file\" data-entity-uuid=\"d35b36ac-62a5-4643-8dba-9291d86dd73e\" src=\"/sites/default/files/inline-images/75.3.png\" />\r\n<p>&nbsp;</p>\r\n\r\n<p>For the classification of patents base don whether they are provisonally filled or awarded:</p>\r\n<img alt=\"Extract from Australia\'s Medical Research Institute Snapshot 2018 (p. 20)\" data-align=\"center\" data-caption=\"Extract from Australia\'s Medical Research Institute Snapshot 2018 (p. 20)\" data-entity-type=\"file\" data-entity-uuid=\"849a3126-b821-4b7a-af20-57cfed40a87c\" src=\"/sites/default/files/inline-images/75.4.png\" />\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,473,482,'en',0,'<p>List of projects that are in Phase III clinical trials in Novartis:</p>\r\n<img alt=\"Extract from Novartis Annual Report 2018 (p. 65).\" data-align=\"center\" data-caption=\"Extract from Novartis Annual Report 2018 (p. 65).\" data-entity-type=\"file\" data-entity-uuid=\"032c4c69-5334-4f70-8493-20490c1b2904\" src=\"/sites/default/files/inline-images/76.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2018-en.pdf\">https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2018-en.pdf</a></p>\r\n','basic_html'),('indicator',0,474,483,'en',0,'<p>European Medicines Agency Stakeholder Engagement report 2017 (pp. 5-7).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf\">https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf</a></p>\r\n','basic_html'),('indicator',0,475,484,'en',0,'<p>For the full list of products and drugs, see&nbsp;GSK Annual Report 2018 (p. 235-240).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.gsk.com/media/5349/annual-report-2018.pdf\">https://www.gsk.com/media/5349/annual-report-2018.pdf</a></p>\r\n','basic_html'),('indicator',0,477,486,'en',0,'<p>Association of Australian Medical Research Institutes Snapshot 2018 (p. 20)</p>\r\n<img alt=\"Extract from Australia\'s Medical Research Institute Snapshot 2018 (p. 20).\" data-align=\"center\" data-caption=\"Extract from Australia\'s Medical Research Institute Snapshot 2018 (p. 20).\" data-entity-type=\"file\" data-entity-uuid=\"8f25ba45-d19f-4006-b567-2c987533926b\" src=\"/sites/default/files/inline-images/81.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://aamri.org.au/wp-content/uploads/2018/09/2018_AAMRI_Members_Snapshot_Report-final.pdf\">https://aamri.org.au/wp-content/uploads/2018/09/2018_AAMRI_Members_Snapshot_Report-final.pdf</a></p>\r\n','basic_html'),('indicator',0,480,489,'en',0,'<p><img alt=\"Source: IMI Innovative Medicines Initiative Annual Report 2017\" data-entity-type=\"file\" data-entity-uuid=\"a9875d79-b458-41d9-bcc3-005a28da0b7b\" src=\"/sites/default/files/inline-images/84.png\" /></p>\r\n\r\n<p>Extract from IMI Innovative Medicines Initiative Annual Report 2017 (p. 166)</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/Governance/Governing-Board/IMI2-GB-DEC-2018-17_Decision%20AAR%202017-GB%20Assessment_signed%2026JUN.pdf\">https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/Governance/Governing-Board/IMI2-GB-DEC-2018-17_Decision%20AAR%202017-GB%20Assessment_signed%2026JUN.pdf</a></p>\r\n','basic_html'),('indicator',0,481,490,'en',0,'<img alt=\"Extract from Era-net Neuron impact report (pp. 17).\" data-align=\"center\" data-caption=\"Extract from Era-net Neuron impact report (pp. 17)\" data-entity-type=\"file\" data-entity-uuid=\"bc38cb7d-1dc9-48f6-bdf9-fab3c2ad8af9\" src=\"/sites/default/files/inline-images/85.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.neuron-eranet.eu/_media/JTC2011_Impact-Report_final.pdf\">https://www.neuron-eranet.eu/_media/JTC2011_Impact-Report_final.pdf</a></p>\r\n','basic_html'),('indicator',0,483,492,'en',0,'<p>For a list of awards (not the total number)&nbsp;see Fraunhofer Institutes Annual Report 2017 (pp. 101-103).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,484,493,'en',0,'<img alt=\"Extract from Vall d\'Hebron Institute of Research Strategic Plan 2011-15 &quot;Five years committed to people\'s health&quot; (p. 34).\" data-align=\"center\" data-caption=\"Extract from Vall d\'Hebron Institute of Research Strategic Plan 2011-15 &quot;Five years committed to people\'s health&quot; (p. 34).\" data-entity-type=\"file\" data-entity-uuid=\"bb50acb8-86cd-47ef-aa23-e6d6fdf29011\" src=\"/sites/default/files/inline-images/88.png\" />\r\n<p>Available at: <a href=\"http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf\">http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf</a>&nbsp;</p>\r\n','basic_html'),('indicator',0,485,494,'en',0,'<p>Fraunhofer Institutes Annual Report 2017 (pp. 104-115).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,486,495,'en',0,'<img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 37).\" data-align=\"center\" data-caption=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 37).\" data-entity-type=\"file\" data-entity-uuid=\"10a191f0-b382-4266-98b9-963228564589\" src=\"/sites/default/files/inline-images/90.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,487,496,'en',0,'<img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 37).\" data-align=\"center\" data-entity-type=\"file\" data-entity-uuid=\"611288c1-51ad-49ae-aba5-1b5172b9c461\" src=\"/sites/default/files/inline-images/91.png\" />\r\n<p>Extract from Fraunhofer Institutes Annual Report 2017 (p. 37).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,488,497,'en',0,'<p>U.S. Department of Health &amp; Human Services:</p>\r\n\r\n<p><a href=\"https://report.nih.gov/categorical_spending_project_listing.aspx?FY=2015&amp;ARRA=N&amp;DCat=Multiple%20Sclerosis\">https://report.nih.gov/categorical_spending_project_listing.aspx?FY=2015&amp;ARRA=N&amp;DCat=Multiple%20Sclerosis</a></p>\r\n','basic_html'),('indicator',0,489,498,'en',0,'<p>Vall d\'Hebron Institue of Research Strategic Plan 2011-15, section&nbsp;\"The organizational basis of success\"&nbsp;(pp. 51-57).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf\">http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf</a></p>\r\n','basic_html'),('indicator',0,491,500,'en',0,'<p>Vall d\'Hebron Institue of Research Strategic Plan 2011-15 \"Five years committed to people\'s health\" (pp. 52-55).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf\">http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf</a></p>\r\n','basic_html'),('indicator',0,493,502,'en',0,'<p>See&nbsp;Proctor et al. (2015) (p. 8-10).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://implementationscience.biomedcentral.com/articles/10.1186/s13012-015-0274-5\">https://implementationscience.biomedcentral.com/articles/10.1186/s13012-015-0274-5</a></p>\r\n','basic_html'),('indicator',0,494,503,'en',0,'<img alt=\"Extract from European Medicines Agency - Stakeholder Engagement Report 2017 (p. 21).\" data-align=\"center\" data-caption=\"Extract from European Medicines Agency - Stakeholder Engagement Report 2017 (p. 21).\" data-entity-type=\"file\" data-entity-uuid=\"76d4587d-272f-4b1a-978f-a05b0ef7f24a\" src=\"/sites/default/files/inline-images/98.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf\">https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf</a></p>\r\n\r\n<p><br />\r\nThe example presents different analyses of the individuals and the events related to the different stakeholder engagement activities.</p>\r\n','basic_html'),('indicator',0,495,504,'en',0,'<img alt=\"Extract from European Medicines Agency - Stakeholder Engagement Report 2017 (p. 18).\" data-align=\"center\" data-caption=\"Extract from European Medicines Agency - Stakeholder Engagement Report 2017 (p. 18)\" data-entity-type=\"file\" data-entity-uuid=\"cab507ed-9ea9-4316-bc86-f8415f11165a\" src=\"/sites/default/files/inline-images/99.png\" />\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,497,506,'en',0,'<p>See the \"Corporate Reputation of Pharma in 2018 - the Global Patient Perspective\" (p. 6-8).</p>\r\n\r\n<p>Available <a href=\"https://www.lundbeck.com/upload/global/files/pdf/features/PATIENTVIEW%20PRESS%20RELEASE%20APRIL%202018.pdf\">https://www.lundbeck.com/upload/global/files/pdf/features/PATIENTVIEW%20PRESS%20RELEASE%20APRIL%202018.pdf</a>at:&nbsp;</p>\r\n','basic_html'),('indicator',0,498,507,'en',0,'<img alt=\"Extract from GSK Annual Report 2018 (p. 244).\" data-align=\"center\" data-caption=\"Extract from GSK Annual Report 2018 (p. 244).\" data-entity-type=\"file\" data-entity-uuid=\"d6f8ec55-89a5-4628-a232-187ee9fe45bf\" src=\"/sites/default/files/inline-images/102.png\" />\r\n<p>Available at: <a href=\"https://www.gsk.com/media/5349/annual-report-2018.pdf\">https://www.gsk.com/media/5349/annual-report-2018.pdf</a></p>\r\n\r\n<p>Also, see the \"Code of practices for the pharmaceutical industry 2016\" (see Sections 21 and 22 pp. 32-34).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=11&amp;ved=2ahUKEwj4qoro2YLnAhWP3eAKHSfVBSMQFjAKegQIBhAC&amp;url=http%3A%2F%2Fwww.codigofarmaindustria.org%2Fservlet%2Fsarfi%2Fdocs%2FPRODF117806.pdf&amp;usg=AOvVaw2fmCHiONPxylcGOch_7J9F\">https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=11&amp;ved=2ahUKEwj4qoro2YLnAhWP3eAKHSfVBSMQFjAKegQIBhAC&amp;url=http%3A%2F%2Fwww.codigofarmaindustria.org%2Fservlet%2Fsarfi%2Fdocs%2FPRODF117806.pdf&amp;usg=AOvVaw2fmCHiONPxylcGOch_7J9F</a></p>\r\n','basic_html'),('indicator',0,499,508,'en',0,'<img alt=\"Extract from Sanofi CSR report 2013 (p. 105).\" data-align=\"center\" data-caption=\"Extract from Sanofi CSR report 2013 (p. 105).\" data-entity-type=\"file\" data-entity-uuid=\"712b22a5-70e9-40a3-9f3e-638796bdcb70\" src=\"/sites/default/files/inline-images/103.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf</a></p>\r\n','basic_html'),('indicator',0,500,509,'en',0,'<p>See Sanofi-Fundamental human rights at work available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/download-center/Fundamental-Human-Rights-at-work-2019.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/download-center/Fundamental-Human-Rights-at-work-2019.pdf</a></p>\r\n','basic_html'),('indicator',0,501,510,'en',0,'<img alt=\"Extract from Novartis Corporate Responsibility Report 2017 (p. 47).\" data-align=\"center\" data-caption=\"Extract from Novartis Corporate Responsibility Report 2017 (p. 47).\" data-entity-type=\"file\" data-entity-uuid=\"575188b3-ce4f-44fb-ac45-8f14997729ae\" src=\"/sites/default/files/inline-images/105.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.novartis.com/sites/www.novartis.com/files/novartis-cr-performance-report-2017.pdf\">https://www.novartis.com/sites/www.novartis.com/files/novartis-cr-performance-report-2017.pdf</a></p>\r\n','basic_html'),('indicator',0,502,511,'en',0,'<img alt=\"Extract from Sanofi Turky Sustainability Report 2017 (p. 89)\" data-align=\"center\" data-caption=\"Extract from Sanofi Turky Sustainability Report 2017 (p. 89).\" data-entity-type=\"file\" data-entity-uuid=\"7fac5f8d-2f5d-43d7-ac5e-b293f18cfa5f\" src=\"/sites/default/files/inline-images/106.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/download-center/Sanofi-Turkey-Sustainability-Report-2017.pdf?la=en\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/download-center/Sanofi-Turkey-Sustainability-Report-2017.pdf?la=en</a></p>\r\n','basic_html'),('indicator',0,505,514,'en',0,'<img alt=\"Extract from GSK Annual Report 2018 (p. 11).\" data-align=\"center\" data-caption=\"Extract from GSK Annual Report 2018 (p. 11).\" data-entity-type=\"file\" data-entity-uuid=\"a1ee004e-943b-49c2-8da0-26a7e7e0cb45\" src=\"/sites/default/files/inline-images/109.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.gsk.com/media/5349/annual-report-2018.pdf\">https://www.gsk.com/media/5349/annual-report-2018.pdf</a></p>\r\n','basic_html'),('indicator',0,506,515,'en',0,'<img alt=\"Extract from Sanofi CSR report 2013 (p. 51).\" data-align=\"center\" data-caption=\"Extract from Sanofi CSR report 2013 (p. 51).\" data-entity-type=\"file\" data-entity-uuid=\"a754d9e4-7c3b-4ec5-ac24-eacccc458e45\" src=\"/sites/default/files/inline-images/110.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf</a></p>\r\n','basic_html'),('indicator',0,507,516,'en',0,'<img alt=\"Extract from Takeda Sustainable Value Report 2018 (p. 61).\" data-align=\"center\" data-caption=\"Extract from Takeda Sustainable Value Report 2018 (p. 61).\" data-entity-type=\"file\" data-entity-uuid=\"258cdf5e-1de0-4571-a4ca-bba994dffc09\" src=\"/sites/default/files/inline-images/111.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.takeda.com/siteassets/system/csr/sustainable-value-report/report_2018_en.pdf\">https://www.takeda.com/siteassets/system/csr/sustainable-value-report/report_2018_en.pdf</a></p>\r\n','basic_html'),('indicator',0,508,517,'en',0,'<p>&nbsp;</p>\r\n<img alt=\"Extract from Novartis Health, Safety and Environment (HSE) Data 2018\" data-align=\"center\" data-caption=\"Extract from Novartis Health, Safety and Environment (HSE) Data 2018.\" data-entity-type=\"file\" data-entity-uuid=\"7e9a28a8-70ac-441a-b437-a60cef97c4e9\" src=\"/sites/default/files/inline-images/Captura%20de%20pantalla%202019-12-27%20a%20las%2011.03.19.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.novartis.com/sites/www.novartis.com/files/novartis-hse-data-2018-restated.pdf\">https://www.novartis.com/sites/www.novartis.com/files/novartis-hse-data-2018-restated.pdf</a></p>\r\n','basic_html'),('indicator',0,510,519,'en',0,'<img alt=\"Extract from Ottawa Public Health Strategic Direction A Background Document September 2016 (p. 14).\" data-align=\"center\" data-caption=\"Extract from Ottawa Public Health Strategic Direction A Background Document September 2016 (p. 14).\" data-entity-type=\"file\" data-entity-uuid=\"5e939ed3-789e-4d2e-919c-8bd643116a66\" src=\"/sites/default/files/inline-images/115.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ottawapublichealth.ca/en/reports-research-and-statistics/resources/Documents/fostering_mental_health_in_our_community_external_acc_final_en.pdf\">https://www.ottawapublichealth.ca/en/reports-research-and-statistics/resources/Documents/fostering_mental_health_in_our_community_external_acc_final_en.pdf</a></p>\r\n','basic_html'),('indicator',0,547,557,'en',0,'<img alt=\"Extract from Progressive MS Alliance Report Progress 2019 (p. 5).\" data-align=\"center\" data-caption=\"Extract from Progressive MS Alliance Report Progress 2019 (p. 5).\" data-entity-type=\"file\" data-entity-uuid=\"339df70e-f0f3-40a1-9b90-3fb01a17a177\" src=\"/sites/default/files/inline-images/78_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.progressivemsalliance.org/wp-content/uploads/2019/06/Alliance_Progress_Report_Apr-2019_digital.pdf\">https://www.progressivemsalliance.org/wp-content/uploads/2019/06/Alliance_Progress_Report_Apr-2019_digital.pdf</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,548,558,'en',0,'<p>List of annual sustainability reports of the&nbsp;Fondazione Italiana Sclerosi Multipla&nbsp;(FISM).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.aism.it/il_bilancio_sociale\">https://www.aism.it/il_bilancio_sociale</a></p>\r\n','basic_html'),('indicator',0,549,559,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,550,560,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,551,561,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,552,562,'en',0,'<p><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></p>\r\n','basic_html'),('indicator',0,553,563,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,554,564,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,585,612,'en',0,'<p>Solaro C, Trabucco E, Signori A, Cella M, Messmer Uccelli M, Brichetto G, Cavalla P, Gironi M, Patti F, Prosperini L. Italian validation of the 12-item multiple sclerosis walking scale. Mult Scler Int. 2015;2015:540828. doi:10.1155/2015/540828. Epub 2015 Mar 26. PubMed PMID: 25883806; PubMed Central PMCID: PMC4391321.</p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html');

--
-- Table structure for table `node__field_exp_freq_of_data_collectio`
--

CREATE TABLE `node__field_exp_freq_of_data_collectio` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_exp_freq_of_data_collectio_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_exp_freq_of_data…';

--
-- Dumping data for table `node__field_exp_freq_of_data_collectio`
--

INSERT INTO `node__field_exp_freq_of_data_collectio` VALUES ('indicator',0,399,408,'en',0,'Annually'),('indicator',0,400,409,'en',0,'Annually'),('indicator',0,401,410,'en',0,'Annually'),('indicator',0,402,411,'en',0,'Annually'),('indicator',0,403,412,'en',0,'Annually'),('indicator',0,404,413,'en',0,'Annually'),('indicator',0,405,414,'en',0,'Annually'),('indicator',0,406,415,'en',0,'Annually'),('indicator',0,407,416,'en',0,'Annually'),('indicator',0,408,417,'en',0,'Annually'),('indicator',0,409,418,'en',0,'Monthly/Annually'),('indicator',0,410,419,'en',0,'Annually'),('indicator',0,411,420,'en',0,'Annually'),('indicator',0,412,421,'en',0,'Annually'),('indicator',0,413,422,'en',0,'Triennial'),('indicator',0,414,423,'en',0,'Annually'),('indicator',0,415,424,'en',0,'Annually'),('indicator',0,416,425,'en',0,'Annually'),('indicator',0,417,426,'en',0,'Annually'),('indicator',0,418,427,'en',0,'Annually'),('indicator',0,419,428,'en',0,'Annually'),('indicator',0,420,429,'en',0,'Annually'),('indicator',0,421,430,'en',0,'Annually'),('indicator',0,422,431,'en',0,'Annually'),('indicator',0,423,432,'en',0,'Annually'),('indicator',0,424,433,'en',0,'Annually'),('indicator',0,425,434,'en',0,'Annually'),('indicator',0,426,435,'en',0,'Annually'),('indicator',0,427,436,'en',0,'Annually'),('indicator',0,428,437,'en',0,'Annually'),('indicator',0,429,438,'en',0,'Annually'),('indicator',0,430,439,'en',0,'Annually'),('indicator',0,431,440,'en',0,'Monthly/Annually'),('indicator',0,432,441,'en',0,'Annually'),('indicator',0,433,442,'en',0,'Monthly/Annually'),('indicator',0,434,443,'en',0,'Annually'),('indicator',0,435,444,'en',0,'Annually'),('indicator',0,436,445,'en',0,'Monthly'),('indicator',0,437,446,'en',0,'Annually'),('indicator',0,438,447,'en',0,'Annually'),('indicator',0,439,448,'en',0,'Annually'),('indicator',0,440,449,'en',0,'Annually'),('indicator',0,441,450,'en',0,'Annually'),('indicator',0,442,451,'en',0,'Annually'),('indicator',0,443,452,'en',0,'Annually'),('indicator',0,444,453,'en',0,'Annually'),('indicator',0,445,454,'en',0,'Annually'),('indicator',0,446,455,'en',0,'Annually'),('indicator',0,447,456,'en',0,'It will be automatically managed by specific services. The information is timely'),('indicator',0,448,457,'en',0,'Annually'),('indicator',0,449,458,'en',0,'Annually'),('indicator',0,450,459,'en',0,'Annually'),('indicator',0,451,460,'en',0,'Continuous'),('indicator',0,452,461,'en',0,'Annually'),('indicator',0,453,462,'en',0,'Annually'),('indicator',0,454,463,'en',0,'Annually'),('indicator',0,455,464,'en',0,'Annually'),('indicator',0,456,465,'en',0,'Annually'),('indicator',0,457,466,'en',0,'Annually'),('indicator',0,458,467,'en',0,'Annually'),('indicator',0,459,468,'en',0,'Annually'),('indicator',0,460,469,'en',0,'Annually'),('indicator',0,461,470,'en',0,'Annually'),('indicator',0,462,471,'en',0,'Annually'),('indicator',0,463,472,'en',0,'Annually'),('indicator',0,464,473,'en',0,'Annually'),('indicator',0,465,474,'en',0,'Annually'),('indicator',0,466,475,'en',0,'Annually'),('indicator',0,467,476,'en',0,'Semi-annually'),('indicator',0,468,477,'en',0,'Semi-annually'),('indicator',0,469,478,'en',0,'Semi-annually'),('indicator',0,470,479,'en',0,'Annually'),('indicator',0,471,480,'en',0,'Annually'),('indicator',0,472,481,'en',0,'Annually'),('indicator',0,473,482,'en',0,'Annually'),('indicator',0,474,483,'en',0,'Annually'),('indicator',0,475,484,'en',0,'Annually'),('indicator',0,476,485,'en',0,'Annually'),('indicator',0,477,486,'en',0,'Annually'),('indicator',0,478,487,'en',0,'Annually'),('indicator',0,479,488,'en',0,'Annually'),('indicator',0,480,489,'en',0,'Annually'),('indicator',0,481,490,'en',0,'Annually'),('indicator',0,482,491,'en',0,'Annually'),('indicator',0,483,492,'en',0,'Annually'),('indicator',0,484,493,'en',0,'Annually'),('indicator',0,485,494,'en',0,'Annually'),('indicator',0,486,495,'en',0,'Annually'),('indicator',0,487,496,'en',0,'Annually'),('indicator',0,488,497,'en',0,'Annually'),('indicator',0,489,498,'en',0,'Annually'),('indicator',0,490,499,'en',0,'Every three-month'),('indicator',0,491,500,'en',0,'Annually'),('indicator',0,492,501,'en',0,'Annually'),('indicator',0,493,502,'en',0,'Annually'),('indicator',0,494,503,'en',0,'Annually'),('indicator',0,495,504,'en',0,'Annually'),('indicator',0,496,505,'en',0,'Annually'),('indicator',0,497,506,'en',0,'Annually'),('indicator',0,498,507,'en',0,'Annually'),('indicator',0,499,508,'en',0,'Annually'),('indicator',0,500,509,'en',0,'Annually'),('indicator',0,501,510,'en',0,'Annually'),('indicator',0,502,511,'en',0,'Annually'),('indicator',0,503,512,'en',0,'Annually'),('indicator',0,504,513,'en',0,'Annually'),('indicator',0,505,514,'en',0,'Annually'),('indicator',0,506,515,'en',0,'Annually'),('indicator',0,507,516,'en',0,'Monthly/Annually'),('indicator',0,508,517,'en',0,'Monthly/Annually'),('indicator',0,509,518,'en',0,'Annually'),('indicator',0,510,519,'en',0,'Annually'),('indicator',0,512,521,'en',0,'Annually'),('indicator',0,547,557,'en',0,'Annually'),('indicator',0,548,558,'en',0,'Annually'),('indicator',0,549,559,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,550,560,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,551,561,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,552,562,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,553,563,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,554,564,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,585,612,'en',0,'It depends on the assessment (usually at every assessment point)');

--
-- Table structure for table `node__field_expected_frequency_of_data`
--

CREATE TABLE `node__field_expected_frequency_of_data` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_expected_frequency_of_data_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_expected_frequency_of…';

--
-- Dumping data for table `node__field_expected_frequency_of_data`
--

INSERT INTO `node__field_expected_frequency_of_data` VALUES ('indicator',0,399,408,'en',0,'Annually'),('indicator',0,400,409,'en',0,'Annually'),('indicator',0,401,410,'en',0,'Annually'),('indicator',0,402,411,'en',0,'Annually'),('indicator',0,403,412,'en',0,'Annually'),('indicator',0,404,413,'en',0,'Annually'),('indicator',0,405,414,'en',0,'Annually'),('indicator',0,406,415,'en',0,'Annually'),('indicator',0,407,416,'en',0,'Annually'),('indicator',0,408,417,'en',0,'Annually'),('indicator',0,409,418,'en',0,'Annually'),('indicator',0,410,419,'en',0,'Annually'),('indicator',0,411,420,'en',0,'Annually'),('indicator',0,412,421,'en',0,'Annually'),('indicator',0,413,422,'en',0,'Triennial'),('indicator',0,414,423,'en',0,'Annually'),('indicator',0,415,424,'en',0,'Annually'),('indicator',0,416,425,'en',0,'Annually'),('indicator',0,417,426,'en',0,'Annually'),('indicator',0,418,427,'en',0,'Annually'),('indicator',0,419,428,'en',0,'Annually'),('indicator',0,420,429,'en',0,'Annually'),('indicator',0,421,430,'en',0,'Annually'),('indicator',0,422,431,'en',0,'Annually'),('indicator',0,423,432,'en',0,'Annually'),('indicator',0,424,433,'en',0,'Annually'),('indicator',0,425,434,'en',0,'Annually'),('indicator',0,426,435,'en',0,'Annually'),('indicator',0,427,436,'en',0,'Annually'),('indicator',0,428,437,'en',0,'Annually'),('indicator',0,429,438,'en',0,'Annually'),('indicator',0,430,439,'en',0,'Annually'),('indicator',0,431,440,'en',0,'Semi-annually'),('indicator',0,432,441,'en',0,'Annually'),('indicator',0,433,442,'en',0,'Annually'),('indicator',0,434,443,'en',0,'Annually'),('indicator',0,435,444,'en',0,'Annually'),('indicator',0,436,445,'en',0,'Monthly'),('indicator',0,437,446,'en',0,'Annually'),('indicator',0,438,447,'en',0,'Annually'),('indicator',0,439,448,'en',0,'Annually'),('indicator',0,440,449,'en',0,'Annually'),('indicator',0,441,450,'en',0,'Annually'),('indicator',0,442,451,'en',0,'Annually'),('indicator',0,443,452,'en',0,'Annually'),('indicator',0,444,453,'en',0,'Annually'),('indicator',0,445,454,'en',0,'Annually'),('indicator',0,446,455,'en',0,'Annually'),('indicator',0,447,456,'en',0,'Annually'),('indicator',0,448,457,'en',0,'Annually'),('indicator',0,449,458,'en',0,'Annually'),('indicator',0,450,459,'en',0,'Annually'),('indicator',0,451,460,'en',0,'Monthly'),('indicator',0,452,461,'en',0,'Annually'),('indicator',0,453,462,'en',0,'Annually'),('indicator',0,454,463,'en',0,'Annually'),('indicator',0,455,464,'en',0,'Annually'),('indicator',0,456,465,'en',0,'Annually'),('indicator',0,457,466,'en',0,'Annually'),('indicator',0,458,467,'en',0,'Annually'),('indicator',0,459,468,'en',0,'Annually'),('indicator',0,460,469,'en',0,'Annually'),('indicator',0,461,470,'en',0,'Annually'),('indicator',0,462,471,'en',0,'Annually'),('indicator',0,463,472,'en',0,'Annually'),('indicator',0,464,473,'en',0,'Annually'),('indicator',0,465,474,'en',0,'Annually'),('indicator',0,466,475,'en',0,'Annually'),('indicator',0,467,476,'en',0,'Annually'),('indicator',0,468,477,'en',0,'Annually'),('indicator',0,469,478,'en',0,'Annually'),('indicator',0,470,479,'en',0,'Annually'),('indicator',0,471,480,'en',0,'Annually'),('indicator',0,472,481,'en',0,'Annually'),('indicator',0,473,482,'en',0,'Annually'),('indicator',0,474,483,'en',0,'Annually'),('indicator',0,475,484,'en',0,'Annually'),('indicator',0,476,485,'en',0,'Annually'),('indicator',0,477,486,'en',0,'Annually'),('indicator',0,478,487,'en',0,'Annually'),('indicator',0,479,488,'en',0,'Annually'),('indicator',0,480,489,'en',0,'Annually'),('indicator',0,481,490,'en',0,'Annually'),('indicator',0,482,491,'en',0,'Annually'),('indicator',0,483,492,'en',0,'Annually'),('indicator',0,484,493,'en',0,'Annually'),('indicator',0,485,494,'en',0,'Annually'),('indicator',0,486,495,'en',0,'Annually'),('indicator',0,487,496,'en',0,'Annually'),('indicator',0,488,497,'en',0,'Annually'),('indicator',0,489,498,'en',0,'Annually'),('indicator',0,490,499,'en',0,'Annually'),('indicator',0,491,500,'en',0,'Annually'),('indicator',0,492,501,'en',0,'Annually'),('indicator',0,493,502,'en',0,'Annually'),('indicator',0,494,503,'en',0,'Annually'),('indicator',0,495,504,'en',0,'Annually'),('indicator',0,496,505,'en',0,'Annually'),('indicator',0,497,506,'en',0,'Annually'),('indicator',0,498,507,'en',0,'Annually'),('indicator',0,499,508,'en',0,'Annually'),('indicator',0,500,509,'en',0,'Annually'),('indicator',0,501,510,'en',0,'Annually'),('indicator',0,502,511,'en',0,'Annually'),('indicator',0,503,512,'en',0,'Annually'),('indicator',0,504,513,'en',0,'Annually'),('indicator',0,505,514,'en',0,'Annually'),('indicator',0,506,515,'en',0,'Annually'),('indicator',0,507,516,'en',0,'Annually'),('indicator',0,508,517,'en',0,'Annually'),('indicator',0,509,518,'en',0,'Annually'),('indicator',0,510,519,'en',0,'Annually'),('indicator',0,512,521,'en',0,'Annually'),('indicator',0,547,557,'en',0,'Annually'),('indicator',0,548,558,'en',0,'Annually'),('indicator',0,549,559,'en',0,'At the end of overall data collection and analysis'),('indicator',0,550,560,'en',0,'At the end of overall data collection and analysis'),('indicator',0,551,561,'en',0,'At the end of overall data collection and analysis'),('indicator',0,552,562,'en',0,'At the end of overall data collection and analysis'),('indicator',0,553,563,'en',0,'At the end of overall data collection and analysis'),('indicator',0,554,564,'en',0,'At the end of overall data collection and analysis'),('indicator',0,585,612,'en',0,'At the end of overall data collection and analysis');

--
-- Table structure for table `node__field_funding_research`
--

CREATE TABLE `node__field_funding_research` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_funding_research_value` tinyint(4) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_funding_research.';

--
-- Dumping data for table `node__field_funding_research`
--

INSERT INTO `node__field_funding_research` VALUES ('initiative',0,1,7,'en',0,0),('initiative',0,306,314,'en',0,1),('initiative',0,307,315,'en',0,1),('initiative',0,309,318,'en',0,1),('initiative',0,310,319,'en',0,0),('initiative',0,516,525,'en',0,1),('initiative',0,518,528,'en',0,1),('initiative',0,519,529,'en',0,0),('initiative',0,520,530,'en',0,0),('initiative',0,521,531,'en',0,0),('initiative',0,522,532,'en',0,0),('initiative',0,523,533,'en',0,1),('initiative',0,524,534,'en',0,1),('initiative',0,525,535,'en',0,0),('initiative',0,526,536,'en',0,1),('initiative',0,527,537,'en',0,1),('initiative',0,528,538,'en',0,1),('initiative',0,529,539,'en',0,1),('initiative',0,530,540,'en',0,0),('initiative',0,531,541,'en',0,1),('initiative',0,534,544,'en',0,0),('initiative',0,535,545,'en',0,0),('initiative',0,536,546,'en',0,0),('initiative',0,537,547,'en',0,0),('initiative',0,538,548,'en',0,1),('initiative',0,539,549,'en',0,1),('initiative',0,540,550,'en',0,0),('initiative',0,541,551,'en',0,1),('initiative',0,542,552,'en',0,0),('initiative',0,543,553,'en',0,1),('initiative',0,544,554,'en',0,0),('initiative',0,545,555,'en',0,0),('initiative',0,546,556,'en',0,0),('initiative',0,555,565,'en',0,1),('initiative',0,556,566,'en',0,0),('initiative',0,557,567,'en',0,0),('initiative',0,564,582,'en',0,1),('initiative',0,572,599,'en',0,1),('initiative',0,589,616,'en',0,0),('initiative',0,590,617,'en',0,1),('initiative',0,592,621,'en',0,1),('initiative',0,593,622,'en',0,1);

--
-- Table structure for table `node__field_geographical_coverage`
--

CREATE TABLE `node__field_geographical_coverage` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_geographical_coverage_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_geographical_coverage_value` (`field_geographical_coverage_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_geographical_coverage.';

--
-- Dumping data for table `node__field_geographical_coverage`
--

INSERT INTO `node__field_geographical_coverage` VALUES ('initiative',0,1,7,'en',0,'Europe'),('initiative',0,1,7,'en',1,'Afghanistan'),('initiative',0,306,314,'en',0,'Afghanistan'),('initiative',0,307,315,'en',0,'Europe'),('initiative',0,309,318,'en',0,'Andorra'),('initiative',0,309,318,'en',1,'Antigua and Barbuda'),('initiative',0,310,319,'en',0,'Afghanistan'),('initiative',0,516,525,'en',0,'Europe'),('initiative',0,518,528,'en',0,'Afghanistan'),('initiative',0,519,529,'en',0,'Afghanistan'),('initiative',0,520,530,'en',0,'Afghanistan'),('initiative',0,521,531,'en',0,'Afghanistan'),('initiative',0,522,532,'en',0,'Europe'),('initiative',0,523,533,'en',0,'Europe'),('initiative',0,524,534,'en',0,'Europe'),('initiative',0,525,535,'en',0,'Europe'),('initiative',0,526,536,'en',0,'Afghanistan'),('initiative',0,527,537,'en',0,'World'),('initiative',0,528,538,'en',0,'Europe'),('initiative',0,528,538,'en',1,'Afghanistan'),('initiative',0,529,539,'en',0,'Argentina'),('initiative',0,529,539,'en',1,'Australia'),('initiative',0,529,539,'en',2,'Austria'),('initiative',0,529,539,'en',3,'Belgium'),('initiative',0,530,540,'en',0,'Andorra'),('initiative',0,530,540,'en',1,'Argentina'),('initiative',0,531,541,'en',0,'World'),('initiative',0,534,544,'en',0,'Italy'),('initiative',0,535,545,'en',0,'World'),('initiative',0,536,546,'en',0,'Europe'),('initiative',0,537,547,'en',0,'Europe'),('initiative',0,538,548,'en',0,'Europe'),('initiative',0,539,549,'en',0,'Europe'),('initiative',0,540,550,'en',0,'Poland'),('initiative',0,541,551,'en',0,'Europe'),('initiative',0,542,552,'en',0,'Europe'),('initiative',0,543,553,'en',0,'World'),('initiative',0,544,554,'en',0,'Czechia (Czech Republic)'),('initiative',0,544,554,'en',1,'Denmark'),('initiative',0,545,555,'en',0,'Europe'),('initiative',0,546,556,'en',0,'Europe'),('initiative',0,555,565,'en',0,'World'),('initiative',0,556,566,'en',0,'Finland'),('initiative',0,557,567,'en',0,'World'),('initiative',0,564,582,'en',0,'Austria'),('initiative',0,572,599,'en',0,'World'),('initiative',0,589,616,'en',0,'Europe'),('initiative',0,590,617,'en',0,'World'),('initiative',0,592,621,'en',0,'World'),('initiative',0,593,622,'en',0,'Europe');

--
-- Table structure for table `node__field_image`
--

CREATE TABLE `node__field_image` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_image_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the file entity.',
  `field_image_alt` varchar(512) DEFAULT NULL COMMENT 'Alternative image text, for the image''s ''alt'' attribute.',
  `field_image_title` varchar(1024) DEFAULT NULL COMMENT 'Image title text, for the image''s ''title'' attribute.',
  `field_image_width` int(10) unsigned DEFAULT NULL COMMENT 'The width of the image in pixels.',
  `field_image_height` int(10) unsigned DEFAULT NULL COMMENT 'The height of the image in pixels.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_image_target_id` (`field_image_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_image.';

--
-- Dumping data for table `node__field_image`
--


--
-- Table structure for table `node__field_indicator`
--

CREATE TABLE `node__field_indicator` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_indicator_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_indicator_target_id` (`field_indicator_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_indicator.';

--
-- Dumping data for table `node__field_indicator`
--

INSERT INTO `node__field_indicator` VALUES ('impact_analysis',0,532,542,'en',0,399),('impact_analysis',0,533,543,'en',0,400),('impact_analysis',0,559,577,'en',0,402),('impact_analysis',0,560,578,'en',0,419),('impact_analysis',0,561,579,'en',0,500),('impact_analysis',0,562,580,'en',0,419),('impact_analysis',0,563,581,'en',0,439),('impact_analysis',0,565,583,'en',0,405),('impact_analysis',0,566,584,'en',0,498),('impact_analysis',0,567,585,'en',0,451),('impact_analysis',0,568,586,'en',0,434),('impact_analysis',0,569,587,'en',0,549),('impact_analysis',0,574,601,'en',0,503),('impact_analysis',0,575,602,'en',0,440),('impact_analysis',0,576,603,'en',0,409),('impact_analysis',0,577,604,'en',0,550),('impact_analysis',0,578,605,'en',0,419),('impact_analysis',0,579,606,'en',0,467),('impact_analysis',0,580,607,'en',0,436),('impact_analysis',0,581,608,'en',0,425),('impact_analysis',0,582,609,'en',0,439),('impact_analysis',0,583,610,'en',0,436),('impact_analysis',0,584,611,'en',0,438),('impact_analysis',0,586,613,'en',0,549),('impact_analysis',0,587,614,'en',0,439),('impact_analysis',0,588,615,'en',0,550),('impact_analysis',0,591,620,'en',0,551);

--
-- Table structure for table `node__field_indicator_code`
--

CREATE TABLE `node__field_indicator_code` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_indicator_code_value` int(11) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_indicator_code.';

--
-- Dumping data for table `node__field_indicator_code`
--

INSERT INTO `node__field_indicator_code` VALUES ('indicator',0,399,408,'en',0,1),('indicator',0,400,409,'en',0,2),('indicator',0,401,410,'en',0,3),('indicator',0,402,411,'en',0,4),('indicator',0,403,412,'en',0,5),('indicator',0,404,413,'en',0,6),('indicator',0,405,414,'en',0,7),('indicator',0,406,415,'en',0,8),('indicator',0,407,416,'en',0,9),('indicator',0,408,417,'en',0,10),('indicator',0,409,418,'en',0,11),('indicator',0,410,419,'en',0,12),('indicator',0,411,420,'en',0,13),('indicator',0,412,421,'en',0,14),('indicator',0,413,422,'en',0,15),('indicator',0,414,423,'en',0,16),('indicator',0,415,424,'en',0,17),('indicator',0,416,425,'en',0,18),('indicator',0,417,426,'en',0,19),('indicator',0,418,427,'en',0,20),('indicator',0,419,428,'en',0,21),('indicator',0,420,429,'en',0,22),('indicator',0,421,430,'en',0,23),('indicator',0,422,431,'en',0,24),('indicator',0,423,432,'en',0,25),('indicator',0,424,433,'en',0,26),('indicator',0,425,434,'en',0,27),('indicator',0,426,435,'en',0,28),('indicator',0,427,436,'en',0,29),('indicator',0,428,437,'en',0,30),('indicator',0,429,438,'en',0,31),('indicator',0,430,439,'en',0,32),('indicator',0,431,440,'en',0,33),('indicator',0,432,441,'en',0,34),('indicator',0,433,442,'en',0,35),('indicator',0,434,443,'en',0,36),('indicator',0,435,444,'en',0,37),('indicator',0,436,445,'en',0,38),('indicator',0,437,446,'en',0,39),('indicator',0,438,447,'en',0,40),('indicator',0,439,448,'en',0,41),('indicator',0,440,449,'en',0,42),('indicator',0,441,450,'en',0,43),('indicator',0,442,451,'en',0,44),('indicator',0,443,452,'en',0,45),('indicator',0,444,453,'en',0,46),('indicator',0,445,454,'en',0,47),('indicator',0,446,455,'en',0,48),('indicator',0,447,456,'en',0,49),('indicator',0,448,457,'en',0,50),('indicator',0,449,458,'en',0,51),('indicator',0,450,459,'en',0,52),('indicator',0,451,460,'en',0,53),('indicator',0,452,461,'en',0,55),('indicator',0,453,462,'en',0,56),('indicator',0,454,463,'en',0,57),('indicator',0,455,464,'en',0,58),('indicator',0,456,465,'en',0,59),('indicator',0,457,466,'en',0,60),('indicator',0,458,467,'en',0,61),('indicator',0,459,468,'en',0,62),('indicator',0,460,469,'en',0,63),('indicator',0,461,470,'en',0,64),('indicator',0,462,471,'en',0,65),('indicator',0,463,472,'en',0,66),('indicator',0,464,473,'en',0,67),('indicator',0,465,474,'en',0,68),('indicator',0,466,475,'en',0,69),('indicator',0,467,476,'en',0,70),('indicator',0,468,477,'en',0,71),('indicator',0,469,478,'en',0,72),('indicator',0,470,479,'en',0,73),('indicator',0,471,480,'en',0,74),('indicator',0,472,481,'en',0,75),('indicator',0,473,482,'en',0,76),('indicator',0,474,483,'en',0,77),('indicator',0,475,484,'en',0,79),('indicator',0,476,485,'en',0,80),('indicator',0,477,486,'en',0,81),('indicator',0,478,487,'en',0,82),('indicator',0,479,488,'en',0,83),('indicator',0,480,489,'en',0,84),('indicator',0,481,490,'en',0,85),('indicator',0,482,491,'en',0,86),('indicator',0,483,492,'en',0,87),('indicator',0,484,493,'en',0,88),('indicator',0,485,494,'en',0,89),('indicator',0,486,495,'en',0,90),('indicator',0,487,496,'en',0,91),('indicator',0,488,497,'en',0,92),('indicator',0,489,498,'en',0,93),('indicator',0,490,499,'en',0,94),('indicator',0,491,500,'en',0,95),('indicator',0,492,501,'en',0,96),('indicator',0,493,502,'en',0,97),('indicator',0,494,503,'en',0,98),('indicator',0,495,504,'en',0,99),('indicator',0,496,505,'en',0,100),('indicator',0,497,506,'en',0,101),('indicator',0,498,507,'en',0,102),('indicator',0,499,508,'en',0,103),('indicator',0,500,509,'en',0,104),('indicator',0,501,510,'en',0,105),('indicator',0,502,511,'en',0,106),('indicator',0,503,512,'en',0,107),('indicator',0,504,513,'en',0,108),('indicator',0,505,514,'en',0,109),('indicator',0,506,515,'en',0,110),('indicator',0,507,516,'en',0,111),('indicator',0,508,517,'en',0,113),('indicator',0,509,518,'en',0,114),('indicator',0,510,519,'en',0,115),('indicator',0,512,521,'en',0,54),('indicator',0,547,557,'en',0,78),('indicator',0,548,558,'en',0,112),('indicator',0,549,559,'en',0,183),('indicator',0,550,560,'en',0,184),('indicator',0,551,561,'en',0,185),('indicator',0,552,562,'en',0,186),('indicator',0,553,563,'en',0,181),('indicator',0,554,564,'en',0,154);

--
-- Table structure for table `node__field_indicator_in_use`
--

CREATE TABLE `node__field_indicator_in_use` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_indicator_in_use_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_indicator_in_use_value` (`field_indicator_in_use_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_indicator_in_use.';

--
-- Dumping data for table `node__field_indicator_in_use`
--

INSERT INTO `node__field_indicator_in_use` VALUES ('indicator',0,399,408,'en',0,'Yes'),('indicator',0,400,409,'en',0,'Yes'),('indicator',0,401,410,'en',0,'Yes'),('indicator',0,402,411,'en',0,'Yes'),('indicator',0,403,412,'en',0,'No'),('indicator',0,404,413,'en',0,'No'),('indicator',0,405,414,'en',0,'Yes'),('indicator',0,406,415,'en',0,'Yes'),('indicator',0,407,416,'en',0,'No'),('indicator',0,408,417,'en',0,'No'),('indicator',0,409,418,'en',0,'Yes'),('indicator',0,410,419,'en',0,'Yes'),('indicator',0,411,420,'en',0,'Yes'),('indicator',0,412,421,'en',0,'Yes'),('indicator',0,413,422,'en',0,'No'),('indicator',0,414,423,'en',0,'No'),('indicator',0,415,424,'en',0,'No'),('indicator',0,416,425,'en',0,'No'),('indicator',0,417,426,'en',0,'Yes'),('indicator',0,418,427,'en',0,'Yes'),('indicator',0,419,428,'en',0,'Yes'),('indicator',0,420,429,'en',0,'Yes'),('indicator',0,421,430,'en',0,'No'),('indicator',0,422,431,'en',0,'No'),('indicator',0,423,432,'en',0,'Yes'),('indicator',0,424,433,'en',0,'Yes'),('indicator',0,425,434,'en',0,'Yes'),('indicator',0,426,435,'en',0,'Yes'),('indicator',0,427,436,'en',0,'Yes'),('indicator',0,428,437,'en',0,'No'),('indicator',0,429,438,'en',0,'Yes'),('indicator',0,430,439,'en',0,'Yes'),('indicator',0,431,440,'en',0,'No'),('indicator',0,432,441,'en',0,'Yes'),('indicator',0,433,442,'en',0,'Yes'),('indicator',0,434,443,'en',0,'No'),('indicator',0,435,444,'en',0,'Yes'),('indicator',0,436,445,'en',0,'Yes'),('indicator',0,437,446,'en',0,'Yes'),('indicator',0,438,447,'en',0,'No'),('indicator',0,439,448,'en',0,'No'),('indicator',0,440,449,'en',0,'Yes'),('indicator',0,441,450,'en',0,'Yes'),('indicator',0,442,451,'en',0,'Yes'),('indicator',0,443,452,'en',0,'Yes'),('indicator',0,444,453,'en',0,'Yes'),('indicator',0,445,454,'en',0,'No'),('indicator',0,446,455,'en',0,'Yes'),('indicator',0,447,456,'en',0,'No'),('indicator',0,448,457,'en',0,'No'),('indicator',0,449,458,'en',0,'Yes'),('indicator',0,450,459,'en',0,'No'),('indicator',0,451,460,'en',0,'No'),('indicator',0,452,461,'en',0,'No'),('indicator',0,453,462,'en',0,'No'),('indicator',0,454,463,'en',0,'Yes'),('indicator',0,455,464,'en',0,'No'),('indicator',0,456,465,'en',0,'No'),('indicator',0,457,466,'en',0,'Yes'),('indicator',0,458,467,'en',0,'Yes'),('indicator',0,459,468,'en',0,'Yes'),('indicator',0,460,469,'en',0,'Yes'),('indicator',0,461,470,'en',0,'No'),('indicator',0,462,471,'en',0,'No'),('indicator',0,463,472,'en',0,'Yes'),('indicator',0,464,473,'en',0,'No'),('indicator',0,465,474,'en',0,'No'),('indicator',0,466,475,'en',0,'Yes'),('indicator',0,467,476,'en',0,'No'),('indicator',0,468,477,'en',0,'No'),('indicator',0,469,478,'en',0,'No'),('indicator',0,470,479,'en',0,'No'),('indicator',0,471,480,'en',0,'No'),('indicator',0,472,481,'en',0,'Yes'),('indicator',0,473,482,'en',0,'Yes'),('indicator',0,474,483,'en',0,'Yes'),('indicator',0,475,484,'en',0,'Yes'),('indicator',0,476,485,'en',0,'No'),('indicator',0,477,486,'en',0,'Yes'),('indicator',0,478,487,'en',0,'No'),('indicator',0,479,488,'en',0,'No'),('indicator',0,480,489,'en',0,'Yes'),('indicator',0,481,490,'en',0,'Yes'),('indicator',0,482,491,'en',0,'No'),('indicator',0,483,492,'en',0,'Yes'),('indicator',0,484,493,'en',0,'Yes'),('indicator',0,485,494,'en',0,'Yes'),('indicator',0,486,495,'en',0,'Yes'),('indicator',0,487,496,'en',0,'Yes'),('indicator',0,488,497,'en',0,'Yes'),('indicator',0,489,498,'en',0,'Yes'),('indicator',0,490,499,'en',0,'No'),('indicator',0,491,500,'en',0,'Yes'),('indicator',0,492,501,'en',0,'No'),('indicator',0,493,502,'en',0,'Yes'),('indicator',0,494,503,'en',0,'Yes'),('indicator',0,495,504,'en',0,'Yes'),('indicator',0,496,505,'en',0,'No'),('indicator',0,497,506,'en',0,'Yes'),('indicator',0,498,507,'en',0,'Yes'),('indicator',0,499,508,'en',0,'Yes'),('indicator',0,500,509,'en',0,'Yes'),('indicator',0,501,510,'en',0,'Yes'),('indicator',0,502,511,'en',0,'Yes'),('indicator',0,503,512,'en',0,'No'),('indicator',0,504,513,'en',0,'No'),('indicator',0,505,514,'en',0,'Yes'),('indicator',0,506,515,'en',0,'Yes'),('indicator',0,507,516,'en',0,'Yes'),('indicator',0,508,517,'en',0,'Yes'),('indicator',0,509,518,'en',0,'No'),('indicator',0,510,519,'en',0,'Yes'),('indicator',0,512,521,'en',0,'No'),('indicator',0,547,557,'en',0,'Yes'),('indicator',0,548,558,'en',0,'Yes'),('indicator',0,549,559,'en',0,'Yes'),('indicator',0,550,560,'en',0,'Yes'),('indicator',0,551,561,'en',0,'Yes'),('indicator',0,552,562,'en',0,'Yes'),('indicator',0,553,563,'en',0,'Yes'),('indicator',0,554,564,'en',0,'Yes'),('indicator',0,585,612,'en',0,'Yes');

--
-- Table structure for table `node__field_inherits_parent_s_assesmen`
--

CREATE TABLE `node__field_inherits_parent_s_assesmen` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_inherits_parent_s_assesmen_value` tinyint(4) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_inherits_parent_s…';

--
-- Dumping data for table `node__field_inherits_parent_s_assesmen`
--

INSERT INTO `node__field_inherits_parent_s_assesmen` VALUES ('initiative',0,1,7,'en',0,0),('initiative',0,306,314,'en',0,0),('initiative',0,307,315,'en',0,0),('initiative',0,309,318,'en',0,0),('initiative',0,310,319,'en',0,1),('initiative',0,516,525,'en',0,0),('initiative',0,518,528,'en',0,0),('initiative',0,519,529,'en',0,0),('initiative',0,520,530,'en',0,0),('initiative',0,521,531,'en',0,0),('initiative',0,522,532,'en',0,0),('initiative',0,523,533,'en',0,1),('initiative',0,524,534,'en',0,0),('initiative',0,525,535,'en',0,0),('initiative',0,526,536,'en',0,0),('initiative',0,527,537,'en',0,0),('initiative',0,528,538,'en',0,0),('initiative',0,529,539,'en',0,0),('initiative',0,530,540,'en',0,1),('initiative',0,531,541,'en',0,0),('initiative',0,534,544,'en',0,0),('initiative',0,535,545,'en',0,1),('initiative',0,536,546,'en',0,0),('initiative',0,537,547,'en',0,0),('initiative',0,538,548,'en',0,0),('initiative',0,539,549,'en',0,0),('initiative',0,540,550,'en',0,0),('initiative',0,541,551,'en',0,0),('initiative',0,542,552,'en',0,0),('initiative',0,543,553,'en',0,1),('initiative',0,544,554,'en',0,0),('initiative',0,545,555,'en',0,0),('initiative',0,546,556,'en',0,0),('initiative',0,555,565,'en',0,0),('initiative',0,556,566,'en',0,0),('initiative',0,557,567,'en',0,0),('initiative',0,564,582,'en',0,0),('initiative',0,572,599,'en',0,0),('initiative',0,589,616,'en',0,0),('initiative',0,590,617,'en',0,0),('initiative',0,592,621,'en',0,0),('initiative',0,593,622,'en',0,0);

--
-- Table structure for table `node__field_initiative`
--

CREATE TABLE `node__field_initiative` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_initiative_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_initiative_target_id` (`field_initiative_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_initiative.';

--
-- Dumping data for table `node__field_initiative`
--

INSERT INTO `node__field_initiative` VALUES ('impact_analysis',0,532,542,'en',0,518),('impact_analysis',0,533,543,'en',0,529),('impact_analysis',0,559,577,'en',0,530),('impact_analysis',0,560,578,'en',0,537),('impact_analysis',0,561,579,'en',0,537),('impact_analysis',0,562,580,'en',0,537),('impact_analysis',0,563,581,'en',0,537),('impact_analysis',0,565,583,'en',0,537),('impact_analysis',0,566,584,'en',0,540),('impact_analysis',0,567,585,'en',0,540),('impact_analysis',0,568,586,'en',0,540),('impact_analysis',0,569,587,'en',0,540),('impact_analysis',0,574,601,'en',0,557),('impact_analysis',0,575,602,'en',0,557),('impact_analysis',0,576,603,'en',0,557),('impact_analysis',0,577,604,'en',0,557),('impact_analysis',0,578,605,'en',0,557),('impact_analysis',0,579,606,'en',0,557),('impact_analysis',0,580,607,'en',0,557),('impact_analysis',0,581,608,'en',0,557),('impact_analysis',0,582,609,'en',0,557),('impact_analysis',0,583,610,'en',0,538),('impact_analysis',0,584,611,'en',0,538),('impact_analysis',0,586,613,'en',0,535),('impact_analysis',0,587,614,'en',0,535),('impact_analysis',0,588,615,'en',0,535),('impact_analysis',0,591,620,'en',0,540);

--
-- Table structure for table `node__field_initiative_type`
--

CREATE TABLE `node__field_initiative_type` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_initiative_type_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_initiative_type_value` (`field_initiative_type_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_initiative_type.';

--
-- Dumping data for table `node__field_initiative_type`
--

INSERT INTO `node__field_initiative_type` VALUES ('initiative',0,1,7,'en',0,'Project'),('initiative',0,306,314,'en',0,'Programme'),('initiative',0,307,315,'en',0,'Project'),('initiative',0,309,318,'en',0,'Programme'),('initiative',0,310,319,'en',0,'Project'),('initiative',0,516,525,'en',0,'Project'),('initiative',0,518,528,'en',0,'Programme'),('initiative',0,519,529,'en',0,'Programme'),('initiative',0,520,530,'en',0,'Project'),('initiative',0,521,531,'en',0,'Project'),('initiative',0,522,532,'en',0,'Project'),('initiative',0,523,533,'en',0,'Project'),('initiative',0,524,534,'en',0,'Project'),('initiative',0,525,535,'en',0,'Programme'),('initiative',0,526,536,'en',0,'Programme'),('initiative',0,527,537,'en',0,'Project'),('initiative',0,528,538,'en',0,'Programme'),('initiative',0,529,539,'en',0,'Programme'),('initiative',0,530,540,'en',0,'Project'),('initiative',0,531,541,'en',0,'Project'),('initiative',0,534,544,'en',0,'Project'),('initiative',0,535,545,'en',0,'Programme'),('initiative',0,536,546,'en',0,'Project'),('initiative',0,537,547,'en',0,'Project'),('initiative',0,538,548,'en',0,'Programme'),('initiative',0,539,549,'en',0,'Project'),('initiative',0,540,550,'en',0,'Project'),('initiative',0,541,551,'en',0,'Programme'),('initiative',0,542,552,'en',0,'Programme'),('initiative',0,543,553,'en',0,'Programme'),('initiative',0,544,554,'en',0,'Project'),('initiative',0,545,555,'en',0,'Project'),('initiative',0,546,556,'en',0,'Programme'),('initiative',0,555,565,'en',0,'Programme'),('initiative',0,556,566,'en',0,'Programme'),('initiative',0,557,567,'en',0,'Project'),('initiative',0,564,582,'en',0,'Project'),('initiative',0,572,599,'en',0,'Programme'),('initiative',0,589,616,'en',0,'Project'),('initiative',0,590,617,'en',0,'Project'),('initiative',0,592,621,'en',0,'Project'),('initiative',0,593,622,'en',0,'Project');

--
-- Table structure for table `node__field_invitation_list`
--

CREATE TABLE `node__field_invitation_list` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_invitation_list_value` varchar(254) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_invitation_list.';

--
-- Dumping data for table `node__field_invitation_list`
--

INSERT INTO `node__field_invitation_list` VALUES ('webform',0,594,623,'en',0,'vassilakis@open.gr'),('webform',0,594,623,'en',1,'mimia@techlink.gr'),('webform',0,594,623,'en',2,'amimi@open.gr'),('webform',0,594,623,'en',3,'annamimi9@gmail.com'),('webform',0,594,623,'en',4,'costas.vassilakis@gmail.com');

--
-- Table structure for table `node__field_invitation_sent`
--

CREATE TABLE `node__field_invitation_sent` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_invitation_sent_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_invitation_sent_value` (`field_invitation_sent_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_invitation_sent.';

--
-- Dumping data for table `node__field_invitation_sent`
--

INSERT INTO `node__field_invitation_sent` VALUES ('webform',0,594,623,'en',0,'yes');

--
-- Table structure for table `node__field_invited_list`
--

CREATE TABLE `node__field_invited_list` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_invited_list_value` varchar(254) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_invited_list.';

--
-- Dumping data for table `node__field_invited_list`
--

INSERT INTO `node__field_invited_list` VALUES ('webform',0,594,623,'en',0,'mimia@techlink.gr'),('webform',0,594,623,'en',1,'amimi@open.gr'),('webform',0,594,623,'en',2,'annamimi9@gmail.com'),('webform',0,594,623,'en',3,'vassilakis@open.gr'),('webform',0,594,623,'en',4,'costas.vassilakis@gmail.com');

--
-- Table structure for table `node__field_limitations`
--

CREATE TABLE `node__field_limitations` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_limitations_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_limitations.';

--
-- Dumping data for table `node__field_limitations`
--

INSERT INTO `node__field_limitations` VALUES ('indicator',0,399,408,'en',0,'The information and data required to produce this indicator could not be easy to find, particularly if there is no formal policy regarding intellectual property.'),('indicator',0,400,409,'en',0,'Comprehensiveness might come at the expense of producing overburdening information.'),('indicator',0,401,410,'en',0,'The indicator does not provide information on the quality of the audit conducted.'),('indicator',0,402,411,'en',0,'Comprehensiveness might come at the expense of overburdening information.'),('indicator',0,403,412,'en',0,'Providing a thorough description might require a large amount of information.'),('indicator',0,404,413,'en',0,'Providing a thorough description might require a large amount of information.'),('indicator',0,405,414,'en',0,'Accurately disaggregating the economic value and attributing it to stakeholders might be difficult and time-consuming.'),('indicator',0,406,415,'en',0,'Althought the ROI specific for health reseach can provide valuable economic and financial information, its calculation might be difficult for some initiatives/projects.'),('indicator',0,407,416,'en',0,'Estimating the direct operating income directly attributed to the exploitation of research findings might be difficult due to the complexity of allocating the operating expenses that are directly related to their obtention. If the initiative/project cannot estimate them, it can use the overall operating income as proxy if its main activity is performing research.'),('indicator',0,408,417,'en',0,'The indicator only evaluates the economic return of patents, but it does not capture the actual effect that the application of patents has on patients.'),('indicator',0,409,418,'en',0,'The indicator requires that all costs and benefits can be identified and appropriately quantified. Assessing monetary values of health outcomes can be difficult.'),('indicator',0,410,419,'en',0,'The indicator only evaluates the economic return of patents, but it does not capture their actual application.'),('indicator',0,411,420,'en',0,'The indicator does not reflect the quality or impact of projects. It needs to be complemented with that information.'),('indicator',0,412,421,'en',0,'The indicator does not account for the products/treatments\' efficacy or impact on patients nor society. It needs to be complemented.'),('indicator',0,413,422,'en',0,'Difficulties in performing the survey and reaching the proper stakeholders.'),('indicator',0,414,423,'en',0,'There might be difficulties in attribution issues regarding costs included in the calculation and indirect costs involved in the production process.'),('indicator',0,415,424,'en',0,'The uncertainty of estimations and the differences in choices of measurement of costs and benefits significantly impact the interpretation of the information. Difficulty of attributing the specific contribution to cost saving of the initiative/project.'),('indicator',0,416,425,'en',0,'The indicator does not inform about the effects on the initiative/project (possibility of wrong judgements). The indicator is particularly relevant for pharma industry.'),('indicator',0,417,426,'en',0,'The indicator does not inform about the quality and long-term horizon of the jobs created.'),('indicator',0,419,428,'en',0,'Combining the data from different sources could be difficult.'),('indicator',0,420,429,'en',0,'Failure to prescribe drugs can also indicate lack of availability in some settings, and this need for local interpretation requires that this be a complementary indicator.'),('indicator',0,421,430,'en',0,'This indicator requires the direct engagement of the research initiative/project and health administrative bodies to identify the development and/or improvement of governance models.'),('indicator',0,422,431,'en',0,'It is hard to estimate and collect data. It needs precise clarification of which impacts are going to be assessed.'),('indicator',0,423,432,'en',0,'Not all individuals participate in screening, so the sample may be biased towards those who care about their health.'),('indicator',0,424,433,'en',0,'The availability of digital technologies may vary depending on the scale and relevance of the initiative/project.'),('indicator',0,425,434,'en',0,'Estimating the denominatar and numerator of the indicator might be complicated and time consuming.'),('indicator',0,426,435,'en',0,'Data disclosed by company needs to be verified by an independent third party.'),('indicator',0,427,436,'en',0,'Quality of data might vary across regions.'),('indicator',0,428,437,'en',0,'Data availability might prove problematic. Percentage does not tell much about the multidisciplinary interventions or their effectiveness.'),('indicator',0,429,438,'en',0,'The indicator requires gathering data from several training providers.'),('indicator',0,431,440,'en',0,'Quality indicators are not a direct measure of quality, because quality is multidimensional requiring many different indicators.'),('indicator',0,432,441,'en',0,'Requires large amount of information on long timescale. Risk is assessed at population level not an individual patient level.'),('indicator',0,433,442,'en',0,'It might be difficult to identify all potentially preventable hospitalisations. Some hospitalisations may not be avoidable. The term \"preventable\" might be understood at different levels for different stakeholders.'),('indicator',0,434,443,'en',0,'Health and safety are relative concepts. The plans developed describe only the risks detected under certain circumstances. Reporting might be time-consuming requiring large amount of data collection.'),('indicator',0,435,444,'en',0,'The indicator has a limited end-user perspective. It does not consider how useful guidelines are for patients.'),('indicator',0,436,445,'en',0,'Calculating QALY or cost effectiveness thresholds is particularly complex. The calculation methodology may need refinement to realize the financial advantages and opportunity costs. '),('indicator',0,437,446,'en',0,'Assessing if a given intervention has contributed to reducing mortality rates among PwMS might be difficult.'),('indicator',0,438,447,'en',0,'Qualitative information is difficult to express in a uniform, comparable fashion.'),('indicator',0,439,448,'en',0,'The measurement of patient satisfaction is disease-specific.'),('indicator',0,440,449,'en',0,'The breath of the information that might be included under this indicator makes it difficult to encapsulate it in a particular format.'),('indicator',0,441,450,'en',0,'Comprehensiveness might come at the expense of producing overburdening information.'),('indicator',0,442,451,'en',0,'The indicator can be used for academic gaming, encouraging researchers to publish papers in high-impact journals and to ignore national channels (valuable for community/society). If the initiative publishes interdisciplinary research across different research areas, the indicator could be difficult to compare (differences of publication cultures/subject areas/research fieds, language used).'),('indicator',0,443,452,'en',0,'The indicator does not account for the long-term relationship of collaborations and whether they have been stable over time.'),('indicator',0,444,453,'en',0,'When interpreting this indicator, users need to consider that publication fees may prevent publishing in open access journals. The possibilities of publishing in open access varies across research topics (number of OA journals). Therefore, some initiatives/projects might have low or null values in this indicator due to the difficulties mentioned above.\r\nThe data can be provided in a graphic (see example).'),('indicator',0,445,454,'en',0,'Although the indicator informs about the level of use of anticipatory design it does not inform the impact of these techniques for patients. It needs to be complemented with additional information.'),('indicator',0,446,455,'en',0,'Citations is just one dimension of the quality of publications. Not all citations are necessarily recorded since not all publications are indexed.'),('indicator',0,447,456,'en',0,'Calculation requires a complex formula and additional citation searching.'),('indicator',0,448,457,'en',0,'Citations may not reflect what is considered valuable in academic terms (basic research)'),('indicator',0,449,458,'en',0,'The indicator does no inform about the quality or intensity of activities. This limitation can be solved considering the quality and the number of participants in the activities.'),('indicator',0,450,459,'en',0,'The indicator does not capture the scope of communication (e.g., how many people have been reached).'),('indicator',0,451,460,'en',0,'The selection of adequate analytic tool/competence needed and the time spent for analysis.'),('indicator',0,452,461,'en',0,'Although the indicator informs about the compliance with clinical guidelines, it does not offer assurance of compliance level. Other limitations are the difficulty and cost of data collection.'),('indicator',0,453,462,'en',0,'The information disclosed in this indicator might be difficult to interpret for layperson stakeholders. To overcome this issue, the description should be clear and try to avoid complicated technical jargon to simplify its understading.'),('indicator',0,454,463,'en',0,'This indicator measures procedures and performance. If bureaucracy timings of the ethical committee are slow this indicator can become too time consuming.'),('indicator',0,455,464,'en',0,'This indicator is descriptive. It might be limited by the fact that it does not include measures of deviation from values, principles, standards and norms of behavior.'),('indicator',0,456,465,'en',0,'Comprehensiveness might come at the expense of producing overburdening information.'),('indicator',0,457,466,'en',0,'The indicator does not account for the success of the research funded with the grants.'),('indicator',0,458,467,'en',0,'The indicator does not inform about the quality or intensity of the collaboration.'),('indicator',0,459,468,'en',0,'The indicator does not inform about the quality or intensity of the public engagement.'),('indicator',0,460,469,'en',0,'The indicator requires a large amount of information.'),('indicator',0,461,470,'en',0,'Comprehensiveness might come at the expense of producing overburdening information.'),('indicator',0,462,471,'en',0,'Comprehensiveness might come at the expense of producing overburdening information.'),('indicator',0,463,472,'en',0,'Comprehensiveness in describing the changes might come at the expense of producing overburdening information.'),('indicator',0,464,473,'en',0,'The indicator does not inform about the quality of research.'),('indicator',0,465,474,'en',0,'Comprehensiveness might come at the expense of producing overburdening information.'),('indicator',0,467,476,'en',0,'The indicator may not reflect the same level of outcomes compared to academic results.'),('indicator',0,468,477,'en',0,'Comprehensiveness might come at the expense of detailed information. It is difficult to evaluate the accuracy and update of information.'),('indicator',0,469,478,'en',0,'The successful implementation of new clinical practices resulting from research outcomes is time consuming and it may take several years before the impact of research is perceived.'),('indicator',0,470,479,'en',0,'In some cases, it might be difficult for the initiative to calculate the actual number of patents that are being applied by the pharma industry. In these situations, the initiative/project should only consider those with evidence proving its actual application.'),('indicator',0,471,480,'en',0,'This indicator evaluates intellectual property sharing, but it does not assess whether the sharing actually leads to new significant discoveries.'),('indicator',0,472,481,'en',0,'This indicator does not evaluate whether or not the patents are being actually applied.'),('indicator',0,473,482,'en',0,'This indicator can give insufficient credit to basic science.\r\nThis indicator could be invalid for research projects not involving clinical trials (rehabilitation, e-Health ICT development, etc).'),('indicator',0,474,483,'en',0,'Comprehensiveness might come at the expense of detailed information. It is difficult to evaluate the accuracy and update of information.'),('indicator',0,475,484,'en',0,'The indicator does not tell about the usefulness of the products for users or their actual influence on patients and their recovery.'),('indicator',0,476,485,'en',0,'The indicator does not inform about the usefulness of the therapeutic advances or their actual influence on patients and their recovery.'),('indicator',0,478,487,'en',0,'The indicator describes the potential effect of new developments, but it does not offer information on their actual effect on patients.'),('indicator',0,479,488,'en',0,'The indicator does not inform about the quality or intensity of collaboration. '),('indicator',0,480,489,'en',0,'The indicator does not tell much about the quality or intensivity of involvement.'),('indicator',0,481,490,'en',0,'The indicator does not tell much about the success of the application efforts.'),('indicator',0,482,491,'en',0,'It needs to be calculated at the individual level (single researchers) and then aggregated at organizational level.'),('indicator',0,483,492,'en',0,'The indicator needs to be calculated at individual level (single researchers or specific programes) and then aggregated at initiative/project level.'),('indicator',0,484,493,'en',0,'The indicator assimilates the contribution to human capital of all people within the same category.'),('indicator',0,485,494,'en',0,'Comprehensiveness might come at the expense of producing overburdening information.'),('indicator',0,486,495,'en',0,'The indicator does not consider the existence of policies to enhance women representation.'),('indicator',0,487,496,'en',0,'The indicator does not consider the existence of policies to enhance women representation.'),('indicator',0,488,497,'en',0,'The company needs to clearly allocate costs to each research project.'),('indicator',0,490,499,'en',0,'The indicator is hard to define, with a lot of possible variation and its outputs are so intangible that it is not possible to come up with a single universal assessment system.'),('indicator',0,491,500,'en',0,'This indicator might require the disclosure of large amounts of information. Additionally, the governance model might be different among research bodies, which could hinder their comparison. To overcome this obstacles, the governance model established by MULTI-ACT might work as a benchmark when producing this indicator.'),('indicator',0,492,501,'en',0,'This indicator provides one way to analyze the relevance of research findings to clinical practice. Stakeholders should be aware about the fact that few or none outreach visits have been paid does not necessarily imply that the practical relevance of research findings is low.'),('indicator',0,493,502,'en',0,'The development of new methodologies might not always be related to future impacts. Therefore, the quality of the methodological improvements needs to be assessed.'),('indicator',0,494,503,'en',0,'The indicator does not tell much about the quality or intensity of collaboration. The perspective/experience of target groups is missing.'),('indicator',0,495,504,'en',0,'The indicator does not provide information on the quality or intensity of the engagement.'),('indicator',0,496,505,'en',0,'The indicator does not provide information on the quality of the engagement.'),('indicator',0,497,506,'en',0,'Computing the indicator requires the use of surveys and interviews to identify the social perception of research.'),('indicator',0,498,507,'en',0,'This indicator measures procedures but not performance (results).'),('indicator',0,499,508,'en',0,'This indicator can suffer for the unclear definition of \"infection\". The idea is to keep this indicator broad and it would consider all sort of accidents.'),('indicator',0,500,509,'en',0,'The information is mainly qualitative, which can be difficult to compare between initiatives/projects.'),('indicator',0,501,510,'en',0,'Employee turnover could be misleading in this sector, as mobility could be a problem, but excellence in research also requires the mobility of talent.'),('indicator',0,503,512,'en',0,'It can be challenging to distinguish how specific research informs a particular policy.'),('indicator',0,504,513,'en',0,'Identifying best practices to adopt improving measures can be time consuming. It requires the establishment of effective identification methodologies.'),('indicator',0,505,514,'en',0,'The breath of the information that might be included under this indicator may be general information about stakeholder engagement.'),('indicator',0,506,515,'en',0,'Informing about the results of environmental audits can be compromising.'),('indicator',0,507,516,'en',0,'This is a rough indicator to measure eco-efficiency. Difficulty in obtaining all the information necessary.'),('indicator',0,508,517,'en',0,'Difficulty in obtaining all the information necessary to calculate GHG emissions for research.'),('indicator',0,509,518,'en',0,'The indicator does not reveal the effectiveness or content of the community development and the engagement actions taken.'),('indicator',0,512,521,'en',0,'Although the indicator informs about the consideration of RRI standards, it does not offers assurance of whether or not the consideration is being effective.'),('indicator',0,547,557,'en',0,'The indicator does not provide information about the quality or intensity of the engagement.'),('indicator',0,548,558,'en',0,'The indicator might be negative in many case which does not necessarily imply lack of transparency. Producing external information could be costly and some research initiatives/projects might not be able to do it.'),('indicator',0,549,559,'en',0,'The measurement of patient satisfaction is diagnosis-specific. '),('indicator',0,550,560,'en',0,'The measurement of patient satisfaction is diagnosis-specific. '),('indicator',0,551,561,'en',0,'The measurement of patient satisfaction is diagnosis-specific. '),('indicator',0,552,562,'en',0,'The measurement of patient satisfaction is diagnosis-specific. '),('indicator',0,553,563,'en',0,'The measurement of patient satisfaction is diagnosis-specific. '),('indicator',0,554,564,'en',0,'The measurement of patient satisfaction is diagnosis-specific. '),('indicator',0,585,612,'en',0,'The measurement of patient satisfaction is diagnosis-specific. ');

--
-- Table structure for table `node__field_links`
--

CREATE TABLE `node__field_links` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_links_value` longtext NOT NULL,
  `field_links_format` varchar(255) CHARACTER SET ascii DEFAULT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_links_format` (`field_links_format`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_links.';

--
-- Dumping data for table `node__field_links`
--

INSERT INTO `node__field_links` VALUES ('indicator',0,403,412,'en',0,'<p>Kalucy, E. C., Jackson-Bowers, E., McIntyre, E., &amp; Reed, R. (2009). The feasibility of determining the impact of primary health care research projects using the Payback Framework.&nbsp;<em>Health Research Policy and Systems</em>,&nbsp;<em>7</em>(1), 11.</p>\r\n\r\n<p>See Table 1.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://link.springer.com/article/10.1186/1478-4505-7-11\">https://link.springer.com/article/10.1186/1478-4505-7-11</a></p>\r\n','basic_html'),('indicator',0,404,413,'en',0,'<p>GRI Standards 2016. GRI 203:&nbsp;Indirect Economic Impacts.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.globalreporting.org/standards/gri-standards-download-center/gri-203-indirect-economic-impacts/\">https://www.globalreporting.org/standards/gri-standards-download-center/gri-203-indirect-economic-impacts/</a></p>\r\n','basic_html'),('indicator',0,406,415,'en',0,'<p>For more information on how to compute the ROI specific for health research, see&nbsp;KPMG, Economic Impact of Medical Research in Australia (2018).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://aamri.org.au/wp-content/uploads/2018/10/Economic-Impact-of-Medical-Research-exec-summary.pdf\">https://aamri.org.au/wp-content/uploads/2018/10/Economic-Impact-of-Medical-Research-exec-summary.pdf</a></p>\r\n','basic_html'),('indicator',0,407,416,'en',0,'<p>Shabaninejad, H., Mirsalehian, M. H., &amp; Mehralian, G. (2014). Development of an integrated performance measurement (PM) model for pharmaceutical industry.&nbsp;<em>Iranian Journal of Pharmaceutical Research: IJPR</em>,&nbsp;<em>13</em>(Suppl), 207.</p>\r\n\r\n<p>See Table 4.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977072/\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977072/</a></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>Process to calculate it considering the information provided in financial statements. For instance, in the&nbsp;Burnet Institute 2018 Financial Report,&nbsp;divide \"total liabilities\" (p. 10) by \"results from operating activity\" (p. 9) times 100.</p>\r\n\r\n<p>The&nbsp;Burnet Institute 2018 Financial Report is available at:&nbsp;<a href=\"https://www.burnet.edu.au/system/annual_report/file/25/Financial_Report_2018_-_digital.pdf\">https://www.burnet.edu.au/system/annual_report/file/25/Financial_Report_2018_-_digital.pdf</a></p>\r\n','basic_html'),('indicator',0,408,417,'en',0,'<p>Banzi, R., Moja, L., Pistotti, V., Facchini, A., &amp; Liberati, A. (2011). Conceptual frameworks and empirical approaches used to assess the impact of health research: an overview of reviews.&nbsp;<em>Health Research Policy and Systems</em>,&nbsp;<em>9</em>(1), 26.</p>\r\n\r\n<p>See Table 2.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://link.springer.com/article/10.1186/1478-4505-9-26\">https://link.springer.com/article/10.1186/1478-4505-9-26</a></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>Example on how to calculate it: Sanofi 2018 Annual report: divide \"other intangible assets\" (see note D.35.3 - page F111) by &nbsp;\"carrying amount of products, trademarks and other rights\" (see note D.4 - page F44)<br />\r\nIf the indicator is difficult to calculate to some initiatives, it could be simplified by dividing the revenues obtained from the exploitation of patents and intellectual property rights by the total number of patents/intellectual property rights owned by &nbsp;the initiative.<br />\r\n&nbsp;</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Sanofi-20-F-2018-EN-PDF-e-accessible_01.pdf?la=en&amp;hash=6AC303E769D68FF95508C93D1CBF6F1A\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Sanofi-20-F-2018-EN-PDF-e-accessible_01.pdf?la=en&amp;hash=6AC303E769D68FF95508C93D1CBF6F1A</a></p>\r\n','basic_html'),('indicator',0,413,422,'en',0,'<p>Krizanova, A., Gajanova, L., &amp; Nadanyiova, M. (2018). Design of a CRM level and performance measurement model.&nbsp;<em>Sustainability</em>,&nbsp;<em>10</em>(7), 2567.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.mdpi.com/2071-1050/10/7/2567\">https://www.mdpi.com/2071-1050/10/7/2567</a></p>\r\n','basic_html'),('indicator',0,414,423,'en',0,'<p>Parisi, C. (2013). The Use of Causal Mapping in the Design of Sustainability Performance Measurement Systems: Evidence from Novo Nordisk.&nbsp;<em>Studies in Managerial and Financial Accounting</em>,&nbsp;<em>26</em>, 231-264.</p>\r\n\r\n<p>See Figure 2.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.emerald.com/insight/content/doi/10.1108/S1479-3512(2013)0000026007/full/html\">https://www.emerald.com/insight/content/doi/10.1108/S1479-3512(2013)0000026007/full/html</a></p>\r\n','basic_html'),('indicator',0,415,424,'en',0,'<p>Kuruvilla, S., Mays, N., Pleasant, A., &amp; Walt, G. (2006). Describing the impact of health research: a Research Impact Framework.&nbsp;<em>BMC Health Services Research</em>,&nbsp;<em>6</em>(1), 134.</p>\r\n\r\n<p>See p. 12</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://link.springer.com/article/10.1186/1472-6963-6-134\">https://link.springer.com/article/10.1186/1472-6963-6-134</a></p>\r\n','basic_html'),('indicator',0,416,425,'en',0,'<p>Access to Medicine Index 2018 - Methodology Report<br />\r\nIndicator D.III.5&nbsp;(p. 50).<br />\r\nAvailable at: <a href=\"https://accesstomedicineindex.org/media/atmi/2017-Methodology-2018-Access-to-Medicine-Index.pdf\">https://accesstomedicineindex.org/media/atmi/2017-Methodology-2018-Access-to-Medicine-Index.pdf</a></p>\r\n','basic_html'),('indicator',0,421,430,'en',0,'<p>Department of Health and Human Services. Victoria State Government.</p>\r\n\r\n<p>Available at:&nbsp;<em><a href=\"https://fac.dhhs.vic.gov.au/policies-and-procedures\">https://fac.dhhs.vic.gov.au/policies-and-procedures</a></em></p>\r\n','basic_html'),('indicator',0,422,431,'en',0,'<p>Oortwijn, W. J., Hanney, S. R., Ligtvoet, A., Hoorens, S., Wooding, S., Grant, J., ... &amp; Bouter, L. M. (2008). Assessing the impact of health technology assessment in the Netherlands.&nbsp;<em>International Journal of Technology Assessment in Health Care</em>,&nbsp;<em>24</em>(3), 259-269.</p>\r\n\r\n<p>See Table 1. Sections 5a and 5b.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.rand.org/pubs/external_publications/EP20080616.html?src=mobile\">https://www.rand.org/pubs/external_publications/EP20080616.html?src=mobile</a></p>\r\n','basic_html'),('indicator',0,428,437,'en',0,'<p>Lindström, J., Wikström, K., Maggini, M., Icks, A., Kuske, S., Rothe, U., ... &amp; Zaletel, J. (2015). Quality indicators for diabetes prevention programs in health care targeted at people at high risk.&nbsp;<em>Annali dell\'Istituto Superiore di Sanità</em>,&nbsp;<em>51</em>, 187-191.</p>\r\n\r\n<p>See Table 1.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.scielosp.org/article/aiss/2015.v51n3/187-191/en/\">https://www.scielosp.org/article/aiss/2015.v51n3/187-191/en/</a></p>\r\n','basic_html'),('indicator',0,431,440,'en',0,'<p>Kuruvilla, S., Mays, N., Pleasant, A., &amp; Walt, G. (2006). Describing the impact of health research: a Research Impact Framework.&nbsp;<em>BMC Health Services Research</em>,&nbsp;<em>6</em>(1), 134.</p>\r\n\r\n<p>See p.11</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://link.springer.com/article/10.1186/1472-6963-6-134\">https://link.springer.com/article/10.1186/1472-6963-6-134</a></p>\r\n','basic_html'),('indicator',0,434,443,'en',0,'<p>Department of Health and Human Services. Victoria State Government (2012).&nbsp;Children with problem sexual behaviours and their families.&nbsp;Best interests case practice model Specialist practice resource.</p>\r\n\r\n<p>See p. 46.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.dhhs.vic.gov.au/sites/default/files/documents/201705/Children_with_problem_sexual_behaviours_-and-_their_families-2012_0.pdf\">https://www.dhhs.vic.gov.au/sites/default/files/documents/201705/Children_with_problem_sexual_behaviours_-and-_their_families-2012_0.pdf</a></p>\r\n','basic_html'),('indicator',0,438,447,'en',0,'<p>Ng, J., Scahill, S., &amp; Harrison, J. (2018). Stakeholder views do matter: a conceptual framework for medication safety measurement.&nbsp;<em>Journal of Pharmaceutical Health Services Research</em>,&nbsp;<em>9</em>(1), 21-31.</p>\r\n\r\n<p>See Table 2.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://onlinelibrary.wiley.com/doi/abs/10.1111/jphs.12203\">https://onlinelibrary.wiley.com/doi/abs/10.1111/jphs.12203</a></p>\r\n','basic_html'),('indicator',0,445,454,'en',0,'<p>Yaghmaei, E. (2018). Responsible research and innovation key performance indicators in industry.&nbsp;<em>Journal of Information, Communication and Ethics in Society 16</em>(2).</p>\r\n\r\n<p>See Table IV.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.emerald.com/insight/content/doi/10.1108/JICES-11-2017-0066/full/html\">https://www.emerald.com/insight/content/doi/10.1108/JICES-11-2017-0066/full/html</a></p>\r\n','basic_html'),('indicator',0,446,455,'en',0,'<p>More information on the use of Google Scholar to estimate the impact of research:</p>\r\n\r\n<p>Van Aalst, Jan. \"Using Google Scholar to estimate the impact of journal articles in education.\"&nbsp;<em>Educational Researcher</em>&nbsp;39.5 (2010): 387-400.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://journals.sagepub.com/doi/full/10.3102/0013189X10371120\">https://journals.sagepub.com/doi/full/10.3102/0013189X10371120</a></p>\r\n','basic_html'),('indicator',0,447,456,'en',0,'<p>Innovative Medicine Initiative (2012).&nbsp;Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking (IMI).</p>\r\n\r\n<p>See p. 11</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/reference-documents/IMI%20JU%20Bibliometric%20Report%201_FINAL.pdf\">https://www.imi.europa.eu/sites/default/files/uploads/documents/reference-documents/IMI%20JU%20Bibliometric%20Report%201_FINAL.pdf</a></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>Carley S, &amp; Porter A (2012). A forward diversity index. Scientometrics, 90:407-427. Available at: <a href=\"https://link.springer.com/article/10.1007/s11192-011-0528-1\">https://link.springer.com/article/10.1007/s11192-011-0528-1</a></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>See a bibliometric analysis of citations of papers in differentes disciplines by&nbsp;Innovative Medicines Initiative Joint Undertaking (IMI)&nbsp;( p. 25).&nbsp;This data can be used to compute the indicator. Available at:&nbsp;<a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/reference-documents/IMI%20JU%20Bibliometric%20Report%201_FINAL.pdf\">https://www.imi.europa.eu/sites/default/files/uploads/documents/reference-documents/IMI%20JU%20Bibliometric%20Report%201_FINAL.pdf</a></p>\r\n','basic_html'),('indicator',0,448,457,'en',0,'<p>Sarli, C. C., Dubinsky, E. K., &amp; Holmes, K. L. (2010). Beyond citation analysis: a model for assessment of research impact.&nbsp;<em>Journal of the Medical Library Association: JMLA</em>,&nbsp;<em>98</em>(1), 17.</p>\r\n\r\n<p>See Table 3.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801963/\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801963/</a></p>\r\n','basic_html'),('indicator',0,450,459,'en',0,'<p>JPND (2016). Recalibrated Monitoring and Evaluation Framework for the EU Joint Programme – Neurodegenerative Disease Research.<br />\r\nSee outcome 44 (p. 10)<br />\r\nAvailable at: <a href=\"https://www.neurodegenerationresearch.eu/wp-content/uploads/2012/05/2016-JPND-Recalibrated-Monitoring-and-Evaluation-Framework.pdf\">https://www.neurodegenerationresearch.eu/wp-content/uploads/2012/05/2016-JPND-Recalibrated-Monitoring-and-Evaluation-Framework.pdf</a></p>\r\n','basic_html'),('indicator',0,451,460,'en',0,'<p>Sarli, C. C., Dubinsky, E. K., &amp; Holmes, K. L. (2010). Beyond citation analysis: a model for assessment of research impact.&nbsp;<em>Journal of the Medical Library Association: JMLA</em>,&nbsp;<em>98</em>(1), 17-23.</p>\r\n\r\n<p>See Table 2.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801963/\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801963/</a></p>\r\n','basic_html'),('indicator',0,452,461,'en',0,'<p>Banzi, R., Moja, L., Pistotti, V., Facchini, A., &amp; Liberati, A. (2011). Conceptual frameworks and empirical approaches used to assess the impact of health research: an overview of reviews.&nbsp;<em>Health Research Policy and Systems</em>,&nbsp;<em>9</em>(1), 26.</p>\r\n\r\n<p>See Table 2.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://link.springer.com/article/10.1186/1478-4505-9-26\">https://link.springer.com/article/10.1186/1478-4505-9-26</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,453,462,'en',0,'<p>Yaghmaei, E. (2018). Responsible research and innovation key performance indicators in industry.&nbsp;<em>Journal of Information, Communication and Ethics in Society 16</em>(2).</p>\r\n\r\n<p>See Table V.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.emerald.com/insight/content/doi/10.1108/JICES-11-2017-0066/full/html\">https://www.emerald.com/insight/content/doi/10.1108/JICES-11-2017-0066/full/html</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,455,464,'en',0,'<p>GRI Standards 2016. General Disclosures.</p>\r\n\r\n<p>Disclosure&nbsp;102-16 Values, principles, standards, and norms of behavior.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.globalreporting.org/standards/gri-standards-download-center/gri-102-general-disclosures/\">https://www.globalreporting.org/standards/gri-standards-download-center/gri-102-general-disclosures/</a></p>\r\n','basic_html'),('indicator',0,456,465,'en',0,'<p>MoRRI – The Evolution and Benefits of Responsible Research and Innovation.<br />\r\nSee p. 74<br />\r\nAvailable at: <a href=\"https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1\">https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1</a></p>\r\n','basic_html'),('indicator',0,461,470,'en',0,'<p>Innovative Medicines Initiative (2018). Annual Activity Report 2017.</p>\r\n\r\n<p>See&nbsp;IMI2 KPI 11</p>\r\n\r\n<p>Available at:<a href=\" https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/Governance/Governing-Board/IMI2-GB-DEC-2018-17_Decision%20AAR%202017-GB%20Assessment_signed%2026JUN.pdf\">&nbsp;https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/Governance/Governing-Board/IMI2-GB-DEC-2018-17_Decision%20AAR%202017-GB%20Assessment_signed%2026JUN.pdf</a></p>\r\n','basic_html'),('indicator',0,462,471,'en',0,'<p>Innovative Medicines Initiative (2018). Annual Activity Report 2017.</p>\r\n\r\n<p>See&nbsp;IMI2 KPI 18</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/Governance/Governing-Board/IMI2-GB-DEC-2018-17_Decision%20AAR%202017-GB%20Assessment_signed%2026JUN.pdf\">https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/Governance/Governing-Board/IMI2-GB-DEC-2018-17_Decision%20AAR%202017-GB%20Assessment_signed%2026JUN.pdf</a></p>\r\n','basic_html'),('indicator',0,464,473,'en',0,'<p>Oortwijn, W. J., Hanney, S. R., Ligtvoet, A., Hoorens, S., Wooding, S., Grant, J., ... &amp; Bouter, L. M. (2008). Assessing the impact of health technology assessment in the Netherlands.&nbsp;<em>International Journal of Technology Assessessment in Health Care</em>,&nbsp;<em>24</em>(3), 259-269.</p>\r\n\r\n<p>See Table 1 (section 2b)</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.rand.org/pubs/external_publications/EP20080616.html?src=mobile\">https://www.rand.org/pubs/external_publications/EP20080616.html?src=mobile</a></p>\r\n','basic_html'),('indicator',0,465,474,'en',0,'<p>CAHS (2009). Making an impact.&nbsp;A Preferred Framework and Indicators to Measure Returns on Investment in Health Research.&nbsp;Report of the Panel on the Return on Investments in Health Research January 2009.</p>\r\n\r\n<p>See p. 109</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.cahs-acss.ca/wp-content/uploads/2011/09/ROI_FullReport.pdf\">https://www.cahs-acss.ca/wp-content/uploads/2011/09/ROI_FullReport.pdf</a></p>\r\n','basic_html'),('indicator',0,467,476,'en',0,'<p>JPND (2016).&nbsp;Recalibrated Monitoring and Evaluation Framework for the EU Joint Programme&nbsp;–&nbsp;Neurodegenerative Disease Research.</p>\r\n\r\n<p>See outcome 13 (p. 12)</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.neurodegenerationresearch.eu/wp-content/uploads/2012/05/2016-JPND-Recalibrated-Monitoring-and-Evaluation-Framework.pdf\">https://www.neurodegenerationresearch.eu/wp-content/uploads/2012/05/2016-JPND-Recalibrated-Monitoring-and-Evaluation-Framework.pdf</a></p>\r\n','basic_html'),('indicator',0,468,477,'en',0,'<p>MoRRI – The Evolution and Benefits of Responsible Research and Innovation.</p>\r\n\r\n<p>See p. 78</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1\">https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1</a></p>\r\n','basic_html'),('indicator',0,469,478,'en',0,'<p>Weiss, A. P. (2007). Measuring the impact of medical research: moving from outputs to outcomes.&nbsp;<em>American Journal of Psychiatry</em>,&nbsp;<em>164</em>(2), 206-214.</p>\r\n\r\n<p>See pp. 208-209.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://ajp.psychiatryonline.org/doi/abs/10.1176/ajp.2007.164.2.206\">https://ajp.psychiatryonline.org/doi/abs/10.1176/ajp.2007.164.2.206</a></p>\r\n','basic_html'),('indicator',0,470,479,'en',0,'<p>D’Este, P., Tribó, J. A., &amp; García-Romero, A. (2008). Colaboración con universidades y desempeño innovador en la industria farmacéutica española (2003-2005).&nbsp;<em>Medicina Clínica</em>,&nbsp;<em>131</em>, 66-70.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.sciencedirect.com/science/article/pii/S0025775308764108\">https://www.sciencedirect.com/science/article/pii/S0025775308764108</a></p>\r\n','basic_html'),('indicator',0,471,480,'en',0,'<p>Access to Medicine Index 2018 - Methodology Report</p>\r\n\r\n<p>Indicator&nbsp;E.III.2 (p. 51).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://accesstomedicineindex.org/media/atmi/2017-Methodology-2018-Access-to-Medicine-Index.pdf\">https://accesstomedicineindex.org/media/atmi/2017-Methodology-2018-Access-to-Medicine-Index.pdf</a></p>\r\n','basic_html'),('indicator',0,476,485,'en',0,'<p>ERA-NET NEURON.&nbsp;‘Development and advancement in methods and technologies towards the understanding of brain diseases’ Joint Transnational Call 2009-&nbsp;Impact Report</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"ERA-NET NEURON ‘Development and advancement in methods and technol- ogies towards the understanding of brain diseases’ Joint Transnational Call 2009 Impact Report\">ERA-NET NEURON ‘Development and advancement in methods and technol- ogies towards the understanding of brain diseases’ Joint Transnational Call 2009 Impact Report</a></p>\r\n','basic_html'),('indicator',0,478,487,'en',0,'<p>Ovseiko, P. V., Oancea, A., &amp; Buchan, A. M. (2012). Assessing research impact in academic clinical medicine: a study using Research Excellence Framework pilot impact indicators.&nbsp;<em>BMC Health Services Research</em>,&nbsp;<em>12</em>(1), 1-23.</p>\r\n\r\n<p>See pp. 13-14.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-12-478\">https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-12-478</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,479,488,'en',0,'<p>Graham, K. E., Chorzempa, H. L., Valentine, P. A., &amp; Magnan, J. (2012). Evaluating health research impact: Development and implementation of the Alberta Innovates–Health Solutions impact framework.&nbsp;<em>Research Evaluation</em>,&nbsp;<em>21</em>(5), 354-367.</p>\r\n\r\n<p>See Table 1. \"Outreach\" indicator.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://academic.oup.com/rev/article-abstract/21/5/354/1559212\">https://academic.oup.com/rev/article-abstract/21/5/354/1559212</a></p>\r\n','basic_html'),('indicator',0,482,491,'en',0,'<p>Kuruvilla, S., Mays, N., Pleasant, A., &amp; Walt, G. (2006). Describing the impact of health research: a Research Impact Framework.&nbsp;<em>BMC Health Services Research</em>,&nbsp;<em>6</em>(1), 134.</p>\r\n\r\n<p>See p. 7-8.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://link.springer.com/article/10.1186/1472-6963-6-134\">https://link.springer.com/article/10.1186/1472-6963-6-134</a></p>\r\n','basic_html'),('indicator',0,490,499,'en',0,'<p>Loughney, D., Claus, B. L., &amp; Johnson, S. R. (2011). To measure is to know: an approach to CADD performance metrics.&nbsp;<em>Drug Discovery Today</em>,&nbsp;<em>16</em>(13-14), 548-554.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.sciencedirect.com/science/article/pii/S1359644611001462\">https://www.sciencedirect.com/science/article/pii/S1359644611001462</a></p>\r\n','basic_html'),('indicator',0,492,501,'en',0,'<p>Sarli, C. C., Dubinsky, E. K., &amp; Holmes, K. L. (2010). Beyond citation analysis: a model for assessment of research impact.&nbsp;<em>Journal of the Medical Library Association: JMLA</em>,&nbsp;<em>98</em>(1), 17.</p>\r\n\r\n<p>See Table 1.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801963/\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801963/</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,496,505,'en',0,'<p>Graham, K. E., Chorzempa, H. L., Valentine, P. A., &amp; Magnan, J. (2012). Evaluating health research impact: Development and implementation of the Alberta Innovates–Health Solutions impact framework.&nbsp;<em>Research Evaluation</em>,&nbsp;<em>21</em>(5), 354-367.</p>\r\n\r\n<p>Table 1. \"Interactions\" indicator</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://academic.oup.com/rev/article/21/5/354/1559212\">https://academic.oup.com/rev/article/21/5/354/1559212</a></p>\r\n','basic_html'),('indicator',0,499,508,'en',0,'<p>Information on injury frequency rate:&nbsp;<a href=\"http://www.hse.gov.uk/statistics/adhoc-analysis/index.htm\">http://www.hse.gov.uk/statistics/adhoc-analysis/index.htm</a></p>\r\n','basic_html'),('indicator',0,503,512,'en',0,'<p>Milat, A. J., Laws, R., King, L., Newson, R., Rychetnik, L., Rissel, C., ... &amp; Bennie, J. (2013). Policy and practice impacts of applied research: a case study analysis of the New South Wales Health Promotion Demonstration Research Grants Scheme 2000–2006.&nbsp;<em>Health research policy and systems</em>,&nbsp;<em>11</em>(1), 5.</p>\r\n\r\n<p>Available at:</p>\r\n\r\n<p><a href=\"https://link.springer.com/article/10.1186/1478-4505-11-5\">https://link.springer.com/article/10.1186/1478-4505-11-5</a></p>\r\n','basic_html'),('indicator',0,504,513,'en',0,'<p>MoRRI (2018).&nbsp;Monitoring the evolution and benefits of responsible Research and Innovation.&nbsp;The evolution of Responsible Research and Innovation&nbsp;–&nbsp;the Indicators report.</p>\r\n\r\n<p>Indicator GOV2</p>\r\n\r\n<p>Available at:</p>\r\n\r\n<p><a href=\"https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1/language-en\">https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1/language-en</a></p>\r\n','basic_html'),('indicator',0,506,515,'en',0,'<p>ISO 14001 provides the guidance for use an environmental management system: &nbsp;<a href=\"https://www.iso.org/standard/60857.html\">https://www.iso.org/standard/60857.html</a></p>\r\n','basic_html'),('indicator',0,507,516,'en',0,'<p>See GRI standards (GRI 301)&nbsp;for more information on how to calculate the indicator:&nbsp;<a href=\"https://www.globalreporting.org/standards/\">https://www.globalreporting.org/standards/</a></p>\r\n','basic_html'),('indicator',0,509,518,'en',0,'<p>GRI Standard 413. Local Communities.</p>\r\n\r\n<p>Available at:</p>\r\n\r\n<p><a href=\"https://www.globalreporting.org/standards/gri-standards-download-center/gri-413-local-communities-2016/\">https://www.globalreporting.org/standards/gri-standards-download-center/gri-413-local-communities-2016/</a></p>\r\n','basic_html'),('indicator',0,512,521,'en',0,'<p>Yaghmaei, E. (2018). Responsible research and innovation key performance indicators in industry.&nbsp;<em>Journal of Information, Communication and Ethics in Society 16 </em>(2), 214-234.</p>\r\n\r\n<p>Available at:&nbsp;</p>\r\n\r\n<p><a href=\"https://www.emerald.com/insight/content/doi/10.1108/JICES-11-2017-0066/full/html\">https://www.emerald.com/insight/content/doi/10.1108/JICES-11-2017-0066/full/html</a></p>\r\n','basic_html'),('indicator',0,549,559,'en',0,'<p><span><span><span><span><span><a href=\"https://pubmed.ncbi.nlm.nih.gov/31659583/\"><span><span><span>https://pubmed.ncbi.nlm.nih.gov/31659583/</span></span></span></a></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,550,560,'en',0,'<p><span><span><span><span><span><a href=\"https://pubmed.ncbi.nlm.nih.gov/31659583/\"><span><span><span>https://pubmed.ncbi.nlm.nih.gov/31659583/</span></span></span></a></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,551,561,'en',0,'<p><span><span><span><span><span><a href=\"https://pubmed.ncbi.nlm.nih.gov/31659583/\"><span><span><span>https://pubmed.ncbi.nlm.nih.gov/31659583/</span></span></span></a></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,552,562,'en',0,'<p><span><span><span><span><span><a href=\"https://pubmed.ncbi.nlm.nih.gov/31659583/\"><span><span><span>https://pubmed.ncbi.nlm.nih.gov/31659583/</span></span></span></a></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,553,563,'en',0,'<p><span><span><span><span><span><a href=\"https://pubmed.ncbi.nlm.nih.gov/31659583/\"><span><span><span>https://pubmed.ncbi.nlm.nih.gov/31659583/</span></span></span></a></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,554,564,'en',0,'<p><span><span><span><span><span><a href=\"https://pubmed.ncbi.nlm.nih.gov/31659583/\"><span><span><span>https://pubmed.ncbi.nlm.nih.gov/31659583/</span></span></span></a></span></span></span></span></span></p>\r\n','basic_html');

--
-- Table structure for table `node__field_meta`
--

CREATE TABLE `node__field_meta` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_meta_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_meta.';

--
-- Dumping data for table `node__field_meta`
--

INSERT INTO `node__field_meta` VALUES ('page',0,305,619,'en',0,'a:1:{s:6:\"google\";s:43:\"XxW8buV32HOTpK6O-m27gG1nha30Ngu6Gm13pOIfGRA\";}');

--
-- Table structure for table `node__field_method_of_measurement_`
--

CREATE TABLE `node__field_method_of_measurement_` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_method_of_measurement__value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_method_of_measurement_.';

--
-- Dumping data for table `node__field_method_of_measurement_`
--

INSERT INTO `node__field_method_of_measurement_` VALUES ('indicator',0,399,408,'en',0,'Provide a narrative description of the policy of the initiative/project regarding its intelectual property strategy. The initiative/project can provide a link to a document where it is disclosed.'),('indicator',0,400,409,'en',0,'Compute a percentage that accounts for the deviations identified. There are different alternatives:\r\n- Number of projects with cost overrun issues / total number of projects\r\n- Number of projects with schedule overrun issues / total number of projects\r\n- Total cost overrun by all the project / expected cost by all the projects\r\nThis information should ideally compared with the previous year or with targets.'),('indicator',0,401,410,'en',0,'Provide the number of observations/audits performed during the reporting period.\r\nThis information should ideally be compared with the two previous years or with targets.'),('indicator',0,402,411,'en',0,'Provide a narrative description of the economic impact for society of commercializing research outputs, for example, creation of employment, import substitution and drug cost. When possible, provide the monetary value of those impacts (e.g. reduced drug cost).'),('indicator',0,403,412,'en',0,'Provide a narrative description of the economic impact on workforce related to the improvement of employees\' health and wellbeing resulting from the initiative/project\'s research.'),('indicator',0,404,413,'en',0,'Provide a narrative description of how the initiative/project\'s research findings lead to the enhancement of well-being and economic conditions among community members.'),('indicator',0,405,414,'en',0,'Provide a table disaggregating the total direct economic value generated (financial resources obtained - financial resources produced) for each stakeholder type to which the initiative/project relates.'),('indicator',0,406,415,'en',0,'There are two alternative methods. The initiative/project can decide to provide one or both.\r\n1) Specific for health research initiatives: Calculate the percentage that health gains and wider economics gain represent relative to the investment in medical research, with a lag between expenditure and outcomes, adjusting for inflation and discounting at a rate of 5% (More detailed information on how to calculate the ratio is provided in KPMG, Economic Impact of Medical Research in Australia (2018)).\r\n2) General ROI: Calculate the percentage that the income generated by the initiative represents respect to the value of its assets.'),('indicator',0,407,416,'en',0,'Divide the total debt registered in the balance sheet of the initiative/project by the operating income registered in the profit and loss statement that can be directly attributed to research result exploitation, and multiple the result times 100.'),('indicator',0,408,417,'en',0,'Divide the revenues obtained from the exploitation of patents and other intellectual property rights during the reporting period by the total value of the patents and intellectual property registered in the balance sheet of the initiative/project, and multiply the result times 100.'),('indicator',0,409,418,'en',0,'Divide the (discounted) benefits of a project expressed in monetary terms by the (discounted) incremental costs. Monetary benefits can be assessed, for instance, through willingness to pay techniques.'),('indicator',0,410,419,'en',0,'Provide the total amount of income (in euros or the domestic currency of the initiative/project) that the initiative obtained from the exploitation of their patents and other intellectual property rights. For the sake of comparison, the initiative shall report the same figure for the two prior periods.'),('indicator',0,411,420,'en',0,'Provide the number and percentage of strategic/plans completed and milestones met.'),('indicator',0,412,421,'en',0,'Count the number of past/potential products and treatments developed by the initiative/project.'),('indicator',0,413,422,'en',0,'Description of the relationships with stakeholders related to the research initiative/project.\r\nQuantitative scores given by stakeholders in surveys disaggregated by stakeholder type.'),('indicator',0,414,423,'en',0,'Calculate the overall costs per unit divided by the number of units (please note that the unit can vary from products to services and processes).'),('indicator',0,415,424,'en',0,'Provide a narrative description of cost-containment strategies as well as monetary information describing the effectiveness of those strategies. Cost-effectiveness can be studied by analyzing research-related changes in health systems in terms of both expenditure and related health outcomes.'),('indicator',0,416,425,'en',0,'Narrative description and numbers of products tracked and whether this information is publicly disclosed (where, when and why a drug recall has taken place).'),('indicator',0,417,426,'en',0,'Count the total number of job created and expected to be created (i.e. the total number of employees) disaggregated by gender.'),('indicator',0,418,427,'en',0,'Calculate the total number and percentage of employee by age group, gender and region.'),('indicator',0,419,428,'en',0,'Calculate the average number of medications used for a certain disease. Provide the change (increase/decrease) in the average number of medications used.'),('indicator',0,420,429,'en',0,'Divide the number of consultations in which no drug is prescribed by the number of consultations surveyed.'),('indicator',0,421,430,'en',0,'Provide a narrative description of the responsible governance structures and monitoring systems that result from the implementation of research results. The initiative can provide a link to a document where it is disclosed.\r\nConsider the Governance Model elaborated by MULTI-ACT.'),('indicator',0,422,431,'en',0,'Assess the degree of the project impact on health benefits using a five-point Likert scale (direct-considerable-moderate-identifiable-non). Describe the broader (societal) impact on health benefits (health gains, improved cost-efficiency/accessibility, qualitative improvements etc.) justifying the selection of the score. Degree of impact on health benefits can be described as free text or classified/quantified as:\r\n10 – At least one of the health benefits was almost solely based on the project’s evidence in a direct instrumental way.\r\n8 – The project made a considerable impact on the health benefits.\r\n6 – The project made a moderate impact on the health benefits.\r\n4 – The project made some identifiable impact on the health benefits.\r\n2 – A claim for impact made but no details given, or details given of a claim for expected future impacts.\r\n0 – No impact on health benefits.'),('indicator',0,423,432,'en',0,'Divide the number of population screened for the disease in which the research of the initiative/project focuses on by the number of the total population. When possible, compute this percentage disaggregated by women and men. '),('indicator',0,424,433,'en',0,'Provide a narrative description of the eHealth/eServices used by the initiative/project.'),('indicator',0,425,434,'en',0,'Calculate the percentage of PwMS receiving treatments respect to the total number of PwMS in a given area.'),('indicator',0,426,435,'en',0,'Indicate whether or not the initiative/project reports on access to medicine issues (Yes/No).'),('indicator',0,427,436,'en',0,'Divide the number of people belonging to marginalized groups (e.g. gender/ethnic) without access to healthcare with the total number of the population. Percentage of men/women/other with access to health services.'),('indicator',0,428,437,'en',0,'Divide the number of interventions using multidisciplinary approach by the number of total interventions.'),('indicator',0,429,438,'en',0,'Calculate number of training courses available for health professionals.'),('indicator',0,430,439,'en',0,'Calculate the number of university employed academics who also work as practitioners that participate in the initiative/project. Provide the share of men/women respect to the total number of employed academics.'),('indicator',0,431,440,'en',0,'Describe how the process was improved (what was done for the patients and how effective) and/or describe the possible outcomes of the improved health care delivery process (impacts on patients health). Improvement efforts of quality of health care may address the perspectives of efficacy, availability and accessibility, responsiveness to population health needs, utilization or coverage of health services etc. After the data collection, evaluate the efforts at national, regional, local level or at hospital/clinical units. These can be specific interventions or processes aiming to improve quality of care.'),('indicator',0,432,441,'en',0,'Describe the risk stratification model applied and the results of its application. A level of risk can be calculated by using diagnosis/procedures codes, for mortality and length-of-stay by using logistic regression/Cox proportional hazards modeling, together these generates an RSI.'),('indicator',0,433,442,'en',0,'Calculate the percentage of potentially preventable hospitalisations (PPH) by dividing hospital admissions (number of visits and people admitted) relative to the patient diagnoses codes in hospital admissions data. PPH is reported using the broad categories of chronic, acute and vaccine preventable conditions and using age-standardized hospitalisation rates (the number of potentially preventable hospitalisations per 1 000 or 100 000 population or the number of hospital bed days per patients admitted for a potentially preventable hospitalization).'),('indicator',0,434,443,'en',0,'Describe how health and safety issues are controlled in practice and identify preventive actions needed.'),('indicator',0,435,444,'en',0,'Count the number of each type of guidelines and tools developed/customized for patient care.'),('indicator',0,436,445,'en',0,'There are several ways to estimate QALY. For instance, calculate the years of life remaining for a patient and weight each year with a quality-of-life score (on a 0 to 1 scale). \"The basic idea underlying the QALY is simple: it assumes that a year of life lived in perfect health is worth 1 QALY (1 Year of Life × 1 Utility = 1 QALY) and that a year of life lived in a state of less than this perfect health is worth less than 1. In order to determine the exact QALY value, it is sufficient to multiply the utility value associated with a given state of health by the years lived in that state.\" (Prieto & Sacristán, 2003, p. 2).'),('indicator',0,437,446,'en',0,'Calculate the number of deaths for the specific population (disease in which the initiative research focuses on) in a given period of time and area and divide it by the number of death in the total population. Describe how the research findings of the initiative project contribute to reducing the mortality rate.'),('indicator',0,438,447,'en',0,'Provide a narrative description of the potential influence on life expectancy of the actions and research outcomes of the initiative/project.'),('indicator',0,439,448,'en',0,'Provide the change in the percentage of patient satisfaction respect to the previous survey. Questions included in the scales should be distinctive to capture the disease-specific issues. The indicator is normalized by measuring the change in patient satisfaction.'),('indicator',0,440,449,'en',0,'Provide a narrative description of the collaboration with other societal stakeholders in health promotion . The initiative can provide a link to a document where it is disclosed.'),('indicator',0,441,450,'en',0,'Provide a narrative description of the engagement activities with relevant patient groups. The initiative can provide a link to a document where it is disclosed.'),('indicator',0,442,451,'en',0,'Count the number of scientific articles published during the period. For the sake of comparison, the initiative shall report the same figure for the two prior periods. Provide a list of the complete references of the publications. Indicate the percentage of publications in high-impact journal by dividing the number of articles in those journals by the total number of publications during the period. The initiative can provide a link to a document where the list of publications is disclosed.'),('indicator',0,443,452,'en',0,'Count the number of scientific articles published during the reporting period resulting from the collaboration with researchers from organizations located in different countries or operating in different sectors.\r\nIndicate the number of organizations with which members of the initiative/project have published articles. For the sake of comparison, the initiative/project shall report the same figure for the two prior reporting periods.'),('indicator',0,444,453,'en',0,'For the number of open access articles: Count the number of open access scientific articles (total/gold/green) published during the reporting period by the initiative/project. For the sake of comparison, the initiative/project shall report the same figure for the two prior reporting periods. For the percentage of open access articles: divide the total number of open access scientific articles (total/gold/green) by the total number of publications during the reporting period, and multiply the result times 100.'),('indicator',0,445,454,'en',0,'Describe the extent to which anticipatory design policies and actions are considered in health research processes.'),('indicator',0,446,455,'en',0,'Count the number of citations of publications resulting from the the initiative/project\'s research since they were published. '),('indicator',0,447,456,'en',0,'Number and disparateness of the fields from citing publications, summarized in a diffusion score developed by Carley and Porter. Score ranges from 0 to 1.\r\nFor more information, see Carley S, & Porter A (2012).'),('indicator',0,448,457,'en',0,'Count the number of times that a publications/research output is cited in guidelines'),('indicator',0,449,458,'en',0,'Provide the number of dissemination activities carried out during the period.'),('indicator',0,450,459,'en',0,'Count the number of times that the initiative/project has been mentioned in the media as a consequence of the relevance of their research findings.'),('indicator',0,451,460,'en',0,'Provide the number of page views, unique visitors, and/or requests from the public/health care providers/researchers for more information.'),('indicator',0,452,461,'en',0,'Provide a narrative description of the extent to the initiative/project complies with clinical guidelines.'),('indicator',0,453,462,'en',0,'Provide a narrative description of the processes that the initiative/project follows to identify potential risks related to the research process and how these risks are managed. The initiative can provide a link to a document where it is disclosed.'),('indicator',0,454,463,'en',0,'Indicate Yes/No depending on the existence of an ethical committee to manage research. If yes, provide a description of f its structure (indicating its composition and gender distribution) and functions.'),('indicator',0,455,464,'en',0,'Provide a narrative description of the initiative/project’s values, principles and standards. Provide a detail description of how they have been  approved, developed, and implemented in the health research process.'),('indicator',0,456,465,'en',0,'Provide a description of whether and how the health research initiative/project integrated any type of ethical assessment/review in its funding decisions. '),('indicator',0,457,466,'en',0,'Count the total number of grants that the initiative/project has received to carry out research. For each grant, indicate the funding organization, amount and duration.'),('indicator',0,458,467,'en',0,'Count the number and the monetary amount of collaborative research projects funded through joint calls.'),('indicator',0,459,468,'en',0,'Indicate Yes/No depending on whether the initiative/project takes public engagement elements into account for the development or evaluation of R&I projects.\r\nProvide a narrative description of how public engagement is taken into account.'),('indicator',0,460,469,'en',0,'Provide the number of new taxonomies of diseases and new stratifications (such as the definition of patient subpopulations, development, validation and use of new diagnostics) developed, expressed as net figure. '),('indicator',0,461,470,'en',0,'Provide a narrative description of the overall impacts for patients (considering both positive and negative impacts) driven by the research and activities carried out by the initiative/project.'),('indicator',0,462,471,'en',0,'Provide a narrative description of the overall impacts for society (considering both positive and negative impacts) driven by the research and activities carried out by the initiative/project.'),('indicator',0,463,472,'en',0,'Provide a narrative description of the expected or targeted changes in knowledge, attitudes and behavior as a result of research dissemination and implementation strategies. The initiative can provide a link to a document where it is disclosed.'),('indicator',0,464,473,'en',0,'Use the following scoring scale and justify the score given:\r\n10 – The initiative/project made a considerable contribution to more than 1 follow-on project by the team and/or by others.\r\n8 – The initiative/project made a contribution to more than 1 follow-on project, considerable in at least one case.\r\n6 – The initiative/project made a contribution to more than 1 follow-on project, moderate in at least one case.\r\n4 – The initiative/project made a moderate contribution to 1 follow-on project, or any contribution to more than one follow-on project.\r\n2 – The initiative/project made a contribution to at least 1 follow-on project.\r\n0 – The initiative/project made no contribution to targeting of future research.'),('indicator',0,465,474,'en',0,'Provide a narrative description of the influence on shaping the R&D agenda.'),('indicator',0,466,475,'en',0,'Narrative description of the adopted research priorities or strategies that mirror the impact of the initiative/project. A questionnaire can be used to collect data.'),('indicator',0,467,476,'en',0,'Count the number of potential outcomes that can be applied in practice or in policy development. When possible, classify and describe the outcomes per type. '),('indicator',0,468,477,'en',0,'Describe the country specific activities and opportunities related to the use of science in decision-making: one dimension concerns the extent of formalized procedures feeding knowledge in decision-making (e.g. institutional sites dealing with these processes), the other dimension concerns the extent to which knowledge and advice have a real impact on decisions.'),('indicator',0,469,478,'en',0,'Describe the use of science in clinical context (e.g. trials, treatment recommendations, algorithms). For example, surveys or “market research” type methods can be useful in assessing the clinical awareness of published research results. The tracking can vary from small scale (e.g. conference posters) to large scale (e.g. international/national reports).'),('indicator',0,470,479,'en',0,'Divide the number of patents or other intellectual property rights owned by the initiative that are or have been exploited by the pharma industry by the total number of patents and other intellectual property rights owned by the initiative. For the sake of comparison, the initiative shall report the same figure for the two prior reporting periods.'),('indicator',0,471,480,'en',0,'Count the research institutions with which the initiative/project has shared intellectual property or research findings during the reporting period to collaborate in and advance the development of R&D. For the sake of comparison, the initiative/project shall report the figure for the two prior reporting periods.'),('indicator',0,472,481,'en',0,'Count the total number of patents that the initiative owns and was awarded during the reporting period. When breaking down the patents considering the options listed in the description, provide a table that summarizes the figures (see examples). For the sake of comparison, the initiative shall report the same figure for the two prior reporting periods.'),('indicator',0,473,482,'en',0,'Provide the total number of advanced phase clinical/pragmatic trials and/or Public Health research project where patient have been engaged. When possible, classify them based on their phase.'),('indicator',0,474,483,'en',0,'Provide a narrative description of how potential users are engaged in the research process.\r\nConsider the Patient Engagement model developed by MultiAct.'),('indicator',0,475,484,'en',0,'Count the total number of new drugs and other products that the initiative developed during the reporting period. For the sake of comparison, the initiative shall report the same figure for the two prior reporting periods. \r\nProvide a list of the products and drugs developed and being developed, indicating their stage.'),('indicator',0,476,485,'en',0,'Count the total number of new therapeutic advances that the initiative/project developed during the reporting period. For the sake of comparison, the initiative/project shall report the same figure for the two prior reporting periods.'),('indicator',0,477,486,'en',0,'Count the total number of spin-offs created during the reporting period. For the sake of comparison, the initiative/project shall report the same figure for the two prior reporting periods. Provide the main information about the spin-offs (e.g. main timeline of the spin-off, description of its business, debt ratios, detailed information of the new listed company etc.).'),('indicator',0,478,487,'en',0,'Provide a narrative description of the new developments generated by the initiative/project (drugs, products, therapeutic treatments, medical interventions, etcetera) and explain their effect on the wellbeing of patients and how they can contribute to solving, mitigating or paliating diseases.'),('indicator',0,479,488,'en',0,'Number and description of the collaborations and partnerships.'),('indicator',0,480,489,'en',0,'Divide the number of projects of the initiative that involve patient organizations in their advisory board by the total number of projects of the initiative.\r\nConsider the Patient Engagement model developed by MultiAct.'),('indicator',0,481,490,'en',0,'Number of consortia applying for traslational funding. Differentiate between total number of submissions and total number of successfull projects.'),('indicator',0,482,491,'en',0,'Calculate:\r\n• Number of public recognition of leadership: (i) number and type of prestigious fellowships, (ii) number and type of awards that mark significant achievement in research, (iii) number and type of membership in honorary scientific societies.\r\n• (i) Number and type of membership of regional, national or international research bodies; (ii) number and type of review boards; (iii) number and type of funding bodies.\r\n• (i) Number and type of editorship of journals, (ii) number and type of membership on journal editorial boards and (iii) number and type of advisory committees.'),('indicator',0,483,492,'en',0,'Provide the number of prizes and awards that were given to researchers or research programs of the initiative/project during the reporting period.'),('indicator',0,484,493,'en',0,'Count the number of each type of researcher  depending on their academic level (e.g. Senior research, Postdoc, Predoc) and gender.'),('indicator',0,485,494,'en',0,'Provide a narrative description of the skills, knowledge and experience of the staff, considering also the equipment and technology required  to complete their work.'),('indicator',0,486,495,'en',0,'Count the number of women on committees. Calculate the percentage of females respect to the total number of committee members.'),('indicator',0,487,496,'en',0,'Divide the number of females by the total number of researchers.'),('indicator',0,488,497,'en',0,'Provide the total amount of money (R&D expenses) invested in each project.'),('indicator',0,489,498,'en',0,'Provide a narrative description of the components and strategies of the research organizational structure.\r\nConsider the Corporate Governance model developed by MultiAct.'),('indicator',0,490,499,'en',0,'Total number of projects with significant impact of knowldege work over total projects. The identification of knowldege work is based on different criteria (for example, criteria established by experts in the field).'),('indicator',0,491,500,'en',0,'Provide a narrative description of the governance structures (indicating their composition and gender distribution)  and procedures that have been established to manage and monitor the research process.'),('indicator',0,492,501,'en',0,'Count the number of outreach visits and people attending them.'),('indicator',0,493,502,'en',0,'Count the number of methodologies advanced or developed by the initiative/project.\r\nProvide a narrative description of those advances and developments'),('indicator',0,494,503,'en',0,'Provide the number of target groups that attend events organized to engage stakeholders and distribute them according to the different categories of stakeholders identified.\r\nThis information should ideally be presented in a table and compared with the previous year data or with targets.'),('indicator',0,495,504,'en',0,'Provide the number of mechanisms applied to interact with citizens and societal stakeholders. Provide a narrative description of the mechanisms and instruments used to engage these stakeholders.'),('indicator',0,496,505,'en',0,'Provide the number of stakeholders consulted by the initiative/project in a given period.\r\nThis information should ideally be compared with previous year or with expected targets.'),('indicator',0,497,506,'en',0,'Provide a narrative description of the social reputation of the research project/initiative.'),('indicator',0,498,507,'en',0,'Indicate Yes/No depending on whether the initiative/project has clearly defined enforcement procedures and (where there has been misconduct) provide evidence of taking disciplinary action against employees or third parties who have violated its code of conduct for ethical marketing or anti-corruption. Provide a description of evidence of follow-up actions taken to mitigate the risk of future breaches.'),('indicator',0,499,508,'en',0,'Calculate the frequency rate of accidents as the number of accidents suffered during the period, divided by the total hours worked in the same period and multiplied by 1,000,000.'),('indicator',0,500,509,'en',0,'Provide a narrative description of the impact on labour at the national/regional/local levels driven by the effect of research findings.'),('indicator',0,501,510,'en',0,'Calculate the employee turnover during the reporting period by age group and gender at the local/regional/national levels.\r\nEmployee turnover is the percentage of employees leaving the organization in a period, relative to the average number of employees during this period.'),('indicator',0,502,511,'en',0,'Divide the hours of training programs for research employees dissagregated by gender group in the reporting period by the average number of research employees during this period. '),('indicator',0,503,512,'en',0,'Provide the number and description of policies and guidelines informed by the research initiative/project. The initiative can provide a link to a document where it is disclosed.'),('indicator',0,504,513,'en',0,'Provide a narrative description of the measures adopted by the project/initiative to improve the governance and organization of its research activities. The initiative/project can provide a link to a document where the description is disclosed.'),('indicator',0,505,514,'en',0,'Narrative description of the interaction between the research initiative/project and external relevant actors (e.g. government agencies). The initiative can provide a link to a document where it is disclosed.'),('indicator',0,506,515,'en',0,'Provide the number of internal and/or external environmental audits conducted.'),('indicator',0,507,516,'en',0,'Identify the total materials used (raw materials, natural resources, materials needed for the manufacturing process, parts, components and materials for packaging purposes). Report the total weight or volume of all raw material needed for developing, producing and packaging the primary products (or services):\r\ni. non-renewable materials used;\r\nii. renewable materials used.'),('indicator',0,508,517,'en',0,'Calculate direct GHG emissions using relevant global warming potential (GWP) rates to translate the amount of emissions of a GHG into CO2 equivalents. Considering the characteristics of research funding and performing initiatives/projects, it could be advisable to consider the change in emissions to demonstrate reduction, rather than the absolute amount of GHG emissions. Following GRI and the Greenhouse Gas Protocol, GHG emissions are measured according to three scopes:\r\n• Direct (Scope 1)\r\n• Energy indirect (Scope 2)\r\n• Other indirect (Scope 3) emissions.'),('indicator',0,509,518,'en',0,'Identify the total number of actions aimed to improve community development and calculate the percentage of actions that have been executed in practice respect to the planned actions (local community engagement, impact assessment, or development programs).'),('indicator',0,510,519,'en',0,'Provide a narrative description of the activities organized by the initiative/project to promote the engagement with community members. The initiative can provide a link to a document where it is disclosed. Patient Engagement model elaborated by MultiAct provides information about engagement activities.'),('indicator',0,512,521,'en',0,'Provide a narrative description of the extent to which standards and regulations regarding RRI are acknowledged, complied with and embedded in the research process.'),('indicator',0,547,557,'en',0,'Provide a narrative description of how the initiative/project engages with clinicians and patients to implement research strategies and research outcomes in health care practice.\r\nConsider the Patient Engagement model developed by MultiAct.\r\n'),('indicator',0,548,558,'en',0,'Indicate whether there is publicly available information on the economic, social and environmental impacts resulting from the research and/or how they are being managed. Provide a reference or link to access the information. '),('indicator',0,549,559,'en',0,'Change in the percentage of patients satisfaction with respect to the previous questionnaire. Questions included in the scales are distinctive to capture the disease-specific issues. The indicator is normalized by measuring the change in patient satisfaction.\r\n'),('indicator',0,550,560,'en',0,'Change in the percentage of patients satisfaction with respect to the previous questionnaire. Questions included in the scales are distinctive to capture the disease-specific issues. The indicator is normalized by measuring the change in patient satisfaction.'),('indicator',0,551,561,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patients\' satisfaction with their level of bladder functions is disease-specific, the measurement of the percentage change provides a standardized measure of patient satisfaction. \r\n'),('indicator',0,552,562,'en',0,'Change in the percentage of patients satisfaction with respect to the previous questionnaire. Questions included in the scales are distinctive to capture the disease-specific issues. The indicator is normalized by measuring the change in patient satisfaction.'),('indicator',0,553,563,'en',0,'Change in the percentage of patients satisfaction with respect to the previous questionnaire. Questions included in the scales are distinctive to capture the disease-specific issues. The indicator is normalized by measuring the change in patient satisfaction.'),('indicator',0,554,564,'en',0,'Change in the percentage of patients satisfaction with respect to the previous questionnaire. Questions included in the scales are distinctive to capture the disease-specific issues. The indicator is normalized by measuring the change in patient satisfaction.'),('indicator',0,585,612,'en',0,'Change in the percentage of patients satisfaction with respect to the previous questionnaire. Questions included in the scales are distinctive to capture the disease-specific issues. The indicator is normalized by measuring the change in patient satisfaction.');

--
-- Table structure for table `node__field_monitoring_evaluation_fram`
--

CREATE TABLE `node__field_monitoring_evaluation_fram` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_monitoring_evaluation_fram_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_monitoring_evaluation_fram_value` (`field_monitoring_evaluation_fram_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_monitoring_evaluation…';

--
-- Dumping data for table `node__field_monitoring_evaluation_fram`
--

INSERT INTO `node__field_monitoring_evaluation_fram` VALUES ('indicator',0,399,408,'en',0,'Process'),('indicator',0,400,409,'en',0,'Process'),('indicator',0,401,410,'en',0,'Process'),('indicator',0,402,411,'en',0,'Impact'),('indicator',0,403,412,'en',0,'Impact'),('indicator',0,404,413,'en',0,'Impact'),('indicator',0,405,414,'en',0,'Outcome'),('indicator',0,406,415,'en',0,'Output'),('indicator',0,407,416,'en',0,'Output'),('indicator',0,408,417,'en',0,'Output'),('indicator',0,409,418,'en',0,'Outcome'),('indicator',0,410,419,'en',0,'Output'),('indicator',0,411,420,'en',0,'Process'),('indicator',0,412,421,'en',0,'Output'),('indicator',0,413,422,'en',0,'Outcome'),('indicator',0,414,423,'en',0,'Input'),('indicator',0,415,424,'en',0,'Outcome'),('indicator',0,416,425,'en',0,'Process'),('indicator',0,417,426,'en',0,'Input'),('indicator',0,418,427,'en',0,'Input'),('indicator',0,419,428,'en',0,'Outcome'),('indicator',0,420,429,'en',0,'Outcome'),('indicator',0,421,430,'en',0,'Process'),('indicator',0,422,431,'en',0,'Impact'),('indicator',0,423,432,'en',0,'Output'),('indicator',0,424,433,'en',0,'Process'),('indicator',0,425,434,'en',0,'Outcome'),('indicator',0,426,435,'en',0,'Process'),('indicator',0,427,436,'en',0,'Impact'),('indicator',0,428,437,'en',0,'Process'),('indicator',0,429,438,'en',0,'Outcome'),('indicator',0,430,439,'en',0,'Input'),('indicator',0,431,440,'en',0,'Outcome'),('indicator',0,432,441,'en',0,'Outcome'),('indicator',0,433,442,'en',0,'Outcome'),('indicator',0,434,443,'en',0,'Process'),('indicator',0,435,444,'en',0,'Outcome'),('indicator',0,436,445,'en',0,'Impact'),('indicator',0,437,446,'en',0,'Outcome'),('indicator',0,438,447,'en',0,'Impact'),('indicator',0,439,448,'en',0,'Outcome'),('indicator',0,440,449,'en',0,'Process'),('indicator',0,441,450,'en',0,'Process'),('indicator',0,442,451,'en',0,'Output'),('indicator',0,443,452,'en',0,'Output'),('indicator',0,444,453,'en',0,'Output'),('indicator',0,445,454,'en',0,'Process'),('indicator',0,446,455,'en',0,'Outcome'),('indicator',0,447,456,'en',0,'Outcome'),('indicator',0,448,457,'en',0,'Outcome'),('indicator',0,449,458,'en',0,'Output'),('indicator',0,450,459,'en',0,'Output'),('indicator',0,451,460,'en',0,'Output'),('indicator',0,452,461,'en',0,'Process'),('indicator',0,453,462,'en',0,'Outcome'),('indicator',0,454,463,'en',0,'Process'),('indicator',0,455,464,'en',0,'Process'),('indicator',0,456,465,'en',0,'Process'),('indicator',0,457,466,'en',0,'Input'),('indicator',0,458,467,'en',0,'Outcome'),('indicator',0,459,468,'en',0,'Process'),('indicator',0,460,469,'en',0,'Impact'),('indicator',0,461,470,'en',0,'Impact'),('indicator',0,462,471,'en',0,'Impact'),('indicator',0,463,472,'en',0,'Impact'),('indicator',0,464,473,'en',0,'Impact'),('indicator',0,465,474,'en',0,'Impact'),('indicator',0,466,475,'en',0,'Impact'),('indicator',0,467,476,'en',0,'Impact'),('indicator',0,468,477,'en',0,'Impact'),('indicator',0,469,478,'en',0,'Impact'),('indicator',0,470,479,'en',0,'Output'),('indicator',0,471,480,'en',0,'Output'),('indicator',0,472,481,'en',0,'Output'),('indicator',0,473,482,'en',0,'Process'),('indicator',0,474,483,'en',0,'Process'),('indicator',0,475,484,'en',0,'Output'),('indicator',0,476,485,'en',0,'Output'),('indicator',0,477,486,'en',0,'Output'),('indicator',0,478,487,'en',0,'Output'),('indicator',0,479,488,'en',0,'Input'),('indicator',0,480,489,'en',0,'Input'),('indicator',0,481,490,'en',0,'Input'),('indicator',0,482,491,'en',0,'Output'),('indicator',0,483,492,'en',0,'Outcome'),('indicator',0,484,493,'en',0,'Input'),('indicator',0,485,494,'en',0,'Input'),('indicator',0,486,495,'en',0,'Process'),('indicator',0,487,496,'en',0,'Input'),('indicator',0,488,497,'en',0,'Input'),('indicator',0,489,498,'en',0,'Process'),('indicator',0,490,499,'en',0,'Outcome'),('indicator',0,491,500,'en',0,'Process'),('indicator',0,492,501,'en',0,'Output'),('indicator',0,493,502,'en',0,'Input'),('indicator',0,494,503,'en',0,'Outcome'),('indicator',0,495,504,'en',0,'Process'),('indicator',0,496,505,'en',0,'Process'),('indicator',0,497,506,'en',0,'Outcome'),('indicator',0,498,507,'en',0,'Process'),('indicator',0,499,508,'en',0,'Impact'),('indicator',0,500,509,'en',0,'Impact'),('indicator',0,501,510,'en',0,'Input'),('indicator',0,502,511,'en',0,'Input'),('indicator',0,503,512,'en',0,'Impact'),('indicator',0,504,513,'en',0,'Process'),('indicator',0,505,514,'en',0,'Outcome'),('indicator',0,506,515,'en',0,'Process'),('indicator',0,507,516,'en',0,'Input'),('indicator',0,508,517,'en',0,'Output'),('indicator',0,509,518,'en',0,'Outcome'),('indicator',0,510,519,'en',0,'Outcome'),('indicator',0,512,521,'en',0,'Process'),('indicator',0,547,557,'en',0,'Process'),('indicator',0,548,558,'en',0,'Process'),('indicator',0,549,559,'en',0,'Outcome'),('indicator',0,550,560,'en',0,'Outcome'),('indicator',0,551,561,'en',0,'Outcome'),('indicator',0,552,562,'en',0,'Outcome'),('indicator',0,553,563,'en',0,'Outcome'),('indicator',0,554,564,'en',0,'Outcome'),('indicator',0,585,612,'en',0,'Outcome');

--
-- Table structure for table `node__field_number_of_organizations_in`
--

CREATE TABLE `node__field_number_of_organizations_in` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_number_of_organizations_in_value` int(11) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_number_of_organizations…';

--
-- Dumping data for table `node__field_number_of_organizations_in`
--

INSERT INTO `node__field_number_of_organizations_in` VALUES ('initiative',0,1,7,'en',0,2),('initiative',0,306,314,'en',0,2),('initiative',0,307,315,'en',0,2),('initiative',0,309,318,'en',0,3),('initiative',0,310,319,'en',0,1),('initiative',0,516,525,'en',0,28),('initiative',0,518,528,'en',0,2),('initiative',0,519,529,'en',0,3),('initiative',0,520,530,'en',0,6),('initiative',0,521,531,'en',0,5),('initiative',0,522,532,'en',0,14),('initiative',0,523,533,'en',0,18),('initiative',0,524,534,'en',0,2),('initiative',0,525,535,'en',0,4),('initiative',0,526,536,'en',0,5),('initiative',0,527,537,'en',0,3),('initiative',0,528,538,'en',0,2),('initiative',0,529,539,'en',0,3),('initiative',0,530,540,'en',0,3),('initiative',0,531,541,'en',0,3),('initiative',0,534,544,'en',0,5),('initiative',0,535,545,'en',0,10),('initiative',0,536,546,'en',0,3),('initiative',0,537,547,'en',0,1),('initiative',0,538,548,'en',0,2),('initiative',0,539,549,'en',0,12),('initiative',0,540,550,'en',0,7),('initiative',0,541,551,'en',0,20),('initiative',0,542,552,'en',0,8),('initiative',0,543,553,'en',0,22),('initiative',0,544,554,'en',0,1),('initiative',0,545,555,'en',0,3),('initiative',0,546,556,'en',0,2),('initiative',0,555,565,'en',0,1),('initiative',0,556,566,'en',0,5),('initiative',0,557,567,'en',0,6),('initiative',0,564,582,'en',0,12),('initiative',0,572,599,'en',0,4),('initiative',0,589,616,'en',0,5),('initiative',0,590,617,'en',0,2),('initiative',0,592,621,'en',0,25),('initiative',0,593,622,'en',0,10);

--
-- Table structure for table `node__field_parent_initiative`
--

CREATE TABLE `node__field_parent_initiative` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_parent_initiative_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_parent_initiative_target_id` (`field_parent_initiative_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_parent_initiative.';

--
-- Dumping data for table `node__field_parent_initiative`
--

INSERT INTO `node__field_parent_initiative` VALUES ('initiative',0,1,7,'en',0,519),('initiative',0,307,315,'en',0,518),('initiative',0,310,319,'en',0,309),('initiative',0,516,525,'en',0,306),('initiative',0,520,530,'en',0,519),('initiative',0,523,533,'en',0,522),('initiative',0,530,540,'en',0,529);

--
-- Table structure for table `node__field_permissions_tags`
--

CREATE TABLE `node__field_permissions_tags` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_permissions_tags_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_permissions_tags_target_id` (`field_permissions_tags_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_permissions_tags.';

--
-- Dumping data for table `node__field_permissions_tags`
--

INSERT INTO `node__field_permissions_tags` VALUES ('webform',0,594,623,'en',0,266);

--
-- Table structure for table `node__field_preferred_data_sources`
--

CREATE TABLE `node__field_preferred_data_sources` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_preferred_data_sources_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_preferred_data_sources.';

--
-- Dumping data for table `node__field_preferred_data_sources`
--

INSERT INTO `node__field_preferred_data_sources` VALUES ('indicator',0,399,408,'en',0,'Initiative/project\'s internal data'),('indicator',0,400,409,'en',0,'Initiative/project\'s internal data'),('indicator',0,401,410,'en',0,'Initiative/project\'s internal data'),('indicator',0,402,411,'en',0,'Information compiled internally by the organization with the input of other stakeholders (if needed)'),('indicator',0,403,412,'en',0,'Initiative/project\'s internal data\r\nNational/regional/local registries'),('indicator',0,404,413,'en',0,'Initiative/project\'s internal data'),('indicator',0,405,414,'en',0,'Annual report\r\nFinancial statement\r\nInitiative/project\'s internal data'),('indicator',0,406,415,'en',0,'Financial report'),('indicator',0,407,416,'en',0,'Initiative/project financial report'),('indicator',0,408,417,'en',0,'Initiative/project financial report'),('indicator',0,409,418,'en',0,'Annual report'),('indicator',0,410,419,'en',0,'Scientific report\r\nFinancial report'),('indicator',0,411,420,'en',0,'Initiative/project\'s internal data'),('indicator',0,412,421,'en',0,'Initiative/project\'s internal data'),('indicator',0,413,422,'en',0,'Surveys'),('indicator',0,414,423,'en',0,'Financial statements\r\nInternal management control systems'),('indicator',0,415,424,'en',0,'National/Regional/Local health systems\' records and financial statements\r\nExpert consultation'),('indicator',0,416,425,'en',0,'Annual report'),('indicator',0,417,426,'en',0,'Annual report\r\nInitiative/project\'s internal data'),('indicator',0,418,427,'en',0,'Initiative/project\'s internal data'),('indicator',0,419,428,'en',0,'Electronic medical records\r\nPatient records'),('indicator',0,420,429,'en',0,'Electronic medical records\r\nPatient records'),('indicator',0,421,430,'en',0,'Initiative/project\'s internal data'),('indicator',0,422,431,'en',0,'Review of research documents\r\nExpert survey'),('indicator',0,423,432,'en',0,'Health care providers\' records\r\nClinical information systems\r\nElectronic health record system\r\nPatient records, surveys and interviews'),('indicator',0,424,433,'en',0,'Initiative/project management control systems'),('indicator',0,425,434,'en',0,'Surveys\r\nRecords of service delivery\r\nAdministrative data'),('indicator',0,426,435,'en',0,'Annual report\r\nSustainability report'),('indicator',0,427,436,'en',0,'Local, regional and national statistics'),('indicator',0,428,437,'en',0,'Administrative/clinical/hospital data\r\nSurveys'),('indicator',0,429,438,'en',0,'Professional associations'),('indicator',0,430,439,'en',0,'Initiative/project\'s internal data\r\nHealthcare providers\r\nClinical academics'),('indicator',0,431,440,'en',0,'Research reports\r\nClinical information system\r\nSurveys and interviews'),('indicator',0,432,441,'en',0,'Hospital record information systems'),('indicator',0,433,442,'en',0,'Hospital record information systems\r\nHealth surveys'),('indicator',0,434,443,'en',0,'Annual report\r\nHuman resource management report'),('indicator',0,435,444,'en',0,'Clinical/treatment guidelines'),('indicator',0,436,445,'en',0,'Medical costs\r\nQuestionaires used in trials\r\nPreference surveys\r\nExpected duration of life and degree of diability'),('indicator',0,437,446,'en',0,'Electronic medical records\r\nAdministrative/clinical/hospital data'),('indicator',0,438,447,'en',0,'Interviews and/or surveys with practitioners/experts'),('indicator',0,439,448,'en',0,'Surveys'),('indicator',0,440,449,'en',0,'Initiative/project\'s internal data'),('indicator',0,441,450,'en',0,'Initiative/project\'s internal data'),('indicator',0,442,451,'en',0,'Initiative scientific report\r\nRankings of journals (e.g. JCR, SJR)'),('indicator',0,443,452,'en',0,'Initiative/project scientific report\r\nBibliometric datasources\r\nAcademic search databases'),('indicator',0,444,453,'en',0,'Initiative/project scientific report\r\nClassification of journals with open access options, such as DOAJ list (Directory of Open Access Journals), PMC (PubMed Central), the ROAD list (Directory of Open Access scholarly Resources), CrossRef, and OpenAIRE'),('indicator',0,445,454,'en',0,'Surveys/ Questionnaires\r\nSustainablity report'),('indicator',0,446,455,'en',0,'Google Scholar\r\nWeb of Science (WoS)\r\nScopus'),('indicator',0,447,456,'en',0,'Google scholar\r\nWeb of Science (WoS)\r\nScopus'),('indicator',0,448,457,'en',0,'Guidelines'),('indicator',0,449,458,'en',0,'Scientific report\r\nInitiative/project\'s internal data'),('indicator',0,450,459,'en',0,'Internal reports by press office'),('indicator',0,451,460,'en',0,'Google analytics or similar web engines'),('indicator',0,452,461,'en',0,'Initiative/project\'s internal data\r\nDesk analysis, database and interviews\r\nCase studies'),('indicator',0,453,462,'en',0,'Initiative/project\'s internal data\r\nDesk analysis, database and interviews\r\nCase studies'),('indicator',0,454,463,'en',0,'Code of ethics/conduct'),('indicator',0,455,464,'en',0,'Code of ethics/conduct\r\nMission statement\r\nInitiative/project\'s internal data'),('indicator',0,456,465,'en',0,'Initiative/project\'s internal data'),('indicator',0,457,466,'en',0,'Annual report\r\nScientific report'),('indicator',0,458,467,'en',0,'Initiative/project\'s internal data'),('indicator',0,459,468,'en',0,'Official documents specifying the criteria to evaluate research proposals'),('indicator',0,460,469,'en',0,'Scientific report\r\nInitiative/project\'s internal data'),('indicator',0,461,470,'en',0,'Dedicated survey'),('indicator',0,462,471,'en',0,'Dedicated survey'),('indicator',0,463,472,'en',0,'Initiative/project\'s internal data'),('indicator',0,464,473,'en',0,'Initiative/project\'s internal data\r\nExternal expert (if needed)'),('indicator',0,465,474,'en',0,'Initiative/project\'s internal data'),('indicator',0,466,475,'en',0,'Initiative/project\'s internal data'),('indicator',0,467,476,'en',0,'Research report'),('indicator',0,468,477,'en',0,'Research report'),('indicator',0,469,478,'en',0,'Interviews with practitioners/clinicians\r\nMarket surveys\r\nCase studies'),('indicator',0,470,479,'en',0,'Initiative scientific report\r\nWorld Intellectual Property Organization Database'),('indicator',0,471,480,'en',0,'Initiative scientific report\r\nInitiative/project\'s internal data'),('indicator',0,472,481,'en',0,'Initiative scientific report\r\nWorld Intellectual Property Organization Database'),('indicator',0,473,482,'en',0,'Information compiled internally by the organization with the input of other stakeholders as patients (if needed)'),('indicator',0,474,483,'en',0,'Initiative/project\'s internal data'),('indicator',0,475,484,'en',0,'Initiative\'s scientific report'),('indicator',0,476,485,'en',0,'Initiative scientific report'),('indicator',0,477,486,'en',0,'Initiative scientific report\r\nInitiative financial report'),('indicator',0,478,487,'en',0,'Initiative scientific report\r\nResearch report\r\nResearchers\' expertise'),('indicator',0,479,488,'en',0,'Initiative/project\'s internal data'),('indicator',0,480,489,'en',0,'Initiative/project\'s internal data'),('indicator',0,481,490,'en',0,'Initiative/project\'s internal data.'),('indicator',0,482,491,'en',0,'Information compiled internally by the organization, with the engagement of the researchers that have been involved in the specific research programme'),('indicator',0,483,492,'en',0,'Initiative/project\'s internal data.'),('indicator',0,484,493,'en',0,'Annual report\r\nScientific report'),('indicator',0,485,494,'en',0,'Annual report\r\nSustainability report'),('indicator',0,486,495,'en',0,'Annual report\r\nSustainability report\r\n'),('indicator',0,487,496,'en',0,'Annual report\r\nSustainability report'),('indicator',0,488,497,'en',0,'Initiative/project\'s internal data'),('indicator',0,489,498,'en',0,'Initiative/project\'s internal data'),('indicator',0,490,499,'en',0,'Information compiled internally by the initiative/project with the input of other stakeholders as experienced workers.'),('indicator',0,491,500,'en',0,'Annual report\r\nPolicy report'),('indicator',0,492,501,'en',0,'Scientific report\r\nInitiative/project\'s internal information'),('indicator',0,493,502,'en',0,'Scientific report\r\nInitiative/project\'s internal data'),('indicator',0,494,503,'en',0,'Initiative/project\'s internal data'),('indicator',0,495,504,'en',0,'Initiative/project\'s internal data'),('indicator',0,496,505,'en',0,'Initiative/project\'s internal data'),('indicator',0,497,506,'en',0,'Surveys\r\nInterviews'),('indicator',0,498,507,'en',0,'Initiative Code of Ethics/Conduct.\r\nThe initiative should provide a link to the public documents where the code of ethics/conduct is provided.'),('indicator',0,499,508,'en',0,'Annual report\r\nSustainability report\r\nInternal report'),('indicator',0,500,509,'en',0,'Sustainability report'),('indicator',0,501,510,'en',0,'Initiative/project\'s internal data\r\nNational/regional/local data registries'),('indicator',0,502,511,'en',0,'Sustainability report'),('indicator',0,503,512,'en',0,'Initiative/project\'s internal data'),('indicator',0,504,513,'en',0,'Initiative/project\'s internal data'),('indicator',0,505,514,'en',0,'Initiative/project\'s internal data'),('indicator',0,506,515,'en',0,'Environmental management system documentary\r\nAnnual report\r\nSustainability report'),('indicator',0,507,516,'en',0,'Production and research sites of the company\r\nSustainabitly report\r\nBilling and accounting systems, procurement or supply management department'),('indicator',0,508,517,'en',0,'Initiative/project management control systems'),('indicator',0,509,518,'en',0,'Initiative/project\'s internal data\r\nSocial/gender/health/environmental impact assessments\r\nStakeholder engagement/community development plans'),('indicator',0,510,519,'en',0,'Initiative/project\'s internal data'),('indicator',0,512,521,'en',0,'Initiative/project\'s internal data'),('indicator',0,547,557,'en',0,'Initiative/project\'s internal data\r\n'),('indicator',0,548,558,'en',0,'Sustainability report\r\nStrategy documents\r\nAnnual report'),('indicator',0,549,559,'en',0,'Questionnaires (also in the form of digital data collection)'),('indicator',0,550,560,'en',0,'Questionnaires (also in the form of digital data collection)'),('indicator',0,551,561,'en',0,'Questionnaires (also in the form of digital data collection)'),('indicator',0,552,562,'en',0,'Questionnaires (also in the form of digital data collection)'),('indicator',0,553,563,'en',0,'Questionnaires (also in the form of digital data collection)'),('indicator',0,554,564,'en',0,'Questionnaires (also in the form of digital data collection)'),('indicator',0,585,612,'en',0,'Questionnaires (also in the form of digital data collection)');

--
-- Table structure for table `node__field_rationale`
--

CREATE TABLE `node__field_rationale` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_rationale_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_rationale.';

--
-- Dumping data for table `node__field_rationale`
--

INSERT INTO `node__field_rationale` VALUES ('indicator',0,399,408,'en',0,'The indicator evaluates if intellectual property strategies are employed to contribute to access to medicine (e.g. companies pressure governments not to adopt TRIPS flexibilities), at least in developing countries.'),('indicator',0,400,409,'en',0,'The analysis of deviation allows identifying their causes, as well as reformulate programs and implement corrective actions.'),('indicator',0,401,410,'en',0,'Audits produce preventive effects in control. The indicator is easy to obtain.\r\nCertifications could be used as a proxy.'),('indicator',0,402,411,'en',0,'The indicator assesses the effect that research findings may have on the overall economy when been commercialized.'),('indicator',0,403,412,'en',0,'The indicator informs about the contribution to a healthy workforce i.e., work-life balance.'),('indicator',0,404,413,'en',0,'The indicator informs about how research findings affect the economic conditions of communities.'),('indicator',0,405,414,'en',0,'This indicator evaluates how the financial resources of the of the initiative/project are distributed among stakeholders.'),('indicator',0,406,415,'en',0,'The indicator evaluates the capacity of the initiative/project to generate economic profits. It measures its economic efficiency. The calculation of the indicator is simple and enables a high level of comparability.'),('indicator',0,407,416,'en',0,'The indicator evaluates the capacity of an initiative/project to pay back their debt through the profit generated by its research activity. The indicator is standard, easy to calculate and enables comparison with other initiatives.'),('indicator',0,408,417,'en',0,'The indicator assesses the generation of income of the initiative/project through the exploitation of their reseach findings compared to the cost or value of obtaining the right to exploit them. The indicator is easy to calculate, and the information required for its computation is accesible.'),('indicator',0,409,418,'en',0,'The indicator measures the overall economic value generated by the initiative/project.'),('indicator',0,410,419,'en',0,'The indicator assesses the initiative/project\'s capacity to generate economic revenues from the exploitation of their patents and intellectual property rights. The indicator is easy to calculate, and the information required for its computation is accesible.'),('indicator',0,411,420,'en',0,'The indicator is clear and applicable to every initiative/project.'),('indicator',0,412,421,'en',0,'The indicator is clear and related to efficacy. It also allows evaluating the scope of the treatment/product audience.'),('indicator',0,413,422,'en',0,'The indicator evaluates the capacity of the initiative/project to develop a multi-stakeholder and the long term perspective, which is key for RR&I.'),('indicator',0,414,423,'en',0,'Cost per unit of product/service/contracted process provides an accepted measure of economic efficiency.'),('indicator',0,415,424,'en',0,'The indicator assesses the influence of research on reducing the cost of health systems and health care delivery.'),('indicator',0,416,425,'en',0,'The indicator provides details on the effectiveness of drug recall systems.'),('indicator',0,417,426,'en',0,'The indicator informs about the capacity of the initiative/project to contribute to employment.'),('indicator',0,418,427,'en',0,'The indicator offers a description of the employees of the initiative/project.'),('indicator',0,419,428,'en',0,'The indicator allows monitoring the increase or decrease in the number and use of drugs for treating a certain disease.'),('indicator',0,420,429,'en',0,'The indicator measures the proportion of patients who are counseled and/or treated without being prescribed with drugs. This indicator can be very revealing for the initiative/project as it allows to identify and foster new research projects.'),('indicator',0,421,430,'en',0,'The indicator provides information to evaluate the impact of the initiative/project\'s research to foster more responsible governance structures that monitor and supervise the management of health service organizations.'),('indicator',0,422,431,'en',0,'The indicator allows an overview of the impact on health benefits. It is strategic to assess the level of achievement of a certain mission.'),('indicator',0,423,432,'en',0,'The indicator allows an overview of the population that the initiative/project can help by improving health management through research.'),('indicator',0,424,433,'en',0,'The indicator provides information on the use of technologies to improve health care.'),('indicator',0,425,434,'en',0,'The indicator gives a comprehensive overview of health service coverage because it is a composite indicator.'),('indicator',0,426,435,'en',0,'The indicator helps to assess whether the initiative/project is transparent about its activities regarding access to medicine.'),('indicator',0,427,436,'en',0,'The indicator takes into consideration that equity of access to healthcare often depends on gender and/or ethnicity.'),('indicator',0,428,437,'en',0,'The indicator measures the proportion of health interventions that have engaged diverse stakeholders among the target group to ensure a comprehensive approach.'),('indicator',0,429,438,'en',0,'The indicator allows to identify the level of training of health professionals and possible gaps to be fulfilled. It also provides information on the contribution to research degrees (PhD) or to training of specific tasks related to research capacity building.'),('indicator',0,430,439,'en',0,'The indicator provides an overview of the level of human capital of healthcare practitioners within the initiative/project.'),('indicator',0,431,440,'en',0,'The indicator allows evaluating the impact that research has on the day-to-day health care delivery.'),('indicator',0,432,441,'en',0,'The indicator identifies the patients likely to be at high risk and prioritizing actions needed for improving management of their care.'),('indicator',0,433,442,'en',0,'The indicator provides a measure to evaluate health care delivery effectiveness.'),('indicator',0,434,443,'en',0,'The indicator allows identifying how the initiative/project manages health and safety risks.'),('indicator',0,435,444,'en',0,'The indicator allows to screen the capability of research activities in supporting patients through guidelines and tools.'),('indicator',0,436,445,'en',0,'The indicator helps to evaluate the health outcomes of interventions/programs and to allocate healthcare resources (health benefits and value for money).'),('indicator',0,437,446,'en',0,'The indicator evaluates how the initiative/project contributes to reducing the mortality rate of the disease on which its research focuses.'),('indicator',0,438,447,'en',0,'The indicator describes actions carried out by the initiative/project that are expected to increase the average life expectancy of patients.'),('indicator',0,439,448,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patient satisfaction needs to be disease-specific, the measurement of the percentage change provides a standardized measure of patient satisfaction.'),('indicator',0,440,449,'en',0,'The indicator describes how the actors collaborate in promoting health.'),('indicator',0,441,450,'en',0,'The indicator describes how the patient groups are taken into account.'),('indicator',0,442,451,'en',0,'The indicator evaluates the extent and level of the academic production of the initiative/project.'),('indicator',0,443,452,'en',0,'The indicator measures the collaboration in publications as a proxy for the quality and broadness of the initiative/project\'s research capacity.'),('indicator',0,444,453,'en',0,'The indicator informs about the committment of the initiative towards transparency by faciliting the transference and openess of their research results and making them accesible to the general public.'),('indicator',0,445,454,'en',0,'The indicator evaluates foresight techniques. Moreover, this indicator has been identified as \"key\" for experts in the field through the interviews carried out in D3.5.'),('indicator',0,446,455,'en',0,'The indicator shows the number of times the article has been cited as proxy for the academic relevance of research outputs.'),('indicator',0,447,456,'en',0,'The indicator measures the applicability of research findings across subject areas, represents the robustness of the findings, incorporates features of traditional measures of diversity in assessing the balance and distribution of citations arising from different topic/subject categories. For example, if an article A is cited by Physics and Chemistry and an article B by Math, Music and Forestry the diffusion score would be greater for article B since there is greater heterogeneity among its citing subject categories.'),('indicator',0,448,457,'en',0,'The indicator shows how the findings are disseminating and cumulating knowledge. It measures the diffusion of research outputs into knowledge transfer, clinical implementation, or community benefit outcomes resulting from research studies.'),('indicator',0,449,458,'en',0,'The indicators reports on the dissemination activities to promote and communicate research outcomes.'),('indicator',0,450,459,'en',0,'The indicator measures the results of public relationship efforts.'),('indicator',0,451,460,'en',0,'The indicator shows the activity of the webpage of the initiative/project.'),('indicator',0,452,461,'en',0,'The indicator provides a starting point to analyze whether the research process is being responsible by fulfilling the basic requirement of complying with clinical guidelines to guarantee the adequate treatment of patients.'),('indicator',0,453,462,'en',0,'The indicator promotes accountability as it allows stakeholders to evaluate the potential risks that could emerge as a result of the research process. Additionally, it also provides benefits to the initiative/project because it helps it to make a self-assessment of its research process.'),('indicator',0,454,463,'en',0,'The indicator provides information that allows evaluating the consideration of ethical issues in research.'),('indicator',0,455,464,'en',0,'The indicator describes in detail the values, principles, standards and norms of behavior of the initiative/project.'),('indicator',0,456,465,'en',0,'The indicator is based on the dedicated survey of the funding organizations and its question ‘Has your organization integrated any type of ethics assessment/review in its funding decisions?’ (MORRI, 2017).'),('indicator',0,457,466,'en',0,'The indicator measures the researh funding obtained from grant applications.'),('indicator',0,458,467,'en',0,'The indicator shows the success of the initiative/project in aligning its research agenda with other partners.'),('indicator',0,459,468,'en',0,'The indicator shows how the public engagement elements are taken into account as evaluative criteria in research proposal evaluations and developments.'),('indicator',0,460,469,'en',0,'The indicator shows the development in defining the diagnosis, treatment, and mechanisms of diseases.'),('indicator',0,461,470,'en',0,'The indicator describes the positive and negative impacts for patients driven by the research and activities carried out by the initiative/project.'),('indicator',0,462,471,'en',0,'The indicator describes the positive and negative impacts for society driven by the research and activities carried out by the initiative/project.'),('indicator',0,463,472,'en',0,'The indicator evaluates whether the excellence of knowledge generated by health research goes together with practice changes in the application of the knowledge generated.'),('indicator',0,464,473,'en',0,'The indicator measures targeting of future research (follow-on projects).'),('indicator',0,465,474,'en',0,'The indicator informs about impact on future research.'),('indicator',0,466,475,'en',0,'The indicator informs about the adopted research priorities or strategies that mirror the impact of the initiative/project.'),('indicator',0,467,476,'en',0,'The indicator informs about the practical/clinical outcomes of projects.'),('indicator',0,468,477,'en',0,'The indicator informs about the extent to which knowledge generated by the initiative/project is effectively used in policy-making.'),('indicator',0,469,478,'en',0,'The indicator informs about how key clinical decision makers are aware of scientific evidence which is important for closing the gap between science and clinical care.'),('indicator',0,470,479,'en',0,'The indicator evaluates the extent to which the initiative/project develops research outputs that are actually being exploited.'),('indicator',0,471,480,'en',0,'The indicator assesses the willingness of the initiative/project to collaborate and share intellectual property with other research institutions to generate more advanced and improved research outputs with the capacity to generate an impact on patients\' wellbeing. Sharing intellectual property can accelerate the development of new products and treatments to maximize their potential.'),('indicator',0,472,481,'en',0,'This indicator evaluates the capacity of the initiative to generate research findings with applicable and economic exploitable potential. The indicator is clear and easy to calculate.'),('indicator',0,473,482,'en',0,'The clinical trial in human beings is a significant indicator for research assessment. Research projects can be assessed on the basis of whether they have progressed to clinical trials.'),('indicator',0,474,483,'en',0,'The indicator describes how potential users were taken into account by the research initiative/project.'),('indicator',0,475,484,'en',0,'The indicator evaluates the generation of drugs and other products that will be administered to patients as part of their treatment.'),('indicator',0,476,485,'en',0,'The indicator evaluates the capacity of the initiative to produce treatments and medical interventions that will improve the health and care of patients.'),('indicator',0,477,486,'en',0,'The indicator evaluates spin-offs as a result of the initiative/project.'),('indicator',0,478,487,'en',0,'The indicator evaluates the potential effect that the new developments of the initiative/project might have on patients.'),('indicator',0,479,488,'en',0,'The indicator evaluates the capacity of the initiative/project to collaborate with external partners.'),('indicator',0,480,489,'en',0,'The indicator shows the collaboration with potential users.'),('indicator',0,481,490,'en',0,'The indicator informs about the capacity to fund the commercialization of research findings.'),('indicator',0,482,491,'en',0,'The indicator is clear and easy to calculate.'),('indicator',0,483,492,'en',0,'This indicator evaluates the social recognition and prestige of the research initiative. The indicator is clear and easy to calculate.'),('indicator',0,484,493,'en',0,'The indicator evaluates the composition of the human capital of the initiative/project.'),('indicator',0,485,494,'en',0,'The indicator describes skills, knowledge and experience of the staff. It takes into account the needed equipment and technology to complete their work.'),('indicator',0,486,495,'en',0,'The indicator monitors female participation in decision-making and the overall gender balance of the decision-making process.'),('indicator',0,487,496,'en',0,'The indicator evaluates the representation of women across the whole initiative/project\'s researchers.'),('indicator',0,488,497,'en',0,'The indicator allows identifying the R&D expenses.'),('indicator',0,489,498,'en',0,'This indicator provides a comprehensive picture of the research organizational structure and its contribution to achieving the research strategy of the initiative/project.'),('indicator',0,490,499,'en',0,'The indicator allows to monitor the performance of research activities in the upstream research effort (e.g. computer-assited drug design).'),('indicator',0,491,500,'en',0,'The indicator provides information to evaluate the governance model and allows stakeholders to evaluate its participatory approch to engage them in the research process.'),('indicator',0,492,501,'en',0,'The indicator evaluates the direct engagement between researchers and practitioners to foster the implementation of research findings in clinical practice. By informing on the number of people that attend outreach visits, it assesses the level at which research findings are considered relevant by practitioners.'),('indicator',0,493,502,'en',0,'The indicator describes the long-term contribution of an initiative/project to improving future research, thereby leading to further knowledge that could lead to creating positive impacts.'),('indicator',0,494,503,'en',0,'The indicator shows the success and extent of participation. According to Graham et al. (2012) \'reach\' covers an aspect of stakeholder engagement that provides a measure of the \'who\' and the ‘interactions’ of stakeholder engagement.'),('indicator',0,495,504,'en',0,'D5.4 recommends (Recommendation 5.2.1) to “Implement structures and processes allowing to inform, engage, and seek feedback from internal and external stakeholders, including concerns about the initiative and its development”.\r\nFurther, D5.4 recommends to report on the number of consultation events with stakeholders.'),('indicator',0,496,505,'en',0,'The indicator provides a simple measure to evaluate the stakeholder engagement of the research initiative/project.'),('indicator',0,497,506,'en',0,'The indicator allows evaluating how research is perceived by society.'),('indicator',0,498,507,'en',0,'The indicator is feasible for research funding and performing organizations. The existence of enforcement procedures for the compliance with the code of ethical marketing and anti-corruption denotes the existence of such code.'),('indicator',0,499,508,'en',0,'The indicator evaluates the effectiveness of health, safety and security policy.'),('indicator',0,500,509,'en',0,'The indicator describes the impact on labour at the national/regional/local levels driven by the effect of research findings.'),('indicator',0,501,510,'en',0,'The comparison of this indicator contributes to evaluate the influence of the initiative/project on the overall labour condition by comparing its trend to the ones of the initiative/project.'),('indicator',0,502,511,'en',0,'The indicator evaluates the contribution of the initiative to improve the human capital and education of its research employees.'),('indicator',0,503,512,'en',0,'The indicator provides an overview of the influence of the research initiative/project in the development of health policies and guidelines.'),('indicator',0,504,513,'en',0,'The indicator allows the initiative/project to self-evaluate the governance and organization its research activities and identify best practices and measures that could help to improve them.'),('indicator',0,505,514,'en',0,'The indicator allows identifying new/closer external relevant actors (e.g. government agencies). The lack of relationships can be a weak point of a research initiative/project. Importance to enhance the possibility of research results to influence policy and practice.'),('indicator',0,506,515,'en',0,'The indicator allows stakeholders to evaluate the commitment regarding the management of environmental impacts resulting from research.'),('indicator',0,507,516,'en',0,'The indicator can be computed by applying clear guidelines. Considering the characteristics of research funding and performing organizations, it could be advisable to consider a relative measure of material intensity.'),('indicator',0,508,517,'en',0,'The indicator informs about the effect of the initiative/project on climate change through their GHG emissions. By providing data of the current and prior reporting periods, stakeholders can evaluate the evolution (reduction or increase) of emissions. Emissions can be computed using clear available guidelines.'),('indicator',0,509,518,'en',0,'The indicator seeks to identify the scope of community engagement efforts applied by the initiative/project.'),('indicator',0,510,519,'en',0,'The indicator provides information on the actions taken by the initiative/project to foster and increase the collaboration with communities.'),('indicator',0,512,521,'en',0,'The indicator informs about the consideration of RRI standards when performing research. In so doing, it provides stakeholders with information to assess the responsibility and ethics of the initiative/project\'s research process.'),('indicator',0,547,557,'en',0,'The indicator describes how the initiative/project takes into account patients and practitioners to implement research findings in health care practice.\r\n'),('indicator',0,548,558,'en',0,'The indicator demonstrates the accountability and transparency of research by providing information for stakeholders to evaluate it.'),('indicator',0,549,559,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patients\' satisfaction with their level of Anxiety and Depression, the measurement of the percentage change provides a standardized measure of patient satisfaction. \r\n'),('indicator',0,550,560,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patients\' satisfaction with their level of functional domains evaluated by the scale is disease-specific (MS), the measurement of the percentage change provides a standardized measure of patient satisfaction. \r\n'),('indicator',0,551,561,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patients\' satisfaction with their level of bladder functions is disease-specific, the measurement of the percentage change provides a standardized measure of patient satisfaction. '),('indicator',0,552,562,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patients\' satisfaction with the level of motor, cognitive, psyco-social fatigue is disease-specific (MS), the measurement of the percentage change provides a standardized measure of patient satisfaction. '),('indicator',0,553,563,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patient satisfaction is disease-specific, the measurement of the percentage change provides a standardized measure of patient satisfaction. '),('indicator',0,554,564,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patients\' satisfaction with their level of upper-limb dexterity is disease-specific, the measurement of the percentage change provides a standardized measure of patient satisfaction. '),('indicator',0,585,612,'en',0,'The indicator facilitates comparisons. Considering that the measurement of patients\' satisfaction with the level of locomotion is disease-specific (MS), the measurement of the percentage change provides a standardized measure of patient satisfaction. ');

--
